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Abstract 
Introduction and aims: Nitric oxide (NO) bioavailability and responsiveness decrease with 
age, leading to a rise in platelet activation and aggregation, however very little evidence 
exists on the changes to platelet function in the elderly. Platelet and vascular responses to NO 
are also impaired in patients with heart failure with reduced ejection fraction (HFrEF) when 
compared to healthy volunteers, due to scavenging of NO with subsequent reduction to 
soluble guanylate cyclase (sGC), thus limiting the therapeutic potential of NO donors. 
“Platelet NO resistance” is widely recognised in HFrEF, but the existence of the phenomenon 
in heart failure with preserved ejection fraction (HFpEF) remains to be elucidated. Many 
pharmacotherapeutic agents utilised in HFrEF are ineffective in HFpEF, thus the discovery of 
a novel agent that circumvents “platelet NO resistance” is desirable. Previous studies have 
shown nitrite to inhibit platelet aggregation in healthy volunteers, however the underlying 
mechanism(s) of the anti-aggregatory effects of nitrite remain unclear. We aimed to 
investigate platelet function in the elderly, the potential for nitrite to be used as an anti-
platelet agent in patients with HFpEF, and the role of NO/sGC/ALDH2 in nitrite-mediated 
platelet inhibition.  
Methods and results: Platelet responses to nitrite and the NO donor sodium nitroprusside 
(SNP) were compared in: 1) young vs old healthy volunteers, 2) age-matched old healthy 
volunteers, heart failure with preserved ejection fraction with chronic atrial fibrillation 
(HFpEF-AF) patients and chronic atrial fibrillation (CAF) patients, and 3) ALDH2 WT vs 
KO mice. Nitrite-mediated platelet inhibition was assessed in the presence of NO 
scavengers/an sGC inhibitor, whilst vasodilator-stimulated phosphoprotein (VASP) 
phosphorylation was measured using Western blotting. Platelet responses to the sGC 
stimulator BAY 41-2272 were also assessed in the presence of nitrite/SNP. Nitrite and SNP 
  
triggered concentration-dependent attenuation of platelet aggregation in healthy volunteers 
and CAF pateints. A diminished response to SNP was observed in washed platelets from 
HFpEF-AF patients, whilst the anti-aggregatory effects of nitrite were not impaired. Nitrite 
also activated sGC independently of NO, phosphorylated VASP and exhibited synergistic 
activity with BAY-41-2272 in human platelets, whilst required ALDH2 to inhibit platelet 
aggregation in mice.  
Conclusion: We demonstrate for the first time that the phenomenon of “platelet NO 
resistance” exists in HFpEF-AF, whilst also revealing that high concentration nitrite is able to 
circumvent “platelet NO resistance” in washed platelets independently of NO. We also show 
that platelet function is maintained in the elderly population, whilst revealing the involvement 
of ALDH2 in nitrite-mediated platelet inhibition in mice. 
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Chapter 1: General introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
1.1 Overview 
 
Cardiovascular disease (CVD) is currently the number one cause of global deaths and affects 
approximately 17.5 million people worldwide (Bhatnagar et al., 2015). With an aging and 
growing population, and improved survival rates from cardiovascular events, it is estimated 
that these numbers may rise further (Chung and Lip, 2006). The vascular endothelium and 
platelets are involved in many aspects of cardiovascular health, including regulating vascular 
tone, haemostasis, thrombosis, and cell adhesion (Marti et al., 2012). In particular, altered 
platelet physiology associated with impaired nitric oxide (NO) bioavailability and increased 
oxidative stress has recently been implicated in the pathophysiology of a number of CVDs, 
including myocardial infarction (MI), atrial fibrillation (AF) and heart failure (HF) (Chung 
and Lip, 2006, Elahi et al., 2009; Marti et al., 2012; Procter et al., 2016; Stamboul et al., 
2015). Abundant research is currently underway to understand the impairment of NO and 
platelet dysfunction in HF, and in particular to identify novel therapeutic interventions to 
inhibit platelet aggregation during this disease state. Herein, we will address these knowledge 
gaps whilst investigating nitrite in: 1) young and old healthy volunteers, 2) patients with heart 
failure with preserved ejection fraction (HFpEF) with chronic atrial fibrillation (CAF) 
(HFpEF-AF patients), and 3) aldehyde dehydrogenase 2 (ALDH2) wild-type (WT) and 
knock-out (KO) mice.  
 
 
 
 
 
 
 
 
3 
 
1.2 Heart failure 
HF is a persistent and progressive condition, whereby the heart is unable to pump blood 
effectively throughout the body. Unfortunately, HF is a huge public health issue that 
contributes significantly to the global burden of CVD and has an overall economic cost of 
approximately $108 billion per year (Borlaug, 2013; Bui et al., 2011; Cook et al., 2014; 
Roger, 2013). It has been estimated that approximately 23 million individuals are currently 
living with HF worldwide, and this prevalence is set to rise due to a number of factors, 
including: the increasing age of the general population, rising awareness and diagnosis of HF, 
advancements in HF medication and mechanical devices, improved survival of patients 
following MI and the shift from acute illness to chronic disease in developing countries (Bui 
et al., 2011; Chung and Lip, 2006; Roger, 2013). 
 
There are various factors which have been shown to increase the risk of HF development, 
these include: 1) clinical risk factors (e.g. hypertension, MI, diabetes, obesity, and smoking), 
2) immune-mediated risk factors (e.g. peripartum cardiomyopathy), 3) infectious risk factors 
(e.g. viral, parasitic and bacterial infections), 4) toxic risk factors (e.g. chemotherapy, cocaine 
and alcohol), 5) genetic risk factors (e.g. congenital heart disease and family history), and 6) 
morphological risk factors (e.g. left ventricular dysfunction and increased LV mass/internal 
dimension) (Bui et al., 2011). Moreover, early diagnosis of HF is also very challenging. 
Many features of the disease lack organ-specificity and obvious signs/symptoms are 
generally masked in the early stages by accompanying compensatory mechanisms (e.g. 
ventricular dilation/hypertrophy, vasoconstriction/venoconstriction and tachycardia) (Bui et 
al., 2011; Jackson et al., 2000). These compensatory mechanisms function to maintain 
cardiac output (CO) and arterial blood pressure (ABP) (thus preserve nutrient delivery) in the 
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short-term. However, long-term compensatory changes often lead to significant deteriorations 
in cardiac function (Jackson et al., 2000).  
 
HF can be divided into groups based on left ventricular ejection fraction (EF). The most 
prevalent forms of HF include: 1) left ventricular heart failure (LVHF) with reduced ejection 
fraction (HFrEF) (EF<40%) and 2) LVHF with preserved ejection fraction (HFpEF) 
(EF≥50%) (ElGuindy and Yacoub, 2012; van Riet et al., 2016). Briefly, HFrEF (or systolic 
failure; ~49% of HF cases) generally results from a direct cardiac insult such as ischaemic 
damage or cardiomyopathy (e.g. genetics or deposition disease) (Loudon et al., 2016). A 
reduction in EF is due to loss of cardiac inotropy/decrease in ventricular contractility and is 
often caused by alterations in the signal transduction mechanisms regulating excitation-
contraction coupling (ElGuindy and Yacoub, 2012; van Riet et al., 2016) In contrast, HFpEF 
tends to occur in patients with hypertension, metabolic syndrome, diabetes and obesity 
(Noordali et al., 2017). HFpEF (or diastolic failure; >50% of HF cases) is caused by adverse 
effects on ventricular filling and stroke volume (SV) (e.g. ventricular hypertrophy and 
reductions in ventricular lusitropy). EF is maintained during HFpEF as reductions in end-
diastolic volume (EDV) and SV are generally proportional (ElGuindy and Yacoub, 2012; 
LeWinter and Meyer, 2013; van Riet et al., 2016).  
 
Whilst current morbidity and mortality rates for HFrEF and HFpEF are relatively similar (e.g. 
3-year mortality rates for HFrEF and HFpEF is approximately 32% and 26%, respectively), it 
has been estimated that HFpEF will become the most dominant HF phenotype within the next 
few decades (Burkhoff, 2012; Chung and Lip, 2006; Hall et al., 2014; van Heerebeek and 
Paulus, 2016). This prediction is based on the alarming rate at which HFpEF prevalence is 
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currently rising (~1% per year, relative to HFrEF prevalence), as well as the present shortage 
of effective HFpEF therapies (Borlaug, 2013; ElGuindy and Yacoub, 2012; van Heerebeek 
and Paulus, 2016). In recent clinical trials, therapies that have been shown to benefit HFrEF 
patients (e.g. neurohormonal antagonist treatments) had very little impact on the HFpEF 
outcome (Borlaug, 2013; ElGuindy and Yacoub, 2012). A number of theories have been 
proposed for the varied responses observed in HFrEF vs HFpEF patients, including: 1) unique 
pathophysiologies in the two phenotypes, 2) pathophysiological heterogeneity in the HFpEF 
patient population, 3) higher mortality associated with other causes in HFpEF, since 
approximately 30% of HFpEF deaths have been shown to have a non-cardiovascular nature, 
and 4) limited reverse remodelling in HFpEF due to the plasticity of the heart/vasculature in 
HFrEF potentially exceeding that in seen in HFpEF (Borlaug, 2013; Burkhoff, 2012). Further 
research into the underlying mechanism(s) of HFpEF and HFpEF therapies is warranted to 
address the predicted increases in HFpEF morbidity and mortality.  
 
Since HFpEF is a heterogenous disease with numerous etiologies/comorbidities, current 
treatments are mostly directed at associated conditions and symptoms, such as hypertension 
and oedema (Oktay and Shah, 2015). The array of accompanying disorders provides potential 
for numerous treatment avenues, however for this study we have chosen to focus on the issue 
of platelet hyperaggregability and thrombosis in HFpEF (Chirkov and Horowitz, 2007; 
Chung and Lip, 2006; Oktay and Shah, 2015). Platelet function in health and HF will now be 
discussed, before addressing nitrite as a potential therapeutic intervention for the impairment 
of NO and platelet dysfunction in HFpEF. 
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1.3 Platelets and their functions in health 
Platelets are derived from the cytoplasm of megakaryocytes and circulate in the blood for 
approximately 7-10 days at a concentration of ~150-400x109/L. These cell fragments are 
anuclear, however do contain other cellular features, including a cytoskeleton, canalicular and 
dense tubular systems, mitochondria, peroxisomes and granules (glycogen granules, α-
granules and δ granules) (Daly, 2011; Michelson, 2010). Receptors on their surface interact 
with a large selection of agonists, antagonists and adhesive proteins, predominantly 
synthesised and secreted by the vascular endothelium and other platelets (Daly, 2011; Jin et 
al., 2005; Michelson, 2010; Sangkuhl et al., 2011). The downstream effects of these receptor 
interactions, along with the regulation provided by other signalling molecules (e.g. NO), 
determine platelet reactivity in a wide range of situations (Jin et al., 2005; Michelson, 2010; 
Sangkuhl et al., 2011).   
 
Although platelets can be seen to participate in many processes, their primary physiological 
function is to assist in the formation of haemostatic thrombi during vascular injury (Li et al., 
2010; Michelson, 2010). Platelets are often found in close association with the apical surface 
of the vascular endothelium and during normal physiological conditions, this positioning is 
desirable as it enables rapid detection of vascular damage (Michelson, 2010). Interactions 
between platelets and their activating factors (surface-bound and/or soluble) stimulate the 
subcellular fragments, causing them to bind, secrete and spread in the area of vascular 
damage. This process leads to the formation of a platelet plug and is known as primary 
haemostasis (Gale et al., 2011; Michelson, 2010; Palta et al., 2014). Insoluble fibrin 
generated through the proteolytic coagulation cascade, is then incorporated into the platelet 
plug for additional strength and stability, during a process recognised as secondary 
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haemostasis (Gale et al., 2011). Both arms of haemostasis occur simultaneously and are 
mechanically linked to ensure all effects are localised to the site of injury (Gale et al., 2011; 
Palta et al., 2014).  Figure 1.1 provides an overview of the signalling pathways involved in 
haemostasis, whilst Sections 1.4 and 1.5 explore the primary and secondary processes in 
further detail.  
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Figure 1.1: Signalling in haemostasis 
Figure legend overleaf.  
(Adapted from Michelson, 2010)  
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Figure 1.1 Signalling in haemostasis 
At sites of vascular injury, platelet adhesion primarily results from interactions between: i) 
collagen-bound von Willebrand factor (VWF) and the platelet surface glycoprotein 1b 
(GP1b)-IX-V complex, ii) collagen and the platelet surface glycoprotein VI (GPVI), and 
iii) collagen and the platelet surface integrin α2β1. Collagen-GPVI binding initiates a 
second messenger cascade to cause platelet activation. A number of soluble agonists, 
including adenosine diphosphate (ADP), serotonin (5HT), thromboxane A2 (TXA2) and 
thrombin, also act on platelet surface receptors to bring about platelet activation. ADP and 
5HT (secreted from δ-granules following platelet activation) stimulate purinergic (P2Y1, 
P2Y12 and P2X1) and serotonin (5HT2A) platelet receptors, respectively. TXA2 (produced 
by the platelet cyclooxygenase 1 (COX1)-dependent signalling pathway) interacts with 
thromboxane prostanoid (TP) receptors on the platelet surface. The terminal serine 
protease thrombin (produced on the procoagulant surface of activated platelets) stimulates 
protease activated receptors (PAR-1 and PAR-4)/the GP1b-IX-V complex on the platelet 
surface. Polymorphonuclear leukocytes (PMN) are also able to activate platelets. The 
binding of the platelet surface protein, P-selectin (secreted from α-granules following 
platelet activation), to P-selectin glycoprotein ligand 1 (PSGL1) on the surface of PMNs, 
activates PMNs. This activation leads to granular release of cathepsin G, which then acts 
on PAR-4 receptors to cause platelet activation. Platelet-platelet adhesion is primarily 
mediated by the binding of activated integrin αIIbβ3 to fibrinogen (at high flow rates 
VWF-integrin αIIbβ3 binding is also required). The close contact between aggregated 
platelets enables signalling through platelet integrins, junctional adhesion molecules 
(JAMs) and receptor tyrosine kinases (RTKs). This signalling, and the binding of 
insoluble fibrin to vascular endothelial-cadherin (VEC), inter-cellular adhesion molecule-
1 (ICAM-1) and integrins αIIbβ3/αvb3 on the platelet surface, helps to stabilise the 
developing thrombus. Thrombus growth and stability is also regulated by a number of 
inhibitory signals. The action of prostacyclin (PGI2) on PGI2 receptors (IP) on the platelet 
surface, inhibits aggregation through the stimulation of adenylyl cyclase (AC)-cyclic 
adenosine monophosphate (cAMP)-protein kinase A (PKA) pathway. Nitric oxide (NO) 
also activates soluble guanylate cyclase (sGC) in platelets, which subsequently 
synthesises cyclic guanosine monophosphate (cGMP) from guanosine triphosphate 
(GTP). cGMP inhibits platelets aggregation through protein kinase G (PKG). cAMP and 
cGMP are rapidly degraded by phosphodiesterase enzymes (PDE).  
(Adapted from Michelson, 2010)  
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1.4 Primary haemostasis    
1.4.1 Platelet adhesion 
Adhesive interactions between exposed extracellular matrix (ECM) components, such as 
collagen-bound von Willebrand factor (VWF), collagen, fibronectin, laminin and 
thrombospondin, and receptors on the surface of platelets, including the glycoprotein 1b-
IX-V (GP1b-IX-V) complex, glycoprotein VI (GPVI) and integrins α2β1, α2β3 and α6β1, are 
generally responsible for initiating thrombus formation at sites of endothelial injury (Figure 
and Table 1.1) (Gale et al., 2011; Rivera et al., 2009). These primary adhesions can be seen to 
vary with the rheological conditions (Jackson et al., 2003; Rivera et al., 2009; Savage et al., 
1998). At low shear rates, such as in larger arteries and veins, platelet interactions with 
denuded subendothelial collagen, fibronectin and laminin are primarily responsible for 
platelet tethering (Jackson et al., 2003; Savage et al., 1998). However, at high shear rates, for 
example in stenotic arteries and the microvasculature, platelet adhesion becomes more or less 
reliant on collagen-bound VWF. Under these hemodynamic conditions, transient VWF 
interactions help to decelerate the platelets, enabling firm bonds with slower binding kinetics 
to form (e.g. collagen with GPVI or integrin α2β1) (Jackson et al., 2003; Savage et al., 1998). 
High affinity interactions between VWF and the GP1bα domain of the GP1b-IX-V complex 
only occur when VWF is immobilized on the ECM (Gale et al., 2011; Schneider et al., 2007; 
Rivera et al., 2009; Wohner et al., 2012). This is because high levels of shear stress, 
generated by blood flow over tethered VWF, are required to extend the multimeric 
glycoprotein and thus reveal it’s platelet-binding A1 domain (Gale et al., 2011; Schneider et 
al., 2007; Rivera et al., 2009; Wohner et al., 2012). The inability of soluble/unbound VWF to 
make high affinity interactions with platelets helps to prevent unnecessary 
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adhesions/aggregations under normal circulatory conditions (Gale et al., 2011; Rivera et al., 
2009).   
 
ECM components Receptors on the platelet surface 
Collagen-bound VWF GP1b-IX-V complex 
Collagen GP1b-IX-V complex, GPVI or integrin 
α2β1 
Fibronectin Integrin α2β3 
Laminin Integrin α6β1 
Thrombospondin GP1b-IX-V complex 
Table 1.1: Primary adhesions 
 
1.4.2 Platelet activation 
The importance of the interaction between VWF and the GP1b-IX-V complex in platelet 
adhesion has been clearly defined, but its involvement in platelet activation still remains a 
controversial topic. Some research groups have detected weak activating signals downstream 
of VWF-GP1b-IX-V binding, whilst other groups have demonstrated that the GP1b-IX-V 
complex lacks signalling ability under the above conditions (Jackson et al., 2003). 
Nonetheless, the interaction between collagen and the constitutively active platelet collagen 
receptor, GPVI, has been shown to play an important role in early platelet activation (Gale et 
al., 2011; Mazzucato et al., 2009). As depicted in Figure 1.2, scaffold molecules and protein 
tyrosine kinases associated with GPVI activate phospholipase C γ2 (PLCγ2), following 
collagen binding (Stalker et al., 2012). The activated enzyme subsequently hydrolyses 
membrane phosphatidylinositol-4,5-bisphosphate (PIP2) to produce second messenger’s 
inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (Jin et al., 2005; Stalker et al., 
2012). Next, IP3 bind receptors on the calcium (Ca2+) storage site. This interaction initiates 
Ca2+ efflux from the dense tubular system and thus causes platelet cytosolic Ca2+ 
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concentration to increase from ~0.1µM in resting platelets to >1µM in activated platelets (Jin 
et al., 2005; Stalker et al., 2012). An increase in intracellular Ca2+ is essential for platelet 
activation and aggregation due to its association with: 1) the activation of kinases required for 
platelet morphological change, such as spreading, 2) the secretion of platelet granular 
content, including adenosine diphosphate (ADP) and serotonin (5HT) (Section 1.4.2.1), 3) the 
activation of phospholipase A2 (PLA2; Section 1.4.2.2), 4) the activation of glycoproteins, 
such as integrins αIIbβ3 and α2β1 (Section 1.4.3), and 5) the presentation of a procoagulant 
surface (Section 1.5) (Jin et al., 2005; Rivera et al., 2009; Sangkuhl et al., 2011; Shin et al., 
2017). 
 
Once a monolayer of activated cells has been deposited over the exposed collagen, additional 
platelets from the flowing blood are recruited to the injury site (Rivera et al., 2009). Recruited 
platelets are predominantly activated by soluble agonists, such as ADP (Section 1.4.2.1), 
Thromboxane A2 (TXA2; Section 1.4.2.2), thrombin (Section 1.4.2.3) and cathepsin G 
(Section 1.4.2.4), which readily bind to and stimulate G-protein coupled receptors (GPCRs) 
on their surface (Figure 1.1 and 1.2) (Jackson et al., 2003; Rivera et al., 2009). Activation of 
GPCRs then promotes the exchange of guanosine diphosphate (GDP) for guanosine 
triphosphate (GTP) (the rate-limiting step in guanine nucleotide-binding protein (G-protein) 
activation), which then causes the associated G proteins (Giα, Gqα or G12α/G13α) to 
dissociate from the receptor and thus act on a wide range of effectors (Offermanns, 2006). In 
platelets, the co-ordinated action of soluble agonists on GPCRs brings about a number of 
effects, including: 1) phospholipase C β (PLCβ) stimulation (via Gqα) leading to increases in 
cytosolic Ca2+ concentration and protein kinase C (PKC) activation, 2) p115-Rho guanine 
nucleotide exchange factor (p115-RhoGEF) stimulation (via G12α/G13α) resulting in actin 
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skeleton reorganisation and platelet shape change, and 3) inhibition of adenylyl cyclase (AC) 
(via Giα) leading to reductions in second messenger cyclic adenosine monophosphate 
(cAMP) production (Section 1.6.2) (Figure 1.2) (Offermanns, 2006; Rivera et al., 2009; 
Woulfe et al., 2004). Activated PKC also stimulates granule secretion, whilst morphological 
platelet changes facilitate the recruitment of additional platelets and neutrophils to the wound 
site (Offermanns, 2006; Rivera et al., 2009).  
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Figure 1.2: Receptor-mediated platelet activation 
Platelet activation primarily results from the stimulation of second messenger cascades by 
receptor-agonist binding. Upon collagen binding, the platelet surface glycoprotein VI 
(GPVI) receptor activates phospholipase C γ2 (PLCγ2) though associated scaffold 
molecules/protein tyrosine kinases. Activated PLCγ2 hydrolyses membrane 
phosphatidylinositol-4,5-bisphosphate (PIP2) to produce second messenger’s inositol-
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which then mediate separate 
activation pathways. IP3 interacts with receptors on the calcium (Ca2+) storage site to 
cause Ca2+ efflux and thus increase the cytosolic Ca2+ concentration. Free Ca2+ stimulates 
platelets by triggering the secretion of platelet granular content and by activating: i) 
kinases necessary for platelet morphological change, ii) phospholipase A2 (PLA2) 
enzymes of the thromboxane (TXA2) production pathway, and iii) glycoproteins essential 
for platelet aggregation. PLA2 is also activated by mitogen-activated protein kinase 
(MAPK) pathway signalling, whilst DAG-stimulated protein kinase C (PKC) contributes 
to granule release. Soluble agonists primarily activate G-protein coupled receptors 
(GPCRs) on the platelet surface. ADP activates purinergic receptors (P2Y1 and P2Y12), 
whilst TXA2 stimulates thromboxane prostanoid (TP) receptors, and thrombin triggers 
protease activated receptors (PAR-1 and PAR-4)/the glycoprotein 1b (GP1b)-IX-V 
complex. Gqα-coupled receptors (e.g. P2Y1, TP, PAR-1 and PAR-4) stimulate 
phospholipase C β (PLCβ) to bring about increases in cytosolic Ca2+ concentration, whilst 
G12α/G13α-coupled receptors (e.g. TP, PAR-1 and PAR-4) activate guanine nucleotide 
exchange factors to cause cytoskeletal reorganisations. Adenylyl cyclase (AC) activity, 
and therefore cyclic adenosine monophosphate (cAMP) production, is inhibited by Giα-
coupled receptors (e.g. P2Y12, PAR-1). (Adapted from Jin et al., 2005) 
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1.4.2.1 ADP and 5HT 
The soluble agonist ADP is secreted from δ-granules following platelet activation by collagen 
and/or soluble agonists (Michelson, 2010). Erythrocytes have also been shown to release 
ADP when in close association with vascular injury. ADP readily binds to purinergic GPCRs, 
P2Y1 (coupled with Gqα) and P2Y12 (coupled with Giα), on the surface of platelets (Gachet, 
2008). These interactions lead to a full range of platelet activation events, such as increases in 
cytosolic Ca2+ concentration, protein phosphorylation, shape change, integrin αIIbβ3 
activation, TXA2 synthesis and granule secretion (Figure 2.2) (Gachet, 2008; Rivera et al., 
2009). In addition, ADP also binds to P2X1 receptors on the platelet surface. These ATP-
gated non-selective ion channels, positively regulate collagen-induced platelet responses 
through their ability to facilitate Ca2+ influx and thus further increase the cytosolic Ca2+ 
concentration (Mahaut-Smith et al., 2011). Additionally, 5HT is also released from platelet δ-
granules. 5HT contributes to platelet activation through its action on 5HT2A receptors (Gale et 
al., 2011).  
 
1.4.2.2 TXA2 
Platelet activation also triggers synthesis of the prostanoid TXA2 in platelets. PLA2 is an 
enzyme which liberates arachidonic acid (AA) from membrane phospholipids and is 
activated by increases in cytosolic Ca2+ concentration and/or mitogen-activated protein kinase 
(MAPK) pathway signalling (Figure 2.2) (Balsinde et al., 2002; Stalker et al., 2012). 
Released AA is metabolised by constitutively active cyclooxygenase-1 (COX-1) enzymes to 
form intermediate compounds, endoperoxides PGG2 and PGH2. Thromboxane sythetase is 
responsible for converting PGH2 to the platelet agonist TXA2 (Rivera et al., 2009; Stalker et 
al., 2012). Once produced, TXA2 is released into the bloodstream, where it acts on 
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thromboxane prostanoid (TP) receptors (coupled to Gqα and G13α) on the platelet surface to 
bring about platelet activation events (Figure 2.2) (Rivera et al., 2009).  
 
1.4.2.3  Thrombin 
 
The serine protease thrombin is produced on the procoagulant surface of activated platelets. 
In addition to its essential role in the coagulation cascade (Section 1.5), thrombin also cleaves 
protease activated receptors (PARs) on the platelet surface, PAR-1 (coupled to Gqα, Giα and 
G12/13α) and PAR-4 (coupled to Gqα and G12/13α), to cause a full range of platelet 
activation events (Figure 2.2) (Gale et al., 2011; Rivera et al., 2009). Due to its high potency 
(thrombin concentrations as low as 0.1nM can be seen to activate platelets) and the efficient 
coupling observed between the PARs and PLCβ, thrombin is considered to be one of the 
most effective platelet activators (Rivera et al., 2009). Furthermore, the GP1bα domain of the 
GP1b-IX-V complex can also form high affinity bonds with thrombin. These thrombin-
GP1b-IX-V complex interactions, which account for ~80-90% of the total protease that binds 
to platelets, can also provoke a full range of platelet activation events (Celikel et al., 2003; 
Dumas et al., 2003; Mazzucato et al., 1998). 
 
1.4.2.4 Polymorphonuclear leukocytes 
Recruited polymorphonuclear leukocytes (PMN) can also activate platelets (Sambrano et al., 
2000; Zarbock et al., 2007). Platelet-PMN adhesions are generally initiated by adhesions 
between the platelet surface protein P-selectin, which is released from α-granules and 
subsequently expressed on the platelet surface following platelet activation, and P-selectin 
glycoprotein ligand 1 (PSGL1) on the surface of PMNs (Zarbock et al., 2007). This 
interaction subsequently facilitates the release of cathepsin G from PMNs, which in turn acts 
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on PAR-4 receptors to bring about platelet activation (Figure 2.2) (Sambrano et al., 2000; 
Zarbock et al., 2007).  
 
1.4.3 Platelet aggregation 
Following platelet activation, platelet-platelet adhesions can then form, and this process is 
known as “platelet aggregation”. Platelet aggregation is primarily mediated by the binding of 
integrin αIIbβ3 to fibrinogen, however at high shear rates, interactions between VWF and 
integrin αIIbβ3 also contribute to this process (Figure 1.1) (Jackson et al., 2003; Rivera et al., 
2009). Before facilitating platelet-platelet adhesions, integrin αIIbβ3 must undergo activation 
mediated by the cytoskeletal protein talin (Michelson, 2010; Rivera et al., 2009). Once 
stimulated by platelet activation events (e.g. increases in cytosolic Ca2+ concentration), talin 
interacts with the β3 cytoplasmic domain of integrin αIIbβ3, promoting the dissociation of the 
cytoplasmic tail/transmembrane domains of the αIIb and β3 subunits. This conformation 
change is required for αIIbβ3 activation and subsequent fibrinogen binding (Michelson, 2010; 
Rivera et al., 2009). Activated integrin αIIbβ3 also binds to other ligands which promote 
platelet aggregation, including collagen, VWF, fibronectin and vitronectin (Gale et al., 2011). 
 
The developing thrombus is then stabilised by a late wave of signalling though integrins, 
junctional adhesion molecules (JAMs) and receptor tyrosine kinases (RTKs), and by the 
addition of insoluble fibrin to the aggregate (Section 1.5) (Rivera et al., 2009). This last-
minute signalling leads to a host of events that are crucial for thrombus development, 
including cytoskeleton reorganisation, the formation/stabilisation of large aggregates, clot 
retraction, and the establishment of a procoagulant surface (Section 1.5) (Watson et al., 2005; 
Woulfe et al., 2004). 
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1.5 Secondary haemostasis  
Secondary haemostasis is a process that occurs simultaneously to platelet aggregation and 
describes the involvement of the coagulation cascade in thrombus formation (Gale et al., 
2011). Briefly, the coagulation cascade contains a number of serine proteases or factors, 
which interact to generate thrombin (Figure 1.3) (Walker and Royston, 2002). Once 
activated, thrombin readily cleaves fibrinogen to form insoluble fibrin strands (Walker and 
Royston, 2002; Mackman, 2009). These fibrin strands then bind to a number of receptors on 
the platelet surface, such as vascular endothelial-cadherin (VEC), inter-cellular adhesion 
molecule-1 (ICAM-1) and integrins αIIbβ3/αvb3 (Litvinov et al., 2016; Yokoyama et al., 
1999). Deposition of a cross-linked fibrin mesh helps to support the developing platelet plug 
at sites of vascular injury, in addition to stabilising thrombi and preventing premature 
disaggregation in conditions of high shear (Walker and Royston, 2002). 
 
The coagulation cascade is activated through two different pathways: 1) the extrinsic/tissue 
factor pathway and 2) the intrinsic/contact pathway (Figure 1.3) (Walker and Royston, 2002; 
Mackman, 2009). Both pathways converge to activate factor X and factor V, which 
subsequently combine to form prothrombinase complexes on the surface of platelets. These 
complexes function to catalyse the conversion of prothrombin to active thrombin, and 
together with thrombin comprise the common pathway (Figure 1.3) (Walker and Royston, 
2002). The extrinsic pathway of activation is stimulated by the interactions between tissue 
factor (TF) (expressed in subendothelial tissue) and factor VII (Kirchhofer and Nemerson, 
1996), which in turn leads to the activation of other factors that induce the production of 
small quantities of thrombin (Gale et al., 2011; Mackman, 2009). In contrast, the intrinsic 
pathway is activated by thrombin’s actions on factor XII (Mackman, 2009). This pathway 
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utilises phospholipid surfaces, such as the exterior of activated platelets, to facilitate a 
cascade of zymogen conversions, which subsequently trigger the common pathway to 
significantly increase thrombin generation/positively regulate coagulation (Figure 1.3) (Gale 
et al., 2011; Mackman, 2009). 
 
 
 
 
 
 
 
 
 
Figure 1.3: Coagulation cascade 
The coagulation cascade is divided into three pathways: the extrinsic, intrinsic and 
common pathways. Firstly, the extrinsic pathway of activation is stimulated by the 
interactions between tissue factor (TF) and factor VII. Resultant TF/VIIa complexes 
activate factor X to Xa, hence triggering the common pathway and the production of small 
quantities of thrombin. The intrinsic pathway however, is stimulated by thrombin’s 
actions on factor XII. The activation of factor XII to XIIa by thrombin leads to a cascade 
of factor stimulation (e.g. XI to XIa and IX to IXa). Once activated, factor IX then acts 
with its cofactor (factor VIII) to form tenase complexes, which activate factor X and 
hence stimulate the common pathway. Activation of the intrinsic pathway significantly 
increases thrombin production. Lastly, the common pathway consists of prothrombinase 
complexes, which form when factor Xa and Va combine on the surface of platelets, and 
thrombin. Prothrombinase complexes function to catalyse the conversion of prothrombin 
to active thrombin, which then cleaves fibrinogen to form insoluble fibrin strands. 
Deposition of a cross-linked fibrin mesh helps to support the developing platelet plug at 
sites of vascular injury. (Adapted from Gale et al., 2011) 
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1.6 Negative regulators of haemostasis 
Under normal physiological conditions, thrombus growth and stability are also regulated by a 
number of inhibitory signals (Rivera et al., 2009; Stalker et al., 2012). Whilst restricting 
ECM-mediated platelet activation through its action as a physical barrier, the vascular 
endothelium also produces a number of these platelet inhibitors, including: 1) NO, 2) 
prostacyclin (PGI2), 3) ectonucleotidase CD39, 4) tissue factor pathway inhibitor, and 5) 
protein C (Jin et al., 2005; Stalker et al., 2012; Walker and Royston, 2002). Herein, only NO 
will be discussed in any further detail, due to the focus of this research project on NO 
impairment in HFpEF. 
 
1.7 Nitric oxide 
NO plays an important role in cardiovascular homeostasis (Förstermann and Sessa, 2012; 
Gkaliagkousi and Ferro, 2011). NO diffuses across membranes and interacts with a number 
of intracellular targets to induce various effects, such as regulating blood pressure, cardiac 
function and the inhibition of platelet aggregation (Gkaliagkousi and Ferro, 2011; Moncada 
et al., 1991). NO is highly unstable in the presence of oxygen (O2), as it is rapidly converted 
to nitrogen dioxide (NO2), and has an extremely short half-life (~5 seconds) in biological 
fluids (Gkaliagkousi and Ferro, 2011).  
 
1.7.1 Nitric oxide synthase 
 
Under normal physiological conditions, NO is produced by a family of nitric oxide synthase 
(NOS) enzymes (Förstermann and Sessa, 2012; Gkaliagkousi and Ferro, 2011). These 
enzymes produce NO via the ‘classical pathway’ by utilising the substrate L-arginine, oxygen 
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and a reduced co-substrate, nicotinamide adenine dinucleotide phosphate (NADPH) (Palmer 
et al., 1988). There are three different NOS enzyme isoforms: 1) endothelial NOS (eNOS or 
NOS III), 2) neuronal NOS (nNOS or NOS I) and 3) inducible NOS (iNOS or NOS II) (Feng 
and Tollin, 2009; Förstermann and Sessa, 2012; Gkaliagkousi and Ferro, 2011). eNOS and 
iNOS are both expressed by endothelial cells and platelets, whilst nNOS is present in the 
central nervous system, spinal cord, sympathetic ganglia, adrenal glands and peripheral 
“nitroxidergic” (non-adrenergic and non-cholinergic) neurones (Förstermann and Sessa, 
2012; Gkaliagkousi and Ferro, 2011; Randriamboavonjy and Fleming, 2005; Naseem and 
Riba, 2008). iNOS is produced by various other cell types, including macrophages, 
neutrophils, smooth muscle cells, cardiomyocytes, hepatocytes and chondrocytes (Soskić et 
al., 2011). Both eNOS and nNOS are constitutively expressed in cells and synthesise NO in 
response to increased intracellular Ca2+ concentrations, whereas cellular iNOS production is 
triggered by cytokines and other inflammatory mediators (e.g. lipopolysaccharides) (Palmer 
et al., 1988).  
 
1.7.1.1 Endothelial nitric oxide synthase 
eNOS-derived NO is considered to be the most important inhibitor of platelet aggregation. 
Endothelial cells and platelets express identical eNOS enzymes, however significantly more 
NO is produced by the vascular endothelium (Radomski et al., 1990). eNOS enzymes 
typically function as a dimer and are comprised of two identical monomers (Feng and Tollin, 
2009; Förstermann and Sessa, 2012; Gkaliagkousi and Ferro, 2011). Each monomer contains 
a C-terminal reductase domain and a N-terminal oxygenase domain connected through a 
Ca2+-calmodulin (CaM) binding domain, which reversibly binds CaM with increases in 
intracellular Ca2+ concentration (Feng and Tollin, 2009; Förstermann and Sessa, 2012; 
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Gkaliagkousi and Ferro, 2011). Binding sites for NADPH and the cofactors flavin adenine 
dinucleotide (FAD)/flavin mononucleotide (FMN) are located on the reductase domain, 
whilst haem, L-arginine and the cofactor tetrahydrobiopterin (BH4) interact with the 
oxygenase domain (Feng and Tollin, 2009; Förstermann and Sessa, 2012). In functional 
eNOS enzymes, electrons are transferred from NADPH in one monomer to the haem site in 
the adjacent monomer, via cofactors FAD and FMN (Förstermann and Sessa, 2012; 
Gkaliagkousi and Ferro, 2011). The formation of eNOS dimers and subsequent interdomain 
electron transfer, only occurs in the presence of haem (Feng and Tollin, 2009; Förstermann 
and Sessa, 2012). Once sufficient L-arginine and BH4 have bound to eNOS, the electrons at 
the haem site reduce/activate O2 and oxidise L-arginine to form NO. L-arginine oxidation is a 
two-stage process, in which L-arginine is transformed into the intermediate, Nω-hydroxy-L-
arginine, before being converted into NO (Förstermann and Sessa, 2012). L-citrulline is also 
formed as a by-product of this process (Förstermann and Sessa, 2012; Gkaliagkousi and 
Ferro, 2011).  
 
Stimuli that trigger increases in intracellular Ca2+ concentration, such as autacoids (e.g. 
histamine), hormones (e.g. vasopressin and catecholamines) and platelet-derived factors (e.g. 
ADP, 5HT and thrombin), activate eNOS constitutively expressed in endothelial cells and 
platelets (Busse and Mülsch, 1990; Gkaliagkousi and Ferro, 2011). eNOS stimulation can 
also be brought about by Ca2+-insensitive manners (Gkaliagkousi and Ferro, 2011). For 
example, the activation of phosphatidylinositol-3-kinase (PI3K) and its downstream kinase 
protein kinase B (Akt), by shear stress, vascular endothelial growth factor (VEGF), 
oestrogen, bradykinin, insulin or hydrogen peroxide, also leads to the phosphorylation and 
stimulation of eNOS (Dimmeler et al., 1999; Fulton et al., 1999; Gkaliagkousi and Ferro, 
 
 
23 
 
2011). Akt-mediated eNOS activation occurs at basal intracellular Ca2+ concentrations due to 
the rise in the Ca2+ sensitivity of the CaM-dependent enzyme (eNOS) following 
phosphorylation (Gkaliagkousi and Ferro, 2011). Furthermore, eNOS is also phosphorylated 
by other kinases, such as cAMP-dependent protein kinase and protein kinase A (PKA), which 
following their activation by shear stress, VEGF, catecholamines, bradykinin or ATP, in turn 
increase NO production. In contrast, PKC and AMP-activated protein kinase (AMPK) reduce 
eNOS activity to attenuate NO synthesis (Fleming et al., 2001; Gkaliagkousi and Ferro, 2011; 
Loot et al., 2009). 
 
1.7.2 The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine 
monophosphate (cGMP)-protein kinase G (PKG) signalling cascade in platelets  
eNOS-derived NO activates the haem-containing cytosolic receptor, soluble guanylate 
cyclase (sGC) (Gkaliagkousi and Ferro, 2011; Naseem and Riba, 2008). Once activated, sGC 
then synthesises cyclic guanosine monophosphate (cGMP) from GTP (Gkaliagkousi and 
Ferro, 2011). In platelets, cGMP decreases cytosolic Ca2+ concentration, predominantly 
through its principle mediator cGMP-dependent protein kinase/protein kinase G (PKG), to 
inhibit platelet aggregation. Activation of the NO-sGC-cGMP-PKG signalling cascade brings 
about these reductions in platelet cytosolic Ca2+ concentration by activating the 
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) pumps, whilst inhibiting IP3 receptors 
on the on the Ca2+ storage site (Gkaliagkousi and Ferro, 2011; Rao et al., 1990; Trepakova et 
al., 1999).  
 
Furthermore, stimulation of the platelet NO-sGC-cGMP-PKG signalling cascade prevents 
platelet aggregation in a number of additional ways (Gkaliagkousi and Ferro, 2011). Firstly, 
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cGMP is known to inhibit the activation of PI3K in platelets (Gkaliagkousi and Ferro, 2011; 
Pigazzi et al., 1999). Since PI3K has recently been shown to stimulate integrin αIIbβ3 on the 
platelet surface, cGMP’s actions on this kinase helps to inhibit platelet aggregation by 
preventing adhesions between integrin αIIbβ3 and fibrinogen (Gkaliagkousi and Ferro, 2011). 
Moreover, cGMP also indirectly upregulates platelet cytosolic cAMP levels by inhibiting the 
enzyme phosphodiesterase type 3 (PDE-3), which functions to catalyse cAMP hydrolysis 
(Gkaliagkousi and Ferro, 2011; Gresele et al., 2011; Naseem and Riba, 2008). The 
subsequent rise in cAMP, enables the second messenger to work synergistically with cGMP 
to prevent platelet aggregation (Gkaliagkousi and Ferro, 2011; Naseem and Riba, 2008). 
cAMP produced by activated AC readily stimulates PKA, which in turn acts on numerous 
target proteins to reduce cytosolic Ca2+ concentration (den Dekker et al., 2002; Schwarz et al., 
2001). Activated PKA/PKG also phosphorylate numerous downstream targets, such as TP 
receptors and vasodilator stimulated phosphoprotein (VASP), to further blunt the platelet 
activation response (den Dekker et al., 2002; Gkaliagkousi and Ferro, 2011; Naseem and 
Riba, 2008; Schwarz et al., 2001). Following phosphorylation, TP receptors uncouple from 
their associated G proteins (Wang et al., 1998). This disruption to receptor function/TXA2-
mediated platelet activation contributes to the prevention of platelet aggregation 
(Gkaliagkousi and Ferro, 2011; Wang et al., 1998). Moreover, phosphorylation of VASP at 
Ser157 (PKA substrate) and Ser239 (PKG substrate), also dampens the platelet activation 
response (den Dekker et al., 2002; Naseem and Riba, 2008; Lohmann et al., 1997; Schwarz et 
al., 2001; Wentworth et al., 2006). Many research groups have demonstrated that 
phosphorylated VASP negatively regulates platelet activation, but the precise mechanism(s) 
remain unclear (Benz et al., 2016; Wentworth et al., 2006). Finally, phosphorylation of PDE-
5 enzymes, which function to hydrolyse cGMP, and IP3 receptors by PKA also helps to 
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inhibit platelet aggregation (den Dekker et al., 2002; Gresele et al., 2011; Schwarz et al., 
2001).  
 
1.7.3 Nitrosation and nitration in platelets  
Recent evidence suggests that NO may also mediate platelet function through cGMP-
dependent and -independent pathways, involving protein nitrosation (Gkaliagkousi and Ferro, 
2011; Naseem and Riba, 2008). Firstly, protein cysteine thiol groups (-SH) readily react with 
NO derivatives (e.g. N2O3) to produce nitrosothiols (Naseem and Riba, 2008). This 
nitrosation process is both ubiquitous and reversible, and primarily functions to protect NO 
from inactivation whilst in the blood (Naseem and Riba, 2008; Stamler et al., 1992). 
Circulating NO is transported as either protein or non-protein S-nitrosothiols (SNOs) (e.g. S-
nitroso-albumin, S-nitrosocysteine and S-nitroso-N-acetylpenicillamine), which release NO 
according to its availability and/or the oxidative status of the plasma (Rassaf et al., 2002). A 
number of enzymes and transporters, including membrane-bound protein disulfide isomerase, 
have been shown to deliver SNO-released NO into the platelet cytosol (Bell et al., 2007; 
Essex et al., 1995; Kleinbongard et al., 2006). These interactions facilitate intraplatelet NO 
accumulation and therefore the activation of the NO-sGC-cGMP-PKG pathway (Bell et al., 
2007). The cGMP-dependent effects of these NO donors have been demonstrated in a number 
of experimental models and small clinical trials (Kaposzta et al., 2001; Scatena et al., 2005). 
For example, a reduction in markers of platelet activation (e.g. P-selectin and integrin 
αIIbβ3), neutrophil stimulation and asymptomatic embolisms have all been observed 
following S-nitrosoglutathione (GSNO) treatment (Kaposzta et al., 2001; Langford et al., 
1994; Salas et al., 1998; Scatena et al., 2005; Ramsay et al., 1995). GSNO has also been 
identified as the most potent platelet inhibitor (Scatena et al., 2005).  
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Moreover, nitrosation of key thiol groups has also been shown to directly modulate the 
function of many proteins implicated in platelet activation and aggregation (Gkaliagkousi and 
Ferro, 2011; Naseem and Riba, 2008). For instance, S-nitrosation of N-ethylmaleimide-
sensitive factor (NSF) and integrin αIIbβ3 in platelets, prevents platelet granule secretion and 
inhibits platelet-platelet adhesions, respectively (Naseem and Riba, 2008; Morrell et al., 
2005; Walsh et al., 2007). S-nitrosation of NSF also indirectly inhibits platelet 
aggregation/thrombus formation by preventing the release of mediators that promote platelet, 
endothelial cell and leucocyte interactions (Gkaliagkousi and Ferro, 2011). Furthermore, S-
nitrosation of the enzyme complex NADPH oxidase reduces superoxide (O2-) production 
(Gkaliagkousi and Ferro; Selemidis et al., 2007). Since BH4 is rapidly oxidised by O2-, this 
nitrosation event helps to maintain cofactor availability, thereby preventing the uncoupling of 
eNOS and the production of O2- by the enzyme (Mueller et al., 2005; Selemidis et al., 2007). 
 
Finally, irreversible protein nitration also mediates platelet function through cGMP-
independent pathways (Gkaliagkousi and Ferro, 2011; Naseem and Riba, 2008). Nitration of 
amino acids containing phenolic rings (e.g. tyrosine) by the reactive oxidant peroxynitrite 
(ONOO-) has been shown to inhibit platelet aggregation (Gkaliagkousi and Ferro, 2011). 
These modifications have been linked to the inhibition of COX-1 enzymes and a reduction in 
platelet surface receptors that interact with collagen and TXA2 (Boulos et al., 2000; Olas and 
Wachowicz, 2007). 
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1.7.4 The biphasic role of nitric oxide in platelets 
Although NO has been shown to inhibit platelet aggregation by numerous research groups, 
recent in vivo studies have demonstrated that platelet eNOS also activates platelets and 
promotes thrombosis in response to low-dose platelet agonists, such as ADP (Marjanovic et 
al., 2005). The NO-sGC-cGMP-PKG pathway plays an important role in eNOS-mediated 
platelet activation, whereby increases in cytosolic cGMP stimulates platelet granule secretion, 
leading to subsequent platelet activation (Li et al., 2003; Marjanovic et al., 2005; Stojanovic 
et al., 2006). It has therefore been suggested that NO plays a dual role in platelet function, 
with low concentrations of NO (e.g. NO produced by platelet eNOS) stimulating platelets and 
higher concentrations of NO (e.g. NO generated by the endothelial eNOS) inhibiting platelet 
activation and aggregation (Marjanovic et al., 2005). A few research groups however, 
disagree with this new hypothesis. These scientists question how NO derived from platelet 
eNOS can be activatory due to the fact that circulating platelets are continually exposed to the 
high concentrations of NO synthesised by endothelial eNOS (Naseem and Riba, 2008). 
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1.8 Platelet dysfunction in cardiovascular disease  
 
Platelets play an essential role in cardiovascular thrombosis, and a rise in pro-aggregatory 
stimuli (e.g. fibrinogen, vWF, P-selectin and noradrenaline) and/or fall in anti-aggregatory 
substances, such as NO, is often observed during CVD (Chirkov and Horowitz, 2007; Chung 
and Lip, 2006; Michelson, 2010; Willoughby et al., 2002). As such, therapies that target key 
pathways of platelet activation and/or boost the levels of anti-aggregatory substances within 
the bloodstream are frequently used to prevent hyperaggregability and thrombosis in CVD 
(Michelson, 2010). NO impairment in HF will now be addressed, before moving onto current 
and potential treatment avenues for this disease state.  
 
1.8.1 Nitric oxide bioavailability and oxidative stress in heart failure  
 
It is estimated that the incidence of embolism and stroke is >9 times greater in HF patients 
when compared to the general population of the same age group, due to the association of HF 
with endothelial dysfunction and platelet abnormalities (Bauersachs and Widder, 2008; 
Chirkov and Horowitz, 2007; Chung and Lip, 2006). Diminished NO bioavailability has been 
reported in the coronary and peripheral vessels of both HFpEF and HFrEF patients (Fischer et 
al., 2005; López Farré and Casado, 2001; Yamamoto et al., 2015), whilst has also been 
shown to impair flow-mediated vasodilation in patients with both ischaemic and non-
ischaemic etiologies of HF (Shantsila et al., 2012). This reduction in NO bioavailability 
results from a number of factors, including decreased eNOS expression, diminished arginine 
availability, up-regulation of asymmetric dimethylarginine (ADMA; an endogenous eNOS 
inhibitor) and/or the overproduction of reactive oxygen species (ROS) (Bauersachs and 
Widder, 2008; Comini et al., 1996; López Farré and Casado, 2001; Smith et al; 1996). 
Interestingly, numerous studies have also linked reductions in NO bioavailability to 
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impairments in myocardial perfusion, exercise intolerance, left ventricular remodelling, 
platelet activation and thrombogenesis in patients with HF (Chung and Lip, 2006; Fischer et 
al., 2005; López Farré and Casado, 2001).   
 
Oxidative stress occurs when ROS production (e.g. O2-, hydrogen peroxide (H2O2) and 
hydroxyl radical (OH-)) exceeds the capacity of the antioxidant defence systems (e.g. 
superoxide dismutase (SOD), catalase and glutathione), that function to scavenge and 
inactivate harmful ROS. For instance, SOD catalyses the breakdown O2- into H2O2 and O2, 
whilst catalase and glutathione promote the decomposition of H2O2 into H2O and O2 
(Förstermann, 2008). Numerous HFpEF and HFrEF studies have reported enhanced levels of 
O2- production (Hiebert et al., 2016). Under these conditions, O2- reacts rapidly with NO, 
causing substantial reductions in NO bioavailability and the formation of the ONOO- 
(Arimura et al., 2001; Bauersachs et al., 2001; Bauersachs and Widder, 2008). Several 
enzymes, such as NADPH oxidase, xanthine oxidase, uncoupled eNOS and enzymes of the 
mitochondrial respiratory chain are capable of producing O2- and have been linked with 
oxidative stress in HF (Bauersachs and Widder, 2008; Mueller et al., 2005).  
 
As mentioned above, eNOS function is compromised in both HFpEF and HFrEF (Yamamoto 
et al., 2015). In conditions of oxidative stress, the flow of electrons between the eNOS 
domains uncouples from NO generation, thus leading to the production of O2- and ONOO- in 
place of NO (Bailey et al., 2014; Förstermann, 2008). ONOO- subsequently exacerbates 
oxidative stress in HF by oxidising/depleting BH4 reserves, and thus promoting the 
uncoupling of eNOS dimers into single dysfunctional monomers (Abudukadier et al., 2013; 
Bailey et al., 2014; Bendall et al., 2005).  
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1.8.2 Chronic atrial fibrillation in heart failure  
 
CAF, which also represents a major cause of morbidity/mortality in the ageing global 
population, often coexists with HFpEF (~40%) and HFrEF (~35%) (Lam et al., 2017; Linssen 
et al., 2011; Procter et al., 2015; Sartipy et al., 2017). As with HF, patients with CAF are 
associated with intra-arterial thrombosis and thromboembolism (Procter et al., 2015). Procter 
and colleagues have also recently reported platelet hyperaggregability, in part resulting from 
impaired NO signalling, in patients with early onset AF (Procter et al., 2015).  
 
1.9 Treatment for heart failure  
1.9.1 Nitric oxide donors and ‘NO resistance’ 
Organic nitrates (e.g. glyceryl trinitrate (GTN)) are currently used to treat angina, MI and HF 
(Bailey et al., 2014; MacAllister, 2000). These NO donors rapidly improve reductions of NO 
bioavailability observed in patients with HF, but tolerance to these nitrates remains a 
persisting therapeutic problem (MacAllister, 2000). A number of studies have demonstrated 
that both the platelets and vasculature from HF patients exhibit reduced responsiveness to NO 
donors, such as GTN and sodium nitroprusside (SNP), a phenomenon referred to as ‘NO 
resistance’ (Anderson et al., 2004; Chirkov and Horowitz, 2007; Rajendran and Chirkov, 
2008). ALDH2 is considered to be the principle enzyme responsible for vascular GTN 
bioactivation and NO release (Li et al., 2006; Mackenzie et al., 2005). However, following 
prolonged GTN exposure, depletion of ALDH2 reductant/s and subsequent oxidative 
inactivation of ALDH2 by O2- and ONOO-, is thought to contribute to vascular GTN 
tolerance and thus ‘vascular NO resistance’ (Chen et al., 2005; Daiber and Münzel, 2015; 
D’Souza et al., 2011; Mayer and Beretta, 2008). The mechanism(s) behind “platelet NO 
resistance” remain less defined, but it has been postulated that reversible inactivation of sGC 
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and/or NO ‘scavenging’ by O2- are associated with this phenomenon (Anderson et al., 2004; 
Rajendran and Chirkov, 2008).  
 
1.9.2 Nitrite as a potential substitute for nitric oxide donors 
Nitrite is currently being investigated with the potential of becoming a novel therapeutic 
agent for many CVDs, including HF and ischaemic heart disease (Borlaug et al., 2015; 
Calvert and Lefer, 2009; Kevil and Patel, 2010). The physiological importance of nitrite and 
its precursor nitrate, which were previously considered to be biologically inert metabolic by-
products of NO, was revealed following the recent discovery of the ‘nitrate-nitrite-NO 
pathway’ (Bailey et al., 2014; Borlaug et al., 2016; Lundberg et al., 2008). Nitrite therapy is 
not associated with the development of tolerance and has been shown to have 
cardioprotective, anti-aggregatory, anti-hypertensive and anti-apoptotic effects in various 
experimental models (Bailey et al., 2014; Borlaug et al., 2016). These protective effects have 
been shown during hypoxic and acidic conditions, and very recently it has been proposed that 
nitrite may also mediate beneficial effects during normoxic conditions via an alternative 
mechanism (Borgognone et al., 2015; Omar et al., 2015).  
 
1.9.2.1 Nitrite during hypoxic and acidic conditions 
Under hypoxic and acidic conditions, nitrite produces NO via a NOS- and O2-independent 
pathway known as the ‘nitrate-nitrite-NO pathway’ (Borlaug et al., 2016; Lundberg et al., 
2008). Reduction of nitrite by various nitrite reductases, such as deoxyhaemoglobin, xanthine 
oxidoreductase (XOR) and ALDH2, helps to maintain NO production during hypoxia and 
acidosis when NOS function is compromised (Calvert and Lefer, 2009; Vitturi and Patel, 
2011). In vivo, nitrite is oxidised to nitrate by cellular and acellular mechanisms, but nitrate 
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can also be reduced back to nitrite via the commensal bacteria within the oral cavity and in 
the gastrointestinal tract (GIT), and by XOR in host tissues (Bailey et al., 2014; Kleinbongard 
et al., 2003; Lundberg et al., 2008; Lundberg et al., 2009; Qin et al., 2012). Approximately 
25% of circulating nitrate is taken up from the blood via the anion exchange channel sialin 
and secreted by the salivary glands into the saliva, before being reduced to nitrite by 
commensal bacteria on the surface of the tongue (Doel et al., 2005; Lundberg et al., 2008; 
Lundberg et al., 2009; Qin et al., 2012). Once swallowed into the stomach, nitrite is either 
protonated to form nitrous acid, which gives rise to NO through a series of reactions, or 
transits into the small intestine where it is reabsorbed into the circulatory pool of nitrite 
(Bailey et al., 2014; Butler and Feelisch, 2008).  
 
1.9.2.2 Dietary sources of nitrate/nitrite  
Green leafy vegetables (e.g. rocket, radish, spinach and beetroot), cured meats and drinking 
water are major sources of dietary nitrate that contribute to the circulating pool of nitrite 
(Bailey et al., 2014). For example, increased plasma nitrite levels have been observed within 
30 minutes of beetroot juice ingestion, where nitrite levels peaked at 3 hours and remained 
high for approximately 24 hours (Kapil et al., 2014; McKnight et al., 1997). Once within the 
oral cavity, dietary nitrate is processed in the same way as described above and this cycle is 
known as the ‘enterosalivary recirculation pathway’ (Bailey et al., 2014).  
 
1.9.2.3 Nitrite during normoxic conditions 
Recent studies have revealed that nitrite can act as a normoxic signalling agent to mediate 
gene expression, cell proliferation, vasorelaxation, myocardial function and wound healing in 
a NO-independent fashion (Wang et al., 2012). It has been proposed that it may involve 
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intermediary ONOO- or NO2 formation (Wang et al., 2012), but to our knowledge no further 
mechanistic information underpinning these effects is available.  
 
 
 
 
 
 
 
 
 
Figure 1.4: ‘Nitrate-nitrite-NO pathway’ in normoxia and hypoxia 
Typically, in normoxic conditions, stimuli activate endothelial nitric oxide synthase 
(eNOS) enzymes constitutively expressed in endothelial cells and platelets, to oxidise L-
arginine to NO (L-citrulline is formed as a by-product). eNOS-derived NO activates 
soluble guanylate cyclase (sGC) in platelets, which then synthesises cyclic guanosine 
monophosphate (cGMP) from guanosine triphosphate (GTP). cGMP inhibits platelets 
aggregation through the cGMP-dependent protein kinase/protein kinase G (PKG). In 
hypoxic/acidic conditions, the ‘nitrate-nitrite-NO pathway’ produces NO independently of 
NOS and O2. Nitrate obtained from dietary sources, such as green leafy vegetables, cured 
meat and drinking water, is reduced to nitrite and then NO, which can subsequently inhibit 
platelet aggregation via the sGC-cGMP-PKG pathway. Nitrite also inhibits platelet 
aggregation in normoxia through both NO-dependent and -independent mechanisms. The 
NO-independent actions of nitrite have been linked to a direct effect on sGC and are 
associated with cGMP production. (Adapted from Bailey et al., 2014) 
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1.9.3 The role of nitrite in HF  
Numerous preclinical and clinical studies have demonstrated the beneficial effects of nitrite 
treatment in HF patients. Short-term infusions of sodium nitrite (NaNO2) has been shown to 
improve cardiac and pulmonary hemodynamics in HFrEF patients (Ormerod et al., 2015). 
Whilst, NaNO2 infusion or inhalation have also been shown to attenuate hemodynamic 
abnormalities (e.g. increased cardiac filling pressures, pulmonary hypertension and 
insufficient CO reserve) that are present at rest and/or develop during exercise 
(hypoxic/acidic conditions) in HFpEF patients (Borlaug et al., 2015; Borlaug et al., 2016). 
Moreover, recent studies in patients with HFpEF have revealed improvements in exercise 
capacity, vasodilation and CO reserve following dietary nitrate supplementation (beetroot 
juice) (Borlaug et al., 2016; Eggebeen et al., 2016; Zamani et al., 2015). These improvements 
have been observed with both single and repeated doses (daily treatments over a one-week 
period) of oral nitrate (Eggebeen et al., 2016; Zamani et al., 2015). These beneficial effects 
are postulated to be mediated via the nitrite-NO pathway, and it appears to be prominent 
during exercise when compared with steady state conditions (Borlaug et al., 2015) 
 
1.9.4 The role of nitrite on platelet aggregation  
Numerous whole-blood and platelet rich plasma (PRP) aggregation studies from healthy 
subjects have shown that nitrite inhibits platelet aggregation through an erythrocyte-
dependent mechanism via deoxyhaemoglobin (Corti et al., 2013; Dautov et al., 2014; 
Parakaw et al., 2017). Velmurugan and colleagues have demonstrated in healthy human 
volunteers that oral administration of nitrate (beetroot juice or potassium nitrate capsules) 
increased circulating nitrate and nitrite, and attenuated platelet aggregation in response to 
ADP/collagen in whole-blood samples (Velmurugan et al., 2013). Furthermore, a reduction in 
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P-selectin expression and rise in platelet cGMP production were associated with the 
inhibitory effects of nitrate/nitrite in whole-blood, whilst nitrite had no effect on platelet 
aggregation in PRP (Corti et al., 2013; Srihirun et al., 2012; Velmurugan et al., 2013). Recent 
studies have also revealed that in the presence of erythrocytes, nitrite inhibits platelet 
aggregation via the conversion to NO by the reductase activity of partially deoxygenated 
haemoglobin, and increases VASP phosphorylation at the Ser239 site in platelets (Parakaw et 
al., 2017; Srihirun et al., 2012).  
 
The involvement of deoxyhaemoglobin in nitrite-NO reduction has also been demonstrated in 
murine platelet studies (Corti et al., 2013; Park et al., 2013). Firstly, reductions in circulating 
nitrate and nitrite have been shown to cause increases in platelet activity and ATP release in 
C57BL/6 mice (Park et al., 2013). A variety of techniques were employed by the research 
group to manipulate mouse plasma nitrate/nitrite concentration, including antibiotics, NOS 
inhibitors, low nitrate/nitrite diets and the disruption of the eNOS gene. Interestingly, dietary 
restriction resulted in the lowest whole-blood values (Park et al., 2013). A prolonged bleeding 
time was also observed in the C57BL/6 mice following nitrate/nitrite supplementation (via 
drinking water), when compared to controls and mice on a low nitrate/nitrite diet (Park et al., 
2013). Moreover, in eNOS WT and KO mice, nitrite administration resulted in a five-fold 
greater increase in plasma nitrite levels in KO mice when compared to WT mice (Apostoli et 
al., 2014). In addition, during an in vivo model of radiolabelled platelet aggregation, a rise in 
plasma nitrite was seen to inhibit platelet function in eNOS KO mice, when compared to WT 
mice (Apostoli et al., 2014). Nitrite therapy in rats has also been associated with increased 
plasma nitrate/nitrite concentration and reduced thrombi weight in vivo, in addition to the 
inhibition of whole-blood platelet aggregation in response to collagen ex vivo (Kramkowski 
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et al., 2016). The XOR inhibitor, febuxostat, was shown to partially reverse the anti-
thrombotic effects of NaNO2 in rats, whilst the anti-aggregatory effects of nitrite were 
completely reversed by febuxostat and another XOR inhibitor, allopurinol (Kramkowski et 
al., 2016).  
 
To date, most studies have investigated the effects of nitrite in whole-blood aggregation and 
PRP. To determine whether nitrite inhibits platelet aggregation independently of 
haemoglobin and other plasma proteins, we have recently shown that nitrite inhibits platelet 
aggregation in washed platelets from young healthy subjects. We showed that high 
concentrations of nitrite (1mM) increased cGMP generation and phosphorylated VASP at 
ser239 from washed platelets (Borgognone et al., 2015). In addition, another study has 
demonstrated that isolated platelets can generate transient NO-cGMP signals independently 
of NOS. These signals were also recorded following NaNO2 treatment and were enhanced 
with Sildenafil (a PDE5 inhibitor) in both the presence and absence of nitrite (Apostoli et al., 
2014). These findings therefore suggest that nitrite can inhibit platelet aggregation 
independently from haemoglobin and extracellular proteins (Apostoli et al., 2014; 
Borgognone et al., 2015).  
 
Furthermore, platelet studies have revealed that 1mM nitrite can also trigger cGMP 
production in isolated platelets, whilst under normoxic conditions (Borgognone et al., 2015). 
Nitrite was seen to stimulate cGMP generation in these platelets through both NO-dependent 
and -independent mechanisms (Borgognone et al., 2015). The NO-independent actions of 
nitrite have been linked to an uncharacterised direct effect on sGC (Borgognone et al., 2015).  
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1.10 Summary  
Since both platelet and vascular responses to NO are impaired in HFpEF when compared to 
healthy volunteers, due to scavenging of NO with subsequent reduction to sGC, this limits the 
therapeutic potential of NO donors. Although NO resistance is well understood in the 
vasculature, the mechanism(s) behind “platelet NO resistance” are far less defined. The 
potential for the ‘nitrate-nitrite-NO pathway’ to act as a novel therapeutic strategy for 
numerous cardiovascular diseases is undoubtedly clear. Since protective effects of nitrite 
have been observed in numerous HF and platelet studies, this suggests that nitrite may have 
the potential to act as a novel therapeutic intervention for the impairment of NO and platelet 
dysfunction in HFpEF. As such, nitrite therapy would help to combat predicted increases in 
HFpEF morbidity and mortality. To date, the existence of platelet NO resistance in patients 
with HFpEF and the potential for nitrite to circumvent “platelet NO resistance” in this disease 
state remains to be elucidated. Considering that CAF often coexists with HFpEF, nitrite will 
be investigated in two patient cohorts: 1) patients with HFpEF-AF and 2) patients with CAF 
only. We therefore hypothesise that nitrite can circumvent the phenomenon of “platelet NO 
resistance” in HFpEF-AF patients, independently of NO. 
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1.11 Objectives 
Despite promising scientific discoveries in both experimental and clinical studies on the role 
of NO and/or nitrite in CVDs, this research project aims to address knowledge gaps relating 
to the phenomenon of “platelet NO resistance” and the role of nitrite on platelet function in 
patients with HFpEF-AF. 
 
To support the HFpEF-AF study and develop our understanding of nitrite biology, the effects 
of nitrite will also be investigated in: 1) young vs old healthy volunteers and 2) ALDH2 WT 
vs KO mice. These experiments aim to explore the effects of ageing on platelet function and 
nitrite-mediated inhibition, whilst the animal experiments will address the role of ALDH2 in 
the anti-aggregatory effects of nitrite and lipidosis.  
 
Several small-scale studies were undertaken and are summarised in chapters as follows: 
1) Chapter 3: Exploration of platelet function and nitrite in young vs old healthy 
volunteers. 
Light transmission aggregation (LTA) experiments will be conducted in healthy volunteers to 
determine suitable parameters (e.g. collagen concentration) for HFpEF-AF/CAF experiments, 
whilst exploring the effect of ageing on platelet function and nitrite-mediated inhibition. The 
potential for nitrite to act synergistically with an sGC stimulator (BAY 41-2272) will also be 
studied during these LTA experiments. Additionally, to understand the normal physiological 
NaNO2 mechanism in platelets, the effect of NaNO2 on VASPser239 phosphorylation will also 
be investigated in healthy volunteers using Western blotting.   
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2) Chapter 4: Evaluation of the phenomenon of “platelet NO resistance” and nitrite in 
patients with HFpEF-AF and CAF only.  
Using LTA experiments, we will assess whether “platelet NO resistance” exists in patients 
with HFpEF-AF and the potential for nitrite to circumvent this phenomenon in HFpEF 
patients. 
 
3) Chapter 5: Exploration of the anti-aggregatory effects of nitrite, lipid content and 
tissue morphology in ALDH2 WT and KO mice.    
In this chapter, we will use ALDH2 WT and KO mice to assess the underlying mechanisms 
of ALDH2 cardioprotection. LTA experiments will be conducted in ALDH2 WT and KO 
mice to determine the importance of ALDH2 in the anti-aggregatory effects of nitrite, whilst 
the lipid content/morphology of ALDH2 WT and KO liver and skeletal muscle tissue will 
also be investigated using staining.  
 
These additional topics and experiments will be discussed further in their chapters.  
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Chapter 2: Research methods  
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2.1 Human experiments  
 
2.1.1 Human ethics 
 
The human experiments adhered to the Declaration of Helsinki and were approved by 
multiple ethical review committees, including the University of Birmingham Ethical Review 
Committee and the West Midlands – Coventry and Warwickshire Research Ethics 
Committee.  
 
2.1.2 Human subjects 
 
Young healthy volunteers (n=13, 9 men and 4 women aged between 21 and 41; 
mean=28.0±5.8), old healthy volunteers (n=11, 8 men and 3 women aged between 65 and 79; 
mean=72.3±5.0), HFpEF-AF patients (n=29, 21 men and 8 women aged between 67 and 79; 
mean=74.3±6.2) and patients diagnosed with CAF in the absence of HF or any known 
coronary artery disease (n=8, 4 men and 4 women aged between 65 and 86; mean=73.9±7.9) 
were recruited for washed platelet aggregation experiments. The heathy volunteers and 
patients were assigned to the pharmacological experiments at random, with each treatment 
group containing 8-11 participants. Blood obtained from the young healthy volunteers was 
also used for Western blotting experiments. All healthy volunteers were Caucasian, free of 
any cardiovascular risk factors, non-smokers, not on any regular medications, and had not 
taken anti-platelet drugs (such as aspirin and ibuprofen) for 10 days prior to blood donation. 
Established criteria for HFpEF-AF diagnosis, which included participants who have an EF 
>55% and persistent AF, was met by all patients (Camm et al., 2010; Lang et al., 2006; 
McMurray et al., 2012; Shantsila et al., 2016). EF was determined by echocardiography. 
Patients with CAF demonstrated permanent AF without evidence of HF or coronary artery 
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disease. Written consent was provided by all the healthy volunteers and patients who 
participated in the study.  
 
2.1.3 Human washed platelet aggregation study  
 
2.1.3.1 Collection of human blood 
 
Human blood samples were collected as previously described (Pearce et al., 2004; Senis et 
al., 2009). Firstly, a VACUETTE® Safety Blood Collection Set, containing a winged safety 
needle, flexible tubing, luer adapter and vacutainer tube holder (Greiner Bio-One; Figure 
2.1), was carefully assembled under sterile conditions. First aid pre-injection swabs (70% 
IPA Alcohol; Robinson Healthcare) were then used to decontaminate the donor’s skin at the 
venepuncture site (the antecubital fossa). A tourniquet, which functioned to distend the 
donor’s veins by limiting blood flow back to the heart, was then applied to the donor’s upper 
arm, roughly a hand width above the venepuncture site. The winged safety needle was then 
slowly inserted into a visible vein (either the basilic, cephalic or median cubital vein) within 
the antecubital fossa. Once venous blood began to flow into the flexible tubing, a 9mL 
vacutainer comprising 3.8% sodium citrate (VACUETTE®; sodium citrate prevented blood 
coagulation by chelating the calcium within the sample) was inserted into the vacutainer 
holder, where the vacutainer seal was pierced by the luer adapter (Figure 2.1). Venous blood 
was then slowly drawn into the vacutainer until the max fill line was reached. Each volunteer 
donated ~27mL of blood (3x 9mL vacutainers with a 1:9 ratio of sodium citrate to blood). 
Following the completion of blood donation, the tourniquet was removed and the needle was 
carefully extracted and discarded. Gauze was then pressed onto the needle entry site to 
minimise bleeding and prevent bruising. Blood-filled vacutainers were labelled, gently mixed 
by inversion and then stored at room temperature until further processing was possible.  
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Figure 2.1: Blood collection kit  
The blood collection kit was assembled under sterile conditions. To construct the kit, the 
luer adapter was first detached from the flexible tubing (the luer adapter, flexible tubing 
and winged safety needle arrived preassembled). The luer adapter was then inserted 
through the bottom of the vacutainer holder and secured in place by the flexible tubing, 
which reattached to the luer adapter at the top of the vacutainer holder.  
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2.1.3.2 Preparation of washed human platelets 
A well-established washed platelet protocol from the Watson Research group was used to 
prepare the human platelets (Borgognone et al., 2014; Jarvis et al., 2002; Pearce et al., 2004; 
Senis et al., 2009). Briefly, warmed Acid-Citrate-Dextrose (ACD) solution (an anticoagulant 
and acidifying agent which chelated calcium and regulated pH; Table 2.1) was added to the 
blood-filled vacutainers at a 1:10 dilution (1mL of ACD was added to 9mL of the 
blood/sodium citrate mixture).  The vacutainers were then gently mixed by inversion, before 
being centrifuged (Denley BS400 Centrifuge, Swinging Bucket) at 1000rpm (200g) for 20 
minutes at room temperature, to fractionate the blood samples (Figure 2.2). The separated 
plasma was then aspirated (care was taken to avoid the buffy coat; Figure 2.2) and pipetted 
into sterile 15mL falcon tubes. Approximately 7-10mL of plasma was collected per 
volunteer. Next, 6µL of 1mg/mL PGI2 (6µL PGI2 aliquots were stored at -20°C; Table 2.2) 
was pipetted into the plasma to prevent premature platelet activation during high speed 
centrifugation. The plasma was then centrifuged (Denley BS400 Centrifuge, Swinging 
Bucket) at 3000rpm (1000g) for 10 minutes at room temperature, to pellet the platelets. The 
resultant supernatant was then aspirated, and the pelleted platelets were re-suspended in 
1.5mL ACD (Table 2.1) and 12.5mL Modified Tyrode’s Buffer (MTB; on the day of 
experimentation 45mg glucose had been added to 50mL MTB and the pH had been adjusted 
(using a H12210 pH meter; HANNA Instruments) to 7.3 at 37°C; Table 2.3). 
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Table 2.1: Masses (g) of reagents required to make ACD solution (1L) 
 
Table 2.2: Volumes (mL) and masses (g) of reagents required to make 1mg/mL PGI2 (2mL) 
 
Table 2.3: Masses (g) of reagents required to make MTB (1L/50mL) 
 
 
 
Reagents (Manufacturer) Molecular Weight  Mass in 1L (g) 
Sodium Citrate.2H2O (SIGMA-ALDRICH®) 294.1 28.48 
Glucose (Fisher Scientific UK) 180.2 20 
Citric Acid.H2O (SIGMA-ALDRICH®) 210.1 16.4 
Reagents (Manufacturer) Mass 
(mg) 
Volume 
(mL) 
Tris Buffer (pH 9.1) Trizma Base  
(SIGMA-ALDRICH®) 
240  
HypureTM Cell Culture Grade Water 
(HycloneTM) 
- 40 
 
PGI2 Tris Buffer (pH 9.1)  
 
- 1 
PGI2  
(Cayman Chemical) 
1 - 
Reagents (Manufacturer) Molecular 
Weight 
Final 
Concentration 
(mM) 
Mass in 1L 
(g) 
Mass in 
50mL 
MTB 
(g) 
NaCl (SIGMA-ALDRICH®) 58.4 134 7.826 - 
KCl (VWR®) 75.0 2.9 0.218 - 
Na2HPO4.12H2O (SIGMA-
ALDRICH®) 
358.1 0.34 0.122 - 
NaHCO3 (Fisher Scientific 
UK) 
84.0 12.0 1.008 - 
HEPES (SIGMA-
ALDRICH®) 
238.1 20.0 4.762 - 
MgCl2 (SIGMA-ALDRICH®) 95.2 1.0 0.095 - 
Glucose (Fisher Scientific 
UK) 
(*added on the day of the 
experiment) 
180.2 5.0 - 0.045 
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Figure 2.2: Blood fractionation  
The unique structure of blood enabled it to be separated into its component parts through 
centrifugation. When centrifuged at the low speed of 1000rpm (200g), blood samples 
separated into three fractions: 1) plasma (55%), 2) the buffy coat (<1%) and 3) 
erythrocytes (45%). The plasma comprised two phases, platelet poor plasma (PPP; plasma 
containing a low number of platelets, <10,000 platelets/mL) and platelet rich plasma 
(PRP; plasma containing a high number of platelets), whilst the buffy coat contained 
leukocytes and a small number of platelets.  
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2.1.3.3 Human platelet count 
 
A Coulter counter (ZTM Series COULTER COUNTER®; Beckman Coulter) was used to 
identify the number of platelets present per millilitre of sample (washed human platelets). 
Firstly, the Coulter system was flushed with isotonic buffered diluent (COULTER® 
ISOTON®) to ensure that platelet counts were not skewed by previously measured samples. 
Next, the human platelet samples were diluted (5µL of each sample was added to 10mL of 
ISOTON) and the platelets were then counted (platelets/mL). Three readings were taken per 
sample and averages were calculated (platelets/mL).  
 
Next, 6µL of 1mg/mL PGI2 was added to the washed human platelets. The washed platelets 
were then gently mixed by inversion and centrifuged (Denley BS400 Centrifuge, Swinging 
Bucket) at 3000rpm (1000g) for 10 minutes at room temperature, to pellet the platelets for the 
final time. The supernatant was then aspirated, and the washed platelets were re-suspended in 
MTB (Table 2.3) at a concentration of 2x108 platelets/mL (Calculation 2.1) for LTA 
experiments. Before commencing the LTA experiments, the washed platelets were rested for 
one hour to allow time for PGI2 degradation (Borgognone et al., 2014; Jarvis et al., 2002; 
Pearce et al., 2004; Senis et al., 2009).  
 
Calculation 2.1: Example of washed platelet calculation (human platelet samples) 
 
Example platelet count = 2.487x108/mL in 14mL 
 
Platelet concentration (platelets/mL) x Volume (mL) = Volume of MTB (mL) to add 
    Desired platelet concentration (platelets/mL)                       to the platelet pellet 
 
2.487x108/mL x 14mL = 17.409 mL MTB 
           2x108/mL 
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2.1.3.4 Human platelet aggregation 
 
Human LTA experiments were primarily completed to compare the effects of NaNO2 vs SNP 
(NO donor) in washed platelets from age-matched healthy volunteers, HFpEF-AF patients 
and CAF patients. Additional LTA experiments were also carried out to investigate NaNO2’s 
mechanism of action in washed platelets from young vs old healthy volunteers. NO 
scavengers, oxyhaemoglobin (OxyHb) and 2-Phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 
3-oxide (PTIO), were used to assess whether NaNO2 was converted to NO under these 
experimental conditions, whilst the sGC inhibitor, 1-H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-l-
one (ODQ), was used to explore the involvement of sGC. BAYER 41-2272 was also used to 
investigate the potential for NaNO2 to exhibit synergistic activity with an sGC stimulator in 
washed platelets from young vs old healthy volunteers.  
 
The equipment required for the human LTA experiments was prepared during the one-hour 
platelet rest period. To start, the aggregometer (LUMI-DUAL aggregometer; CHRONO-
LOG Corporation) was switched on and set to 37°C (the aggregometer took ~30 minutes to 
reach 37°C). Next, the cuvettes (CHRONO-LOG Corporation) were prepared. Firstly, 
magnetic stirrer bars (CHRONO-LOG Corporation) were placed into the cuvettes to enable 
future sample mixing within the stirring channels of the aggregometer. Each cuvette was also 
fitted with a spacer (CHRONO-LOG Corporation) to ensure that the platelet samples sat 
between the light source and the photo cell (light detector) within the stirring channels of the 
aggregometer. Washed platelet samples were then pipetted into the prepared cuvettes (300µL 
washed platelets at a concentration of 2x108 platelets/mL/cuvette). Reference blanks 
containing 500µL MTB (Table 2.3) were also prepared (these cuvettes did not require a 
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stirrer or spacer) and placed into the ‘blank’ channels of the aggregometer (Jarvis et al., 2002; 
Pearce et al., 2004; Senis et al., 2009).  
 
The compounds (NaNO2, SNP, OxyHb, PTIO, ODQ and BAYER 41-2272; Tables 2.4 and 
2.5) and collagen dilutions (Collagen Reagens HORM® Suspension, Takeda; agonist used to 
trigger platelet activation/aggregation; Table 2.6) required for the human LTA experiments 
were also prepared or appropriately diluted from previously made stock solutions (one 
exception was OxyHb, which was used at the stock concentration; Table 2.4) during the 
platelet rest period.  		
2.1.3.4.1 Oxyhaemoglobin preparation 
 
OxyHb was prepared using a well-established protocol from Professor Martin Feelisch (Kelm 
et al., 1997; Salvemini et al., 1989). To start, 20mg of human haemoglobin containing a 
mixture of OxyHb and methemoglobin was dissolved in 1mL of distilled water. Next, 
>0.6mg of sodium dithionite (Na2S2O4; equivalent to a 10-fold molar excess) was added to 
the haemoglobin solution, which was then stirred and left to air for approximately 10 
minutes. During this period, haemoglobin was reduced to its pure oxy-form (excess Na2S2O4 
reduced methemoglobin to deoxyhaemoglobin, whilst airing facilitated the oxidation of 
deoxyhaemoglobin to OxyHb). 
 
Excess reductant was then removed from the OxyHb solution by gel filtration through a PD-
10 desalting column containing 8.3mL of SephadexTM G-25 resin (GE Healthcare Life 
Sciences; column set-up is demonstrated by Figure 2.3). The PD-10 desalting column was 
first equilibrated with 25mL of distilled water (flow-through collected during the 
equilibration step was discarded). Next, the OxyHb solution was added to the column (1.5mL 
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of distilled water was also added to make a total volume of 2.5mL). The desalted/purified 
OxyHb was then eluted from the column with 3.5mL of distilled water and the middle run of 
the eluate (~800µL) was collected in a 15mL falcon tube.  
 
The concentration of the OxyHb eluate was then determined spectrophotometrically (GE 
Healthcare/Amersham Biosciences Ultrospec 3100 Pro UV/Visible Spectrophotometer with a 
1cm path length). A small proportion of the OxyHb eluate was first diluted (1:300; 10µL 
OxyHb in 2990µL distilled water) and the required cuvettes (Fisherbrand®) were then 
prepared (cuvette 1/reference blank; 1mL of distilled water, and cuvette 2/sample; 1mL of 
diluted OxyHb eluate). The amount of light absorbed by the reference blank/OxyHb sample 
was then measured by the spectrophotometer at two different wavelengths (510nm and 
542nm; at each wavelength, three readings were taken per cuvette and averages were 
generated). Once the concentration of the OxyHb eluate had been calculated (Calculation 2.2; 
the OxyHb sample and reference blank were compared at each wavelength to account for any 
background absorbance), the OxyHb eluate was appropriately diluted to a stock concentration 
of 300µM (Calculation 2.2), before being aliquoted (100µL was pipetted into 0.6mL 
Eppendorf tubes) and stored at -80°C. On the day of experimentation, OxyHb was removed 
from the freezer, thawed on ice and used at the stock concentration (Table 2.4).  
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Reagents Stock 
Concentration 
(µM) 
Volume 
Added to 
the 
Washed 
Platelet 
Samples  
(µL) 
Final 
Concentration 
Within the 
Washed 
Platelet 
Samples 
(µM) 
Reagent 
(Manufacturer) 
Mass 
(mg) 
Volume 
(mL) 
Haemoglobin 
(SIGMA-
ALDRICH®) 
20 - 300 
(100µL 
aliquots stored 
at -80°C) 
10 10 
Na2S2O4 
(SIGMA-
ALDRICH®) 
>0.6 - 
Distilled Water - ~30 
(* ~30mL 
distilled water 
was required 
for OxyHb 
preparation, 
however the final 
stock solution 
does not contain 
this much water). 
Table 2.4: OxyHb preparation (human LTA experiments) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: PD-10 desalting column setup for OxyHb preparation  
The protective cap was first removed from the top of the PD-10 desalting column and the 
preservative liquid, which maintained the column quality during storage, was discarded. 
The column was then secured in a clamp in an upright position (the clamp was screwed 
into a boss attached to a lab bench). Flow-through was collected from the bottom of the 
column. 
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Calculation 2.2: Example of OxyHb eluate concentration calculation (human LTA 
experiments) 
 
 
 
 
 
 
 
 
 
 
 
 
 Concentration of OxyHb = ∆A542-510*dilution factor 
                    (extinction coefficient) 
 
Concentration of OxyHb = (0.019-0.000)-(0.001-0.000)*300 
 9.61mM-1cm-1 
 
               = 0.018*300 
            9.61mM-1cm-1 
 
            = 0.561mM (561µM) 
 
Concentration 1 x Volume 1 = Concentration 2 x Volume 2  
561µM x 800µL = 300µM x XµL 
561µM x 800µL = 300µM x XµL              (x800) 
448800 = 300 x X      (÷300) 
1496 = X = 1496 µL       
1496 – 800 = 696µL 
       
Add 696µL of distilled water to the 800µL OxyHb eluate sample to give a 
concentration of 300µM (total volume = 1496µL (14 aliquots (100µL)). 
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2.1.3.4.2 NaNO2, SNP, PTIO, ODQ, BAYER 41-2272 and collagen preparation  
 
To prepare NaNO2, SNP, PTIO, ODQ and BAYER 41-2272 solutions (Table 2.5), the 
compounds were first weighed out into Eppendorf tubes and then solubilised in their relevant 
solvents (Eppendorf tubes were vigorously vortexed to dissolve the compounds; Table 2.5). 
PTIO, ODQ and BAYER 41-2272 solutions were prepared, diluted, aliquoted (into 0.6mL 
Eppendorf tubes; Table 2.5) and then stored at -20°C until the day of experimentation. When 
required, the stock solutions were removed from the freezer, thawed on ice and further 
diluted before use (Table 2.5). Alternatively, NaNO2 and SNP solutions were prepared, 
appropriately diluted and then used on the day of experimentation (Table 2.5). Three collagen 
dilutions were also prepared on the day of experimentation. Collagen (taken from a 1mg/mL 
stock solution) and its diluent were pipetted into Eppendorf tubes, which were then 
vigorously vortexed to dissolve the collagen (Table 2.6). 
 
All of the above compounds (including OxyHb) and collagen dilutions were stored on ice for 
the entirety of the human LTA experiments (the compounds/collagen dilutions were briefly 
removed for regular vortexing).  
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Table 2.6: Collagen preparations (human LTA experiments) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dilution 
 
Volume 
of 
Collagen  
(µL) 
Volume 
of 
Diluent  
(µL) 
Ratio of 
Collagen 
to 
Diluent  
Stock  
Concentration 
 
Volume 
Added to 
the 
Washed 
Platelet 
Samples  
(µL) 
Final Collagen 
Concentration 
Within the 
Washed 
Platelet 
Samples 
(µg/mL) 
1 5 45 1:10 100 µg/mL 3 1 
2 30 70 3:10 300 µg/mL 3 3 
3 5 - - 1mg/mL 3 10 
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2.1.3.4.3 Human LTA experiments  
 
On completion of the platelet rest period, aggregatory responses to collagen (platelet 
activator/agonist) were recorded under a variety of conditions (Borgognone et al., 2014; 
Borgognone et al., 2018). 
 
Approximately 34 LTA experiments were completed per healthy volunteer (young and old):  
• Collagen (1µg/mL, 3µg/mL or 10µg/mL) (collagen controls) 
• NaNO2 (10µM, 100µM or 1mM NaNO2) + 3µg/mL collagen 
• SNP (10nM or 100nM) + 3µg/mL collagen 
• OxyHb (10µM) + 3µg/mL collagen  
• OxyHb (10µM) + NaNO2 (10µM, 100µM or 1mM NaNO2) + 3µg/mL collagen 
• OxyHb (10µM) + SNP (10nM or 100nM) + 3µg/mL collagen 
• PTIO (100µM) + 3µg/mL collagen 
• PTIO (100µM) + NaNO2 (10µM, 100µM or 1mM NaNO2) + 3µg/mL collagen 
• PTIO (100µM) + SNP (10nM or 100nM) + 3µg/mL collagen 
• ODQ (10µM) + 3µg/mL collagen  
• ODQ (10µM) + NaNO2 (10µM, 100µM or 1mM NaNO2) + 3µg/mL collagen 
• ODQ (10µM) + SNP (10nM or 100nM) + 3µg/mL collagen 
• BAYER 41-2272 (10nM, 30nM or 100nM) + 3µg/mL collagen 
• BAYER 41-2272 (30nM) + NaNO2 (10µM, 100µM or 1mM NaNO2) + 3µg/mL 
collagen 
• BAYER 41-2272 (30nM) + SNP (10nM or 100nM) + 3µg/mL collagen 
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Approximately six LTA experiments were completed per patient (HFpEF-AF and CAF): 
• Collagen (3µg/mL) (collagen control) 
• NaNO2 (10µM, 100µM or 1mM NaNO2) + 3µg/mL collagen 
• SNP (10nM or 100nM) + 3µg/mL collagen 
 
When carrying out the collagen controls in healthy volunteers and patients, cuvettes 
containing washed human platelets were first placed into the incubating channels of the 
aggregometer, where the samples were heated for four minutes at 37°C. The cuvettes were 
then transferred to the stirring channels of the aggregometer, which functioned to reproduce 
vascular wall shear stress, and each contained a light source/photo cell to monitor light 
transmission through the samples during the LTA experiments (MTB reference blanks, which 
represented 100% light transmission/aggregation, were positioned behind the washed platelet 
samples for comparison). Whilst the samples were stirred for one minute at 37°C, the 
attached chart recorders (CHRONO-LOG Corporation) were set to run (e.g. at 10 
squares/minute) and the aggregation baselines were then recorded (Figure 2.5). Next, 3µL of 
collagen (100µg/mL, 300µg/mL or 1mg/mL; Table 2.6) was pipetted into the washed 
platelets (300µL) to give a final concentration of 1µg/mL, 3µg/mL or 10µg/mL, respectively 
(the cuvettes were not removed from the aggregometer whilst collagen was added to the 
samples). The subsequent changes to light transmission (which were proportional to the 
extent of platelet aggregation induced by collagen) were monitored for five minutes and 
graphic readouts/traces of the aggregatory responses were produced in real-time by the chart 
recorders (Figure 2.5). 
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For the remainder of the human LTA experiments, washed platelets from healthy volunteers 
and patients were incubated with one or two of the prepared compounds (see list of LTA 
experiments above), before being activated with 3µL of 300µg/mL collagen (3µg/mL final 
concentration in 300µL washed platelet samples; Table 2.6). Firstly, 3µL of NaNO2 (1mM, 
10mM or 100mM solutions with final concentrations of 10µM, 100µM or 1mM, respectively; 
Table 2.5), 3µL of SNP (1µM or 10µM solutions with final concentrations of 10nM or 
100nM, respectively; Table 2.5), 10µL of OxyHb (300µM solution with a final concentration 
of 10µM; Table 2.6) or 3µL of PTIO (10mM solution with a final concentration of 100µM; 
Table 2.5) was pipetted into the washed platelets as the cuvettes were placed into the 
incubating channels of the aggregometer (Figure 2.4A). These samples were then incubated 
for four minutes at 37°C, before being stirred for one minute at 37°C and then activated with 
collagen (Figure 2.4A). When simultaneously incubating OxyHb or PTIO with NaNO2 (1mM 
final concentration; Table 2.5) or SNP (100nM final concentration; Table 2.5), the 
OxyHb/PTIO was pipetted into the cuvettes just prior to the NaNO2/SNP (Figure 2.4A). 
Moreover, 3µL of ODQ (1mM solution with a final concentration of 10µM; Table 2.5) was 
incubated with the washed platelets for 19 minutes at 37°C (Figure 2.4B). These samples 
were also stirred for one minute at 37°C, before being activated with collagen (Figure 2.4B). 
When simultaneously incubating ODQ with NaNO2 (1mM final concentration; Table 2.5) or 
SNP (100nM final concentration; Table 2.5), the NaNO2/SNP was pipetted into the cuvettes 
15 minutes into the 19-minute ODQ incubation period (Figure 2.4B). Finally, 3µL of 
BAYER 41-2272 (1µM, 3µM or 10µM solutions with final concentrations of 10nM, 30nM or 
100nM, respectively; Table 2.5) was pipetted into the cuvettes as the incubated washed 
platelets were transferred to the stirring channels of the aggregometer (data published on 
BAYER 41-2272 was used to determine suitable final concentrations for the LTA 
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experiments (Roger et al., 2010)). These samples were also stirred for one minute at 37°C 
and then activated with collagen (Figure 2.4C). When simultaneously incubating BAYER 41-
2272 (30nM final concentration; Table 2.5) with NaNO2 (10µM, 100µM or 1mM final 
concentrations; Table 2.5) or SNP (10nM or 100nM final concentrations; Table 2.5), NaNO2 
or SNP was pipetted into the cuvettes four minutes before BAYER 41-2272 (Figure 2.4C).  
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 Figure 2.4: Aggregation protocols (human platelet samples) 
Figure legend overleaf. 
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Figure 2.4: Aggregation protocols (human platelet samples) 
A) Washed human platelets were incubated for four minutes at 37°C. NaNO2 (at a final 
concentration of 10µM, 100µM or 1mM), SNP (at a final concentration of 10nM or 
100nM), OxyHb (at a final concentration of 10µM) and PTIO (at a final concentration of 
100µM) were added to the washed platelets as the cuvettes were placed into the 
incubating channels of the aggregometer. After one minute of stirring at 37°C, collagen (at 
a final concentration of 3µg/mL) was added to the samples and the response of the washed 
platelets to the agonist was recorded for five minutes.  
B) Washed human platelets were incubated for 19 minutes at 37°C. ODQ (at a final 
concentration of 10µM) was added to the washed platelets as the cuvettes were placed into 
the incubating channels of the aggregometer, whilst NaNO2 (at a final concentration of 
1mM) and SNP (at a final concentration of 100nM) were added to the samples 15 minutes 
into the 19-minute ODQ incubation period. After one minute of stirring at 37°C, collagen 
(at a final concentration of 3µg/mL) was added to the samples and the response of the 
washed platelets to the agonist was recorded for five minutes. 
C) Washed human platelets were incubated for four minutes at 37°C. NaNO2 (at a final 
concentration of 1mM) and SNP (at a final concentration of 100nM) were added to the 
washed platelets as the cuvettes were placed into the incubating channels of the 
aggregometer, whilst BAYER 41-2272 (at a final concentration of 10nM, 30nM or 
100nM) was added to the samples as the cuvettes were transferred to the stirring channels 
of the aggregometer. After one minute of stirring at 37°C, collagen (at a final 
concentration of 3µg/mL) was added to the samples and the response of the washed 
platelets to the agonist was recorded for five minutes. 
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2.1.3.5 Data analysis (human platelet aggregation) 
 
To quantify the aggregatory responses produced during the human LTA experiments, each 
trace was analysed as shown in Figure 2.5, and percentage aggregation was then calculated 
(Calculation 2.3). This data was then transferred to Prism Version 7.0 (Graphpad Software, 
Inc., La Jolla, CA) for statistical analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Trace analysis  
To analyse each trace, the baseline and % light transmission recorded five minutes after 
the addition of the agonist were measured (grid squares were counted). Percentage 
aggregation was then established by carrying out the calculation shown below 
(Calculation 2.3).  
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Calculation 2.3: Example of percentage aggregation calculation for human washed platelet 
samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
2.1.4 Western blotting (human platelet samples)  
 
2.1.4.1 Platelet homogenate preparation (human platelet samples) 
 
To confirm the involvement of the sGC-cGMP-PKG pathway in NaNO2-mediated inhibition 
of platelet aggregation, Western blotting analysis was carried out to explore the effects of 
NaNO2 on the phosphorylation status of the downstream PKG substrate VASPser239 
(Borgognone et al., 2014; Borgognone et al., 2018). OxyHb, PTIO and ODQ were also used 
to establish whether the underlying mechanism of NaNO2 was NO-dependent/independent.  
 
To prepare the platelet homogenates, whole-blood samples were first obtained from young 
healthy volunteers (Section 2.1.3.1). Washed platelets were then prepared as described in 
Section 2.1.3.2, before being counted, diluted to a concentration of 5x108 platelets/mL for 
biochemistry experiments (Western blotting) and then rested for one hour (Section 2.1.3.3). 
During the platelet rest period, the equipment and compounds required to produce the platelet 
homogenates were prepared. The aggregometer was switched on and set to 37°C, whilst the 
cuvettes (which contained 300µL of washed platelets at a concentration of 5x108 platelets/mL 
and a stirrer bar), compound dilutions (NaNO2, SNP, OxyHb, PTIO and ODQ; Sections 
2.1.3.4.1 and 2.1.3.4.2) and the 5x reduced Laemmli sample buffer (Table 2.7) were all 
prepared.  
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On completion of the platelet rest period, up to 27 platelet homogenates were prepared per 
young healthy volunteer: 
• Washed platelets only 
• Washed platelets + 10µM NaNO2 (5, 10, 25 or 45-minute incubation) 
• Washed platelets + 100µM NaNO2 (5, 10, 25 or 45-minute incubation) 
• Washed platelets + 1mM NaNO2 (5, 10, 25 or 45-minute incubation) 
• Washed platelets + 10nM SNP (5, 10, 25 or 45-minute incubation) 
• Washed platelets + 100nM SNP (5, 10, 25 or 45-minute incubation) 
• Washed platelets + 10µM OxyHb  
• Washed platelets + 10µM OxyHb + 1mM NaNO2 
• Washed platelets + 100µM PTIO 
• Washed platelets + 100µM PTIO + 1mM NaNO2 
• Washed platelets + 10nM OQD 
• Washed platelets + 10µM ODQ + 1mM NaNO2 
 
To prepare the human homogenates, cuvettes containing washed platelets were first placed 
into the incubating channels of the aggregometer, where the samples were heated for four 
minutes at 37°C. The cuvettes were then transferred to the stirring channels of the 
aggregometer, where the washed platelets were mixed for six minutes at 37°C. Once stirred, 
75µL of 5x reduced Laemmli sample buffer (Table 2.7) was added to the cuvettes to lyse the 
washed platelets.  
 
When incubating the samples with increasing concentrations of NaNO2 or SNP, 3µL of 
NaNO2 (1mM, 10mM or 100mM solutions with final concentrations of 10µM, 100µM or 
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1mM, respectively; Table 2.5) or SNP (1µM or 10µM solutions with final concentrations of 
10nM or 100nM, respectively; Table 2.5) was pipetted into the washed platelets as the 
cuvettes were placed into the incubating channels of the aggregometer (Figures 2.6A and B). 
These samples were then incubated for one/four minutes at 37°C, before being stirred for 4, 
6, 21 or 41 minutes at 37°C, and then lysed with 75µL of 5x reduced Laemmli sample buffer 
(Figures 2.6A and B).  
 
OxyHb (10µL, 300µM solution with a final concentration of 10µM; Table 2.6), PTIO (3µL, 
10mM solution with a final concentration of 100µM; Table 2.5) or ODQ (3µL, 1mM solution 
with a final concentration of 10µM; Table 2.5) was also pipetted into the washed platelets as 
the cuvettes were placed into the incubating channels of the aggregometer (Figures 2.7A and 
B). Once incubated at 37°C (OxyHb or PTIO; 4 mins, ODQ; 14 mins), the washed platelets 
were stirred for six minutes at 37°C and then lysed with 75µL of 5x reduced Laemmli sample 
buffer (Figures 2.7A and B). When simultaneously incubating OxyHb, PTIO or ODQ with 
NaNO2 (1mM final concentration; Table 2.5), the OxyHb/PTIO was pipetted into the cuvettes 
just prior to NaNO2, whilst NaNO2 was pipetted into the washed platelets 10 minutes into the 
14-minute ODQ incubation period (Figures 2.7A and B).  
 
After the addition of 5x reduced Laemmli sample buffer (Table 2.7), all platelet homogenates 
were left to stir for a few seconds before being moved onto ice. Once thawed at room 
temperature, a long-tipped pipette was then used to transfer the platelet homogenates into 
labelled Eppendorf tubes. The platelet homogenates were stored at -20°C until further 
analysis. 
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A 
B 
Figure 2.6: Preparation of platelet homogenates 1 (human samples) 
A) Washed human platelets were incubated for one minute at 37°C. NaNO2 (at a final 
concentration of 10µM, 100µM or 1mM) and SNP (at a final concentration of 10nM or 
100nM) were also incubated with samples for one minute. The washed platelets were then 
stirred for four minutes at 37°C, before 5x reduced Laemmli sample buffer was added to 
the washed platelets to lyse the samples.  
B) Washed human platelets were incubated for four minutes at 37°C. NaNO2 (at a final 
concentration of 10µM, 100µM or 1mM) and SNP (at a final concentration of 10nM or 
100nM) were also incubated with samples for four minutes. The washed platelets were 
then stirred for 6, 21 or 41 minutes at 37°C, before 5x reduced Laemmli sample buffer 
was added to the washed platelets to lyse the samples. 
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A 
B 
Figure 2.7: Preparation of platelet homogenates 2 (human samples) 
A) Washed human platelets were incubated for four minutes at 37°C. NaNO2 (at a final 
concentration of 1mM), OxyHb (at a final concentration of 10µM) and PTIO (at a final 
concentration of 100µM) were also incubated with samples for four minutes. The washed 
platelets were then stirred for six minutes at 37°C, before 5x reduced Laemmli sample 
buffer was added to the washed platelets to lyse the samples.  
B) Washed human platelets were incubated with ODQ (at a final concentration of 10µM) 
for 14 minutes at 37°C. NaNO2 (at a final concentration of 1mM) was added to the 
samples 10 minutes into the ODQ incubation period. The washed platelets were then 
stirred for six minutes at 37°C, before 5x reduced Laemmli sample buffer was added to 
the washed platelets to lyse the samples. 
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Reagents 
(Manufacturer) 
Final 
Concentration 
in the 
Reduced 
Laemmli 
Sample Buffer 
(%) 
5x Laemmli Sample 
Buffer 
Function 
Mass 
(g) 
Volume (mL) 
SDS 
(SIGMA-
ALDRICH® 
2 1 - An anionic detergent that 
binds to and neutralises 
positive charges on sample 
proteins, to denature 
secondary/tertiary structures 
and enable protein separation 
by size, and not shape, during 
SDS-PAGE.  
β-
mercaptoethanol 
(SIGMA-
ALDRICH®) 
5 - 2.5 
*on the day of the 
experiment β-
mercaptoethanol 
(β-ME) 
was added to the 
aliquot of 
Laemmli sample 
buffer. 
A disulfide reducing agent 
that disturbs both intra and 
inter-molecular 
disulfide bonds, to facilitate 
protein separation by size 
during SDS-PAGE.  
Glycerol  
(SIGMA-
ALDRICH®) 
10 - 5 A simple polyol that increases 
sample density, to aid 
pipetting and prevent sample 
spill-over into the buffer. 
1M Tris-HCL 
(pH 6.8) 
(Trizma base 
=SIGMA-
ALDRICH®, 
37% HCL = 
VWR®) 
5 - 2.5 An effective buffer solution 
that regulates lysate acidity 
and osmolarity.  
Brilliant Blue-R 
(SIGMA-
ALDRICH®) 
Add a trace 
amount 
- Add a trace 
amount 
A methanol-based protein 
stain that is required for 
protein band detection after 
gel electrophoresis. 
Table 2.7: Volumes (mL) and masses (g) of reagents used to make 5x reduced Laemmli 
sample buffer (10 mL) 
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2.1.4.2 Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) gels containing 8% 
acrylamide (Table 2.8) were constructed using numerous accessories, including casting 
stands, casting frames, short glass plates, glass spacer plates (1mm) and 10-well combs (Bio-
Rad Mini-PROTEAN® Tetra handcast system). The gels produced contained two 
components: 1) stacking gel and 2) resolving gel. The stacking gel functioned to concentrate 
sample proteins into a single band and thus ensure all proteins started their migration through 
the resolving gel in unison, whilst the resolving gel separated sample proteins according to 
their molecular weight. SDS was added to the gels (Table 2.8) and the reservoir buffer (Table 
2.9) to neutralise any charges present on the proteins. 
 
Whilst the SDS-PAGE gels were setting, the human platelet homogenates were removed 
from the -20⁰C freezer and thawed on ice. Once thawed, the homogenates were lightly 
vortexed, boiled for five minutes at 95⁰C (Eppendorf ThermoMixer, C) to ensure complete 
protein denaturation and then centrifuged (Eppendorf Centrifuge, 5430R) at 1000 RPM for 
five minutes at room temperature. Long gel loading pipette tips were then used to load the 
Bio-Rad Precision Plus ProteinTM ladder (5µL/well) and platelet homogenates (20µL/well) 
into the 8% acrylamide gels. Loaded gels were placed into Bio-Rad Mini-PROTEAN® Tetra 
Systems filled with reservoir buffer (Table 2.9), which were then supplied with 150 volts for 
one hour and 20 minutes to perform SDS-PAGE.  
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Reagents (Manufacturer) Volume (µL) 
Resolving Gel (8% 
Acrylamide) 
Stacking Gel (8% 
Acrylamide) 
30% Acrylamide (National Diagnostics) 2.67x103 9.0x102 
Deionised Water 3.38x103 4.00x103 
1M Tris-HCL (pH 8.8) (Trizma base =SIGMA-
ALDRICH®, 37% HCL = VWR®) 
3.80x103 - 
1M Tris-HCL (pH 6.8) (Trizma base =SIGMA-
ALDRICH®, 37% HCL = VWR®) 
- 720 
10% SDS (SDS=SIGMA-ALDRICH®) 100 60 
TEMED (SIGMA-ALDRICH®) 10 10 
APS (SIGMA-ALDRICH®) 100 100 
Table 2.8: Volumes (µL) of reagents used to make 8% acrylamide SDS-PAGE gels (x2) 
Table 2.9: Volumes (µL) of reagents used to make SDS-PAGE reservoir buffer (1L) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents (Manufacturer) Volume (µL) 
10x Reservoir Buffer 1.0x105 
10% SDS (SDS=SIGMA-ALDRICH®) 1.0x104 
Distilled Water 8.9x105 
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2.1.4.3 Wet transfer  
Following the completion of gel electrophoresis, wet transfer was then carried out to transfer 
the separated proteins from the 8% acrylamide gels onto AmershamTM HybondTM 
polyvinylidene fluoride (PVDF) blotting membranes. The components necessary for the wet 
transfer process (two sponge pads, two pieces of blotting paper and one clamping cassette 
(Bio-Rad) per gel) were first soaked in ice-cold wet transfer buffer (Table 2.10) for 
approximately 15 minutes. At the same time, the PVDF blotting membranes were placed into 
methanol (BDH PROLABO® VWR Chemicals) and then soaked on the shaker for 
approximately 15 minutes. This process activated the membranes. The PVDF membranes 
were then removed from the methanol and stored in ice-cold wet transfer buffer for 
approximately five minutes. 
 
Following apparatus soaking and membrane activation, gel sandwiches (Figure 2.8) were 
constructed under ice-cold wet transfer buffer to prevent gel dehydration. These sandwiches 
were then fitted into a Bio-Rad Mini Trans-Blot® Cell, which was filled with ice-cold wet 
transfer buffer (Table 2.10) and contained an ice pack. The tank was then supplied with 100 
volts for one hour and 30 minutes to complete the wet transfer process.  
Table 2.10: Volumes (µL) and masses (g) of reagents used to make wet transfer buffer (2L) 
 
 
 
Reagents (Manufacturer) Volume (µL) Mass (g) 
Trizma Base (SIGMA-ALDRICH®) - 6 
Glycine (SIGMA-ALDRICH®) - 28.8 
Methanol (VWR®) 4.0x105 - 
Distilled Water ~1.6x106 - 
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Figure 2.8: Gel sandwich 
Gel sandwiches were constructed under wet transfer buffer. A clamping cassette was first 
opened out and placed into the wet transfer buffer. A sponge pad and piece of blotting 
paper were then positioned onto the back section (black side) of the cassette. An 8% 
acrylamide gel (which had been carefully released from its glass plates under distilled 
water) was then placed onto the blotting paper, ensuring that the ladder was observed on 
the right-hand side of the gel. Next, a PVDF membrane was positioned onto the gel and a 
small tube was rolled across the surface of the membrane to remove any air bubbles 
between the gel and the membrane. A piece of blotting paper and a sponge pad were then 
placed onto the membrane and the clamping cassette was closed to secure the gel 
sandwich. 
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2.1.4.4 Antibody incubation and film development (human platelet samples) 
 
To evaluate the normal physiological NaNO2 mechanism in washed platelets from young 
healthy volunteers, Western blot analysis was carried out to explore the phosphorylation 
status of VASPser239 (48 and 50 kDa) under a variety of conditions (Section 2.1.4.1). 
 
Following wet transfer, 5% milk (Bio-Rad Blotting-Grade Blocker, non-fat dry milk) in 
Phosphate Buffered Saline 0.1% Tween (PBS-T) was used to block the PVDF membranes, 
for two hours at room temperature on a shaker. Once blocked, the PVDF membranes were 
probed with anti-Phospho-VASP (Ser293) (Table 2.11; Antibody 1) overnight at 4⁰C on a 
shaker. The next morning, the membranes were retrieved from the cold room and the primary 
antibodies were removed (anti-Phospho-VASP (Ser293) was stored at -20⁰C and used 
approximately three to five times before being discarded). The membranes were then washed 
thoroughly with PBS-T for one hour (PBS-T was changed every 15 minutes). Next, anti-Rb 
IgG (Table 2.11; Antibody 2) was added to the washed membranes and incubated for one 
hour at room temperature on a shaker. The secondary antibody was then discarded, and the 
membranes were washed thoroughly with PBS-T for another hour (PBS-T was changed every 
15 minutes). 
 
Pierce® Enhanced Chemiluminescence (ECL) Western Blotting Substrate (1mL) was then 
incubated on the washed membranes for three minutes on a shaker. The ECL was then 
discarded and the PVDF membranes were gently dabbed onto tissue paper to remove any 
excess solution, before being mounted into a HypercassetteTM. Once within the darkroom, 
sheets of Amersham HyperfilmTM were exposed to the membranes (film exposure times are 
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detailed in Table 2.12). An Xograph Compact X4 Automatic X-Ray Film Processor was then 
used to develop the films obtained.  
 
Once blotting images had been captured, the membranes were rinsed with PBS-T to remove 
any residual ECL and then blocked with 5% milk in PBS-T, for two hours at room 
temperature on the shaker. To enable the reuse of the membranes and for the assessment of 
control loading, 10% sodium azide (50µl) was added to the milk after the first hour of 
blocking to inhibit any Horseradish Peroxidase (HRP)-conjugate secondary antibodies 
residing on the membranes. Next, the membranes were probed for the loading control, α-
Tubulin, using Anti-α-Tubulin (Table 2.11; Antibody 3), which was incubated on the 
membranes overnight at 4⁰C on a shaker. The next morning, the membranes were retrieved 
from the cold room and the primary antibodies were removed (Anti-α-Tubulin was stored at -
20⁰C and used approximately five times before being discarded). PBS-T was then used to 
thoroughly wash the membranes for one hour (PBS-T was changed every 15 minutes). 
Following washing, Anti-Ms IgG (Table 2.11; Antibody 4) was applied to the washed 
membranes and incubated for one hour at room temperature on a shaker. After the secondary 
antibody was discarded, the membranes were once again washed with PBS-T for one hour 
(PBS-T was changed every 15 minutes), before being incubated with ECL and then 
developed as described above. Film exposure times are detailed in Table 2.12. 
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Table 2.11 Western blotting antibodies (human platelet samples) 
For each antibody used during the human platelet study, this table details: their classification, 
their code, their manufacturer and the dilution at which they were used during Western 
blotting. Goat (Gt), Rabbit (Rb), Mouse (Ms), Antibody (Ab), Polyclonal Antibody (pAb), 
Monoclonal Antibody (mAb) and Horse Radish Peroxidase (HRP). 
 
Primary Antibody Secondary Antibody Exposure Time (Seconds) 
Anti-Phospho-VASP (Ser293) Anti-Rb IgG 600 
Anti-α-Tubulin               Anti-Ms IgG               20 
Table 2.12: Optimum exposure time of the Amersham HyperfilmTM to each membrane  
 
2.1.4.5 Data analysis (Western blotting) 
 
To quantify the protein bands on the VASP Western blot films, densitometric analysis was 
carried out using Adobe® Photoshop® CS Version 8.0. The densitometry data collected was 
then transferred to Prism Version 7.0 (Graphpad Software, Inc., La Jolla, CA) for statistical 
analysis. 
 
 
Antibody 
(Antibody code, Antibody type) 
Manufacturer Dilution factor used 
1 
Anti-Phospho-VASP (Ser293) 
Rb pAb 
(3114, Primary Ab) 
Cell Signalling 1:1000  
in 5% BSA/PBS-Tween 
2 
Anti-Rb IgG 
HRP-linked Gt pAb 
(7074, Secondary Ab) 
Cell Signalling 1:10,000  
in 1% Milk/PBS-Tween 
3 
Anti-α-Tubulin 
Ms mAb 
(T6199, Primary Ab) 
SIGMA-ALDRICH® 1:5000                                     
in 5% BSA/PBS-Tween 
4 
Anti-Ms IgG 
HRP-linked Gt pAb 
(P0447, Secondary Ab) 
Dako  1:10,000                                         
in 1% Milk/PBS-Tween 
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2.2 Animal experiments  
 
2.2.1 Animal ethics  
 
Adult male ALDH2 wild type (WT) and knockout (KO) mice (25-30g, background C57BL/6 
mice; supplied by RIKEN, Japan) were used throughout the research project. The 
experimental procedures performed on the mice had been approved by the UK Home Office 
and adhered to the UK Animals (Scientific Procedures) Act 1986. Cervical dislocation was 
used as a schedule one method for culling mice in the present study. 
 
2.2.2 Genotyping 
 
The ALDH2 breeding colony was maintained with heterozygous (HET) mice paired with 
either (i) HET, (ii) WT and/or (iii) KO mice. Regular genotyping was therefore necessary to 
identify male ALDH2 WT and KO mice for experimentation. The deoxyribonucleic acid 
(DNA) required for genotyping was obtained from mouse ear clippings, which were stored 
(at -20°C) until further analysis was possible (Section 2.2.2.1).  
 
2.2.2.1 Sample digestion, DNA isolation and extraction 
 
DNA AWAYTM surface decontaminant (ThermoFisher Scientific) was used to degrade traces 
of DNA contaminating the laboratory benches and equipment required for genotyping. DNA 
AWAYTM was sprayed before each major step in the genotyping protocol (Sections 2.2.2.1, 
2.2.2.2 and 2.2.2.3) and left to stand for two minutes. The surfaces and equipment were then 
dried thoroughly using disposable paper towels.  
 
An ISOLATE II genomic DNA Kit (BIOLINE) was used according to the manufacturer’s 
guidelines to digest the tissue samples, and to isolate and extract their contained DNA. 
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Firstly, samples (a maximum of 11 at any one time) were removed from the -20°C freezer 
and allowed to defrost for a short period of time. Lysis buffer GL (180µL; BIOLINE) and the 
peptidase proteinase K (25µL; BIOLINE) were then added to each tissue sample. Next, the 
samples were thoroughly vortexed (WhirliMixerTM, Fisons Scientific Equipment), before 
being heated at 56°C, 300rpm (Eppendorf ThermoMixer, C) for minimum of two hours. Each 
sample was completely immersed by the proteinase K/lysis buffer GL mixture to ensure that 
all proteins and cell membranes were effectively digested. 
 
Following tissue digestion, the lysates were removed from the heating block and vigorously 
vortexed. Lysis buffer G3 (200µL; BIOLINE) was then added to the Eppendorf tubes and the 
lysates were vortexed, before undergoing a 10-minute incubation at 70°C to denature 
proteinase K. The lysates were then transferred back to room temperature and vortexed once 
again. Next, ethanol (200µL, 96-100%; BDH PROLABO® VWR Chemicals), which 
functioned to precipitate the DNA from the aqueous solutions, was added to the Eppendorf 
tubes and the lysates were vigorously vortexed.  
 
The lysates were then transferred from the Eppendorf tubes to labelled genomic DNA spin 
columns containing silica gel membranes (BIOLINE). The lysate-filled spin columns were 
then centrifuged at 11,000xg for one minute at room temperature (Eppendorf Centrifuge, 
5430R). This spinning process forced the lysates through the silica membranes, thus 
facilitating interactions between the DNA and the silica surface. The flow-through collected 
from each lysate was discarded from the collection tubes.  
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Impurities and enzyme inhibitors were then removed from the membrane-bound DNA with a 
three-stage washing and drying process. Firstly, wash buffer GW1 (500µL; BIOLINE) was 
pipetted into the spin columns, which were then centrifuged at 11,000xg for one minute at 
room temperature. The resultant flow-through was discarded. Wash buffer GW2 (600µL; 
BIOLINE) was then pipetted into the spin columns. Once again, the columns were 
centrifuged at 11,000xg for one minute at room temperature and the flow-through was 
discarded. Finally, a dry spin (11,000xg for one minute at room temperature) was carried out 
to eradicate any residual ethanol from the membrane-bound DNA. This step was essential 
due to the ability of the ethanol to significantly inhibit the polymerase chain reaction (PCR; 
Section 2.2.2.2).  
 
The spin columns were then transferred from the collection tubes to autoclaved, labelled 
1.5mL Eppendorf tubes. The isolated/purified DNA was then extracted from the silica 
membranes using elution buffer G (100µL; BIOLINE, a low ionic strength buffer), which had 
been previously heated to 70°C. The eluent was applied directly onto the silica membranes 
and left to incubate at room temperature for one minute. The spin columns were then 
centrifuged for a final time at 11,000xg for one minute at room temperature. The flow-
through collected contained the purified DNA and was stored in the fridge prior to PCR 
(Section 2.2.2.2).  
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2.2.2.2 Polymerase chain reaction  
 
PCR was then used to amplify specific fragments within the extracted DNA. This expansion 
process facilitated the detection of the DNA fragments, following the separation of the PCR 
products by gel electrophoresis (Section 2.2.2.3), and thus enabled the identification of mouse 
genotype. To avoid contamination, PCR reagents/samples were prepared under sterile 
conditions (safety cabinet; Thermo Scientific Holten Safe 2010). Firstly, master mix 
components (Tables 2.13 and 2.14) were pipetted into a 1.5mL Eppendorf tube and then 
thoroughly mixed by inversion. PCR samples, which contained 18.5µL of master mix and 
1µL purified DNA, were then prepared in autoclaved, labelled PCR tubes. Three positive 
controls (18.5µL master mix + 1µL purified HET, WT or KO DNA from previously 
genotyped mice) and one negative control (18.5µL master mix) were also prepared. Once 
mixed by inversion, the PCR samples and controls were transferred to a thermocycler 48 
PCR machine (SENSOQUEST) and the ALDH2 PCR programme (Figure 2.9) was initiated. 
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Reagents (Manufacturer) Volume 
per 
Sample 
(µL) 
E.g. Volume for 10 Samples (5 
samples, 3 positive controls, 1 
negative control and 1 extra 
‘sample’ to allow for any pipetting 
errors) (µL) 
Ready Mix PCR Master Mix (2x 
concentrated solution of Taq DNA 
polymerase, DNA nucleotide bases and 
all components required for PCR (e.g. 
buffer to ensure the right conditions for 
the reaction), excluding the DNA 
template and relevant primers) 
(ThermoFisher SCIENTIFIC) 
10 100 
Primer 1 (ALDH2_F1) (SIGMA-
ALDRICH®) 
1 10 
Primer 2 (ALDH2_Int3_Rv) (SIGMA-
ALDRICH®) 
1 10 
Primer 3 (ALDH2_R3) (SIGMA-
ALDRICH®) 
0.5 5 
HypureTM Cell Culture Grade Water 
(HycloneTM) 
6 60 
Table 2.13: Volumes of reagents (µL) used to produce the PCR master mix 
 
Primer Name 
(Manufacturer) 
Primer 
Direction 
Primer Sequence Length 
(bp) 
Bands 
Recognised 
(bp) 
ALDH2 _F1 
(SIGMA-
ALDRICH®) 
Forward CCGTACTGACTGTCCCATGCAGTGCT 26 WT band at 
597 and KO 
band at 280 
ALDH2_Int3_Rv 
(SIGMA-
ALDRICH®) 
Reverse GTTCACTCTGGTGACCACCATAGAG 25 WT band at 
597 
ALDH2_R3 
(SIGMA-
ALDRICH®) 
Reverse GGTGGATGTGGAATGTGTGCGAGGC 25 KO band at 
280 
Table 2.14: ALDH2 primers used at a final concentration of 10µM during PCR 
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Figure 2.9: ALDH2 PCR programme (thermal cycling) 
The one hour and 38 minute ALDH2 PCR programme comprised three stages: (i) a 
denaturing stage (two phases, 94°C for 3 minutes (1x) and 94°C for 30 seconds (30x)), (ii) 
an annealing stage (one phase, 55°C for 30 seconds (30x)) and (iii) an extending stage 
(two phases, 72°C for one minute (30x) and 72°C for five minutes (1x)). Firstly, the high 
temperature (94°C) maintained during the denaturing stage of the PCR programme 
functioned to break the hydrogen bonds between the base pairs of the template DNA, and 
thus led to the complete unwinding of the DNA double helix. DNA strand separation then 
enabled DNA primers (ALDH2_F1 (forward primer), ALDH2_Int3_Rv (reverse primer) 
and ALDH2_R3 (reverse primer)) to base pair, via hydrogen bonds, to the complementary 
regions of the template DNA. This base pairing process only commenced once the 
temperature had been significantly reduced during the annealing phase (55°C) of the PCR 
programme. Moreover, the rise in temperature during the extending stage (72°C) of the 
PCR programme then facilitated complementary base paring of DNA nucleotide bases 
(dNTPS: A, C, G and T) to the template DNA. dNTPs were one-by-one added to the 
template DNA by Taq polymerase (a thermostable enzyme with 5’ to 3’ polymerase and 
exonuclease activity), which attached at the primers in order to synthesise the 
complementary DNA strand. The three stages of the PCR cycle were repeated many times 
to produce numerous copies of the desired DNA sequences in a relatively short time 
frame. 
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2.2.2.3 Agarose gel electrophoresis  
 
To determine the genotype of each ALDH2 mouse, PCR products were separated using 
agarose gel electrophoresis. Firstly, a 2% agarose gel was produced by combining agarose 
(2g; BIOLINE) and 1x Tris acetate-EDTA buffer (TAE) (100ml; SIGMA-ALDRICH®, made 
from a 10x TAE stock) in a 250ml beaker. This mixture was then heated intermittently for 
one minute in a microwave (PROline Micro Chef ST44, 950W) to dissolve the agarose 
crystals. Once the solution was completely transparent, SYBR® Safe DNA gel stain (5µL; 
Invitrogen) was added to the beaker. The agarose solution was then swirled to release any 
trapped air and left to cool for approximately five minutes, before being poured into an 
agarose gel casting tray (HU13). A cooler agarose solution resulted in a gel with a more 
constant pore size and averted gel apparatus warping from excessive heat. Sample wells were 
then formed with a 16-well comb (HU13), which was inserted into the agarose solution soon 
after pouring. Once set, the agarose gel was transferred to a gel electrophoresis unit (HU13 
Mini-Plus Horizontal) filled with 1x TAE. The 16-well comb was then carefully removed. 
Next, the 100bp DNA ladder (5µL; PROMEGA), control PCR products (15µL; three positive 
controls (HET, KO and WT) and one negative control) and sample PCR products (15µL) 
were carefully pipetted into the wells of the agarose gel. The gel was then supplied with 100 
volts for 40 minutes to separate the PCR products. After run completion, a GeneGenius gel 
imaging system (Syngene) containing a dark room, UV transilluminator, PC with GeneSnap 
software and thermal printer, was used to visualise and capture images of the DNA 
fragments. The genotype of each mouse was then determined from the printouts, with the 
positive controls acting as references (Figure 2.10). PCR and agarose gel electrophoresis 
were repeated when bands appeared in the negative control lane due to the potential for 
contamination to distort the genotyping results. 
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Figure 2.10: Identification of ALDH2 mouse genotype  
DNA fragments were separated during agarose gel electrophoresis on the basis of their 
size (length in bp). Larger DNA fragments moved more slowly through the gel than 
smaller DNA fragments, thus larger DNA fragments could be seen to move a shorter 
distance through the gel and were visualised closer to the sample wells than smaller DNA 
fragments. The first lane in the gel contained the 100bp DNA ladder. The ladder was used 
for band identification and to establish DNA fragment size. The second lane in the gel 
comprised DNA from an ALDH2 HET mouse (HET control). The HET mice possessed 
one complete copy of the ALDH2 gene (demonstrated by the 597bp band) and one 
incomplete copy of the ALDH2 gene (demonstrated by the 280bp band). The third lane in 
the gel contained DNA from an ALDH2 KO mouse (KO control). The KO mice had two 
incomplete copies of the ALDH2 gene (demonstrated by the presence of the 280bp band 
only). The ALDH2 gene was knocked out by inserting a stop codon and neomycin 
selection cassette into exon three of the ALDH2 gene (these insertions disrupted the gene 
and thus prevented normal protein expression). The fourth lane in the gel comprised DNA 
from an ALDH2 WT mouse (WT control). The WT mice possessed two complete copies 
of the ALDH2 gene (demonstrated by the presence of the 597bp band only). 
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2.2.3 ALDH2 blood and tissue harvest 
 
2.2.3.1 Collection of mouse blood  
 
The blood samples required for the mouse washed platelet aggregation study (Section 2.2.4) 
and Western blotting investigations (Section 2.2.5) were collected from the inferior vena cava 
(IVC) as previously described (Adeghe and Cohen, 1986; Cazenave et al., 2004). Firstly, 
inhalation anaesthetics were used to anesthetise a male ALDH2 WT or KO mouse (25-30g) 
during terminal bleeding. A downdraft table (DDT; LEEC), comprising a source of oxygen 
(supplied at 1.5-2mL/min; Clinipath), flow meter, precision vaporizer, breathing circuit (non-
rebreathing “Bain circuit”) and scavenging system (PUREX), was used to deliver Isoflurane 
(a halogenated ether; IsoFlo®) to the mouse. Anaesthesia was first induced using an attached 
induction chamber (VetTech Solutions Ltd), which supplied isoflurane at a concentration of 
4-5% + 0.8-1 L/min. Once sedated, and following cessation of the pedal withdrawal reflex, 
the mouse was quickly removed from the induction chamber, placed onto a dissection board 
and fitted with a face mask (Patterson Scientific). The face mask supplied isoflurane at a 
concentration of 1-3% + 0.8-1L/min to maintain anaesthesia for the remainder of the bleeding 
process.  
 
The mouse was secured to the dissection board as shown in Figures 2.11A and B. The 
abdomen was then swabbed with 70% ethanol, before sterile surgical forceps and scissors 
(WEISS) were used to make a midline longitudinal incision approximately 3-4cm in length. 
The resultant skin flaps were then moved aside to enable the dissection of the peritoneum. 
Next, the viscera (e.g. intestines) was displaced from the abdomen to reveal the vertebral 
column and IVC (Figure 2.11A). A 1mL syringe with a 25G needle, containing 100µL of the 
anticoagulant ACD (Table 2.1), was then carefully inserted into the widest section of the IVC 
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(just above the confluence of the common iliac veins; Figure 2.11B). Once blood had entered 
the syringe (aided by capillary action), gentle suction was applied with the plunger until 
blood flow ceased. Approximately 1mL of blood was collected per mouse.  
 
Following exsanguination, death was confirmed by cervical dislocation. The needle was then 
carefully removed from the syringe and discarded, before the collected blood was slowly 
transferred into a 1.5mL Eppendorf tube containing 200µL of MTB (on the day of 
experimentation 45mg glucose had been added to 50mL MTB and the pH had been adjusted 
(using a H12210 pH meter; HANNA Instruments) to 7.3 at 37°C; Table 2.3). The Eppendorf 
tube was gently inverted to mix the blood with the MTB.  
 
 
 
 
 
 
 
 
 
Figure 2.11: Blood collection via the IVC in ALDH2 WT and KO mice 
A) This image demonstrates the anatomical position of the IVC within the mouse 
abdomen. To expose the inferior vena cava a 3-4cm midline longitudinal abdominal 
incision was carried out. This opening revealed the peritoneum, which was carefully 
dissected before the viscera was displaced from the abdomen to reveal the desired vessel.  
B) This image details the 1mL syringe (25G needle, 100µL of ACD) inserted into the IVC 
ready for blood collection.  
 
(Images taken from Im and Muschel, 2017) 
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2.2.3.2 Collection of mouse tissue 
 
For the assessment of ALDH2 expression (Section 2.2.5) and/or lipid accumulation (Section 
2.2.6), the median and left lateral liver lobes (liver tissue), quadriceps of the hind limb 
(skeletal muscle tissue) and heart (cardiac tissue) were all harvested from the ALDH2 WT 
and KO mice, following exsanguination (Section 2.2.3.1). After extraction, the tissues were 
briefly washed in ice-cold Krebs-Henseleit buffer (KHB; Table 2.15) and blotted dry, before 
being placed into previously labelled cryovials. The tissue samples were then immediately 
snap-frozen in liquid nitrogen and stored at -80°C until further processing. 
Table 2.15: Concentration (mM) of reagents in the Krebs-Henseleit Buffer 
 
 
 
 
 
 
 
 
 
Reagents (Manufacturer) Concentration (mM) 
NaCl (SIGMA-ALDRICH®) 118.5 
NaHCO3 (Fisher Scientific UK) 25 
KCl (VWR®) 4.7 
MgSO4.7H2O (VWR®) 1.2 
KH2PO4 (VWR®) 1.2 
Glucose (Fisher Scientific UK) 1.1 
CaCl2.H2O (VWR®) 
(*the Krebs solution was gassed with 
95%O2/5%CO2 for 10-15 minutes before 
CaCl2.H2O was added) 
1.4 
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2.2.4 Mouse washed platelet aggregation study 
 
2.2.4.1 Preparation of washed mouse platelets 
 
Washed mouse platelets were prepared as previously described (Cazenave et al., 2004). 
Firstly, Eppendorf tubes comprising blood samples from ALDH2 WT and KO mice (Section 
2.2.3.1), were first centrifuged (MSE Micro Centaur) at 2000rpm (<200xg) for five minutes 
at room temperature, to fractionate the samples (Figure 2.2). The separated plasma and top 
two thirds of the erythrocyte layer were then aspirated and pipetted into sterile 1.5mL 
Eppendorf tubes. The plasma/erythrocyte mixtures were then centrifuged (Denley BS400 
Centrifuge, Swinging Bucket) at 1000rpm (200xg) for six minutes at room temperature, to 
pellet any contaminating erythrocytes and leukocytes. The separated plasma was then 
aspirated (care was taken to avoid the buffy coat; Figure 2.2) and pipetted into sterile 1.5mL 
Eppendorf tubes. Next, 200µL MTB (Table 2.3) was added to the pellets, which were then 
gently mixed by inversion, before being centrifuged (Denley BS400 Centrifuge, Swinging 
Bucket) for a second time at 1000rpm (200xg) for six minutes at room temperature. The 
separated plasma was then carefully aspirated and pooled with the previously collected 
plasma.  
 
The plasma volume was then standardised to 1mL with MTB (approximately 600-800µL of 
plasma was collected per mouse). Next, 1µL of 1mg/mL PGI2 (Table 2.2) was added to the 
plasma to prevent platelet activation during high-speed centrifugation. The plasma was then 
centrifuged (Denley BS400 Centrifuge, Swinging Bucket) at 2800rpm (1000xg) for six 
minutes at room temperature, to pellet the platelets. The resultant supernatant was aspirated, 
and the washed platelets were re-suspended in 200µL MTB. 
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2.2.4.2 Mouse platelet count 		
The ZTM Series COULTER COUNTER® was used to identify the number of platelets present 
in the ALDH2 WT and KO mouse platelet samples. As described in Section 2.1.3.3, the 
Coulter counter was first cleaned with ISOTON, before platelet samples were diluted 
(washed platelets; 5µL, ISOTON; 10mL) and then counted (platelets/mL) a total of three 
times. Once again, averages were calculated (platelets/mL). 
  
The ALDH2 WT and KO mouse platelets were then further diluted in MTB to a 
concentration of 2x108 platelets/mL for LTA experiments (Calculation 2.4 and Section 
2.2.4.3). Before commencing these experiments, the washed platelets were rested for one 
hour to allow time for PGI2 degradation (Cazenave et al., 2004). 
 
Calculation 2.4: Example of washed platelet calculation (mouse platelet samples) 
 
Example of platelet count = 15.66x108/mL in 200µL 
Concentration 1 x Volume 1 = Concentration 2 x Volume 2  
15.66x108/mL x 0.2mL = 2x108/mL x (X + 0.2mL)                   
15.66x108/mL x 0.2mL = 2x108/mL x (X + 0.2mL)                  (÷2) 
15.66 x 0.1 = X + 0.2                                                                   (x0.1) 
1.566 = X + 0.2                                                                            (-0.2) 
1.566-0.2 = X = 1.366mL = 1366µL 
 
Add 1366µL of MTB to the 200µL platelet sample to give a washed platelet 
concentration of 2x108/mL for aggregation experiments (total volume = 1566µL). 
 
Total volume of platelets = Number of possible aggregations  
    Volume of platelets  
required for aggregation 
 
1566µL = 5.22 = 5 aggregations 
 300µL  
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2.2.4.3 Mouse platelet aggregation 
 
Mouse LTA experiments were conducted to compare the effects of NaNO2 vs SNP (NO 
donor) in washed platelets from ALDH2 WT and KO mice (Borgognone et al., 2014; 
Borgognone et al., 2018). During the one-hour platelet rest period, the aggregometer, cuvettes 
(samples; 300µL of washed ALDH2 WT or KO platelets at a concentration of 2x108 
platelets/mL, reference blanks; 500µL of MTB) and compounds (NaNO2, SNP and collagen 
dilutions) required for the mouse LTA experiments were prepared as described in Section 
2.1.3.4.  
 
On completion of the platelet rest period, aggregatory responses to collagen were recorded 
under a variety of conditions. 
 
A total of five LTA experiments were conducted per mouse: 
• Collagen (3µg/mL) (collagen control) 
• NaNO2 (10µM, 100µM or 1mM NaNO2) + 3µg/mL collagen 
• SNP (100nM) + 3µg/mL collagen 
 
Similar protocols were used for both the human (Section 2.1.3.4.3) and mouse LTA 
experiments.  
 
2.2.4.4 Data analysis (mouse platelet aggregation) 
 
The aggregatory responses produced during the mouse LTA experiments were analysed as 
described in Section 2.1.3.5.  
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2.2.5 Western blotting (mouse platelet and tissue samples) 
 
2.2.5.1 Platelet homogenate preparation (mouse platelet samples) 
 
To investigate ALDH2 expression in washed platelets and tissues (liver, skeletal muscle and 
cardiac tissue), Western blot analysis was conducted (Borgognone et al., 2014; Borgognone 
et al., 2018). 
 
To prepare the platelet homogenates, blood was first collected from ALDH2 WT and KO 
mice (Section 2.2.3.1). Washed platelets were then prepared as described in Section 2.2.4.1, 
before being counted, diluted to a concentration of 5x108 platelets/mL for Western blotting 
and then rested for one hour (Section 2.2.4.2). The aggregometer, cuvettes (which contained 
300µL of ALDH2 WT or KO washed platelets at a concentration of 5x108 platelets/mL and a 
stirrer bar) and 5x reduced Laemmli sample buffer (Table 2.7) were all prepared during this 
rest period. 
 
Similar protocols were used to prepare the human (Section 2.1.4.1) and mouse platelet 
homogenates.  
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2.2.5.2 Tissue homogenate sample preparation (mouse liver, skeletal muscle and cardiac 
tissue samples) 
 
On the day of homogenate preparation, liver, skeletal muscle and cardiac tissue samples 
collected from ALDH2 WT and KO mice (Section 2.2.3.2) were removed from the -80°C 
freezer and placed into liquid nitrogen. Each sample was then individually extracted from the 
liquid nitrogen dewar, before being crushed into a fine powder with a sterile mortar and 
pestle, whilst still under liquid nitrogen conditions. By processing one sample at a time, this 
prevented tissue thawing and therefore helped to maintain sample quality. 
 
Once crushed, the tissue samples were immediately mixed with ice-cold homogenate buffer 
(HB; Table 2.16). Due to the variability in tissue mass, 250µL of HB was added to the 
skeletal muscle and cardiac tissue samples, whilst 500µL of HB was added to the liver tissue 
samples. As the tissues began to thaw, another volume of HB (skeletal muscle/cardiac tissue 
samples; 250µL, liver tissue samples; 500µL) was thoroughly stirred into each sample. The 
thawed homogenates were then pipetted into labelled Eppendorf tubes and snap-frozen in 
liquid nitrogen. To ensure each sample was entirely homogenised, a freeze-thawing process 
was then carried out. During this process, the homogenates were first removed from the 
liquid nitrogen and allowed to thaw on ice for 15 minutes. The homogenates were then snap-
frozen for the second time, before being extracted from the liquid nitrogen and left to thaw on 
ice for approximately 30 minutes. Next, the thawed samples were centrifuged (13,000 RPM; 
Eppendorf Centrifuge, 5430R) for 15 minutes at 4⁰C, to pellet the debris. The supernatant 
was then pipetted into sterile Eppendorf tubes and the liver, skeletal muscle and cardiac tissue 
homogenates were stored on ice until the protein assay (Section 2.2.5.3) could be completed. 
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Reagents 
(Manufacturer) 
Volume 
(µL) 
Quantity Function 
100mM Tris 
Buffer (pH 7.4) 
(Trizma base 
=SIGMA-
ALDRICH®)                                       
4.9x104 - An effective buffer solution that regulates sample 
acidity and osmolarity. 
200mM 
Sodium 
Orthovanadate 
Stock (SIGMA-
ALDRICH®) 
500 - Following cell 
lysis, phosphatases, 
kinases and 
proteases, which 
are usually 
regulated, 
compartmentalised 
and trafficked 
within cells, move 
freely throughout 
the sample and can 
therefore target 
sample proteins. 
A competitive inhibitor of 
protein tyrosine 
phosphatases, alkaline 
phosphatase, ATPase, 
adenosine kinase and 
phosphofructokinase, that 
maintains the 
phosphorylation state of 
proteins within the sample. 
500mM 
Sodium 
Fluoride Stock 
(SIGMA-
ALDRICH®) 
500 - An inhibitor of protein 
phosphoseryl and 
phosphothreonyl 
phosphatases, that maintains 
the phosphorylation state of 
proteins within the sample. 
Protease 
Inhibitor Tablet 
(ROCHE) 
- 1 tablet Inhibitors of serine-
proteases, cysteine-
proteases, aspartic acid-
proteases and 
aminopeptidases, that 
prevent proteolytic 
degradation of proteins 
within sample. 
Table 2.16: Volumes (µL) of reagents used to make HB (50mL) 
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2.2.5.3 Protein assay 
 
To determine the protein content of the ALDH2 WT and KO mouse tissue homogenates 
(liver, skeletal muscle and cardiac tissue; Section 2.2.5.2), a Bio-Rad DCTM protein assay 
(detergent compatible colorimetric assay for protein concentration) was carried out according 
to the manufacturer guidelines. Firstly, working reagent A was prepared by combining 
reagent S with reagent A (20µL of reagent S was added to each mL of reagent A; Calculation 
2.5). Next, each sample was appropriately diluted (1:20 dilution in HB; Table 2.16) and 
bovine serum albumin (BSA; SIGMA-ALDRICH®) standards were prepared from a 1mg/mL 
BSA stock solution (Table 2.17). Both the standards and samples were stored on ice.  
 
Triplicates (5µL per well) of the standards and samples were then pipetted into a sterile 96-
well microtiter plate (FALCON®). Working reagent A (25µL) and Reagent B (200µL) were 
also loaded into the filled wells. To protect the UV sensitive reagents, the prepared microtiter 
plate was carefully covered with foil, before being left to incubate for 15 minutes at room 
temperature on a shaker. At the end of this incubation period, the foil was removed and a 
spectrophotometer (GE Healthcare/Amersham Biosciences Ultrospec 3100 Pro UV/Visible 
Spectrophotometer) was used to measure the absorbance of each well at 750nm. The 
absorbance readings were reliant on the development of colour, which resulted from the 
reaction between standard/sample proteins and reagent components, such as alkaline copper 
tartrate solution and Folin reagent. High levels of colour, and therefore high absorbance 
readings, were produced by wells with a high protein content, whereas low levels of 
colour/low absorbance readings resulted from wells with a low protein content. An average 
absorbance was calculated for each triplicate.  
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A BSA standard curve was then constructed to identify the protein content of the liver, 
skeletal muscle and cardiac tissue homogenates from their absorbance readings. The linear 
relationship between absorbance and concentration enabled this cross-referencing process. 
When sample absorbance correlated with the extreme top or bottom of the BSA standard 
curve, the protein assay was repeated at an alternative sample dilution (e.g. 1:10 or 1:50) due 
to the potential for reagent saturation and experimental error. Following the establishment of 
protein content, the tissue homogenates were diluted to a protein concentration of 25µg in 
Bio-Rad Laemmli Buffer with 5% β-mercaptoethanol, and then stored at -20⁰C for future 
Western blotting analysis. 
Calculation 2.5: Reagent A/working reagent A requirement calculation 
 
Concentration of the BSA 
Standard 
(µg/µL) 
Volume of 1µg/µL BSA 
Stock Solution 
(µL) 
Volume of HB 
(µL) 
0 0 300 
0.2 60 240 
0.4 120 180 
0.6 180 120 
0.8 240 60 
1.0 300 0 
Table 2.17: Volumes (µL) of reagents used to make BSA standards (300µL) 
 
E.g. 6 BSA standards and 6 samples   
 
6 BSA standards x 3 wells = 18 wells  
6 samples x 3 wells = 18 wells  
18 wells + 18 wells = 36 wells  
 
25µL of working reagent A per well  
25µL x 36 wells = 900µL working reagent A required 
 
For 900µL working reagent A  
20µL of reagent S + 1000µL reagent A = 1020µL working reagent A (120µL spare) 
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2.2.5.4 SDS-PAGE  
 
An SDS-PAGE gel containing 8% acrylamide was constructed as described in Section 
2.1.4.2. The ALDH2 WT and KO mouse homogenates (platelets, liver tissue, skeletal muscle 
tissue and cardiac tissue) were also vortexed, boiled and centrifuged, prior to SDS-PAGE 
(Section 2.1.4.2). The prepared homogenates (20µL/well) and protein ladder were then 
loaded into the 8% acrylamide gel, which was ran as detailed in Section 2.1.4.2.  
 
2.2.5.5 Wet transfer  
 
Following gel electrophoresis, wet transfer was carried out as described in Section 2.1.4.3. 
This process transferred the separated proteins from the gel onto a PVDF membrane.  	
2.2.5.6 Antibody incubation and film development  
 
To determine ALDH2 expression (52.6 kDa) in ALDH2 WT and KO mouse washed platelets 
and tissues (liver, skeletal muscle and cardiac tissue), Western blot analysis was carried out. 
Similar protocols were used to complete Western blotting in the human (Section 2.1.4.4) and 
mouse homogenates.  
 
Following wet transfer, the PVDF membrane was blocked and then probed with anti-ALDH2 
(Table 2.18; Antibody 1; stored at -20⁰C and used approximately three to five times before 
being discarded) overnight at 4⁰C on a shaker. Once washed, the membrane was probed with 
anti-Gt IgG (Table 2.18; Antibody 2) for one hour at room temperature on a shaker. After the 
secondary antibody had been discarded, the membrane was washed, incubated with ECL and 
then developed (film exposure times are detailed in Table 2.19).  
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The membrane was then rinsed and blocked with milk and sodium azide. Next, the membrane 
was probed for the loading controls, α-Tubulin and GAPDH, using Anti-α-Tubulin (Table 
2.18; Antibody 3) and Anti-GAPDH (Table 2.18; Antibody 4), respectively. The membrane 
was first probed for α-Tubulin, before being blocked with milk and azide, and then probed for 
GAPDH. Following an overnight incubation at 4⁰C on a shaker, the primary antibodies were 
removed (Anti-α-Tubulin and Anti-GAPDH were stored at -20⁰C and used approximately 
five times before being discarded) and the membrane was washed. Anti-Ms IgG (Table 2.18; 
Antibody 5) was then applied to the membrane and incubated for one hour at room 
temperature on a shaker. Once the secondary antibody had been discarded, the membrane 
was washed, incubated with ECL and then developed (film exposure times are detailed in 
Table 2.19). 
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Table 2.18: Western blotting antibodies (ALDH2 WT and KO platelet and tissue samples) 
For each antibody used during the mouse study, this table details: their classification, their 
code, their manufacturer and the dilution at which they were used during Western blotting. 
Goat (Gt), Mouse (Ms), Antibody (Ab), Polyclonal Antibody (pAb), Monoclonal Antibody 
(mAb) and Horse Radish Peroxidase (HRP). 
 
Primary Antibody Secondary Antibody Exposure Time (Seconds) 
Anti-ALDH2                  Anti-Gt IgG                600 
Anti-α-Tubulin               Anti-Ms IgG               20 
Anti-GAPDH Anti-Ms IgG 10 
Table 2.19: Optimum exposure time of the Amersham HyperfilmTM to each membrane  
 
2.2.5.7 Data analysis (Western blotting) 
 
To quantify the protein bands on the ALDH2 Western blot films, analysis was carried out as 
described in Section 2.1.4.5.  
 
Antibody 
(Antibody code, Antibody type) 
Manufacturer Dilution factor used 
1 
Anti-ALDH2 
Gt pAb 
(48837, Primary Ab) 
Santa Cruz 
Biotechnology 
1:1000                                    
in 5% BSA/PBS-Tween 
2 
Anti-Gt IgG 
HRP-linked Dk mAb 
(2033, Secondary Ab) 
Santa Cruz 
Biotechnology 
1:10,000                                         
in 5% Milk/PBS-Tween 
3 
Anti-α-Tubulin 
Ms mAb 
(T6199, Primary Ab) 
SIGMA-ALDRICH® 1:5000                                     
in 5% BSA/PBS-Tween 
4 
Anti-GAPDH 
Ms mAb 
(9484, Primary Ab) 
Abcam® 1:20,000  
in 5% Milk/PBS-Tween 
5 
Anti-Ms IgG 
HRP-linked Gt pAb 
(P0447, Secondary Ab) 
Dako  1:10,000                                         
in 1% Milk/PBS-Tween 
 
 
99 
 
2.2.6 Oil red O staining 
 
2.2.6.1 Tissue sectioning  
 
A Bright Clinicut 60 Cryostat was used to section ALDH2 WT and KO mouse tissue (liver 
and skeletal muscle tissue; Section 2.2.3.2), prior to Oil Red O (ORO) staining and 
haematoxylin counterstaining. All tissue sections were cut as previously described (Mehlem 
et al., 2013).  
 
Firstly, the liver and skeletal muscle samples were removed from the -80°C freezer and 
placed into liquid nitrogen. The tissue samples were then transferred to the cryostat chamber, 
which was maintained at a temperature of -40°C. Next, the tissues were carefully extracted 
from their cryovials and then mounted with optimum cutting temperature (OCT) compound 
(Tissue-Tek®), onto pre-cooled grooved specimen disks. Once the OCT compound had 
solidified, a specimen disk was fitted into the specimen head, which had been previously set 
at a 13° angle. The cutting handle was then rotated to move the specimen head towards the 
blade, and the sample was roughly trimmed at a cutting thickness of 30µM, until a cross-
sectional tissue face was created. All liver samples were sectioned along the coronal plane, 
whilst skeletal muscle samples were sectioned along the transverse plane.  
 
Traces of tissue and ice were removed from the blade with a stiff bristle paint brush. A few 
practice sections were completed at a cutting thickness of 6µM, to align the anti-roll plate 
with the edge of the blade and fine-tune the speed of handle rotation. Once the blade was 
clear, tissue sections were then cut and mounted, if undamaged, onto room temperature 
microscope slides (KLINIPATH; three sections were mounted onto each slide and two slides 
were prepared per sample). The anti-roll plate was carefully lifted for mounting and 
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repositioned before further sectioning. Any remaining tissue was prised from the specimen 
disk, trimmed and placed back into its cryovial for snap-freezing. The blade was thoroughly 
cleaned with the paintbrush, before trimming and sectioning the next sample. All tissue 
sections were left to dry at room temperature for 10-15 minutes, before being carefully 
wrapped in tin foil (two slides back to back) and stored at -20°C.   
 
2.2.6.2 Oil red O staining  
 
To enable the visualisation and quantification of fat cells and neutral lipids in sectioned 
ALDH2 WT and KO mouse liver and skeletal muscle tissue, ORO staining was completed 
(Mehlem et al., 2013). In the days leading up to staining, the ORO stock solution, which 
contained 0.5% ORO powder (SIGMA-ALDRICH®) in isopropanol (Fisher Scientific), was 
prepared. Approximately 30 minutes of simultaneous heating and shaking was required to 
dissolve the ORO powder in the isopropanol. 
 
On the day of staining, the liver and skeletal muscle sections were first removed from the 
freezer, laid out on staining rods in a staining tray and then left to defrost for 30 minutes. 
Whilst the sections were thawing, the ORO working solution was prepared. After mixing the 
reagents (ORO stock solution; 30mL, distilled water; 20mL), the solution was left to stand for 
10 minutes, before being filtered with Grade 1 Whatman filter paper (SIGMA-ALDRICH®) 
to remove any undissolved ORO powder.  Next, a liquid blocking pen (Dako pen, Agilent 
Technologies) was used to draw around the liver and skeletal muscle sections. This provided 
a barrier to any liquids applied to the sections and therefore enabled uniform staining, whilst 
reducing reagent usage by preventing the need for constant reapplication.  
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To begin the staining process, 60% isopropanol was first incubated on the liver and skeletal 
muscle sections for five minutes (Figure 2.12). At the end of this incubation period, the slides 
were tilted to remove the solvent and ORO working solution was then incubated on the 
sections for 15 minutes (Figure 2.12). During this time, the slides were monitored to ensure 
that the liver and skeletal muscle sections remained completely covered with ORO working 
solution, to prevent the stain from drying and becoming uneven throughout the sections. 
Next, the ORO working solution was removed and 60% isopropanol was incubated on the 
sections for another five minutes (Figure 2.12). Isopropanol incubations encouraged ORO 
staining within the sections as ORO was more soluble in lipids than its solvent.  
 
After removing the isopropanol, Mayer’s haematoxylin counterstain (pfm medical UK Ltd) 
was applied to half of the slides to visualise tissue morphology and cell nuclei (per mouse; 4x 
slides stained with ORO working solution (2x liver and 2x skeletal muscle), 2x slides 
counterstained with Mayer’s haematoxylin (1x liver and 1x skeletal muscle)). The sections 
were incubated with Mayer’s haematoxylin for one minute (Figure 2.12). Following the 
removal of the counterstain, the slides were placed into a horizontal slide staining rack 
(TRAJAN) and rinsed with tap water for 15 minutes to remove excess stains (Figure 2.12). 
Once dry, a small amount of water-soluble mounting medium (IMMU-MOUNT, 
SHANDON) was applied to the slides in the region of the sections. Great care was taken to 
avoid the creation of bubbles in the mounting medium. Coverslips (Deckgläser) were then 
placed over the liver and skeletal muscle sections and the slides were left at room temperature 
until dry. The stained sections were stored in a cool dark place until imaging could be 
completed (Mehlem et al., 2013).  
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A Slide Scanner Axio Scan. Z1 (Zeiss) with brightfield and fluorescence imaging, set at a 
magnification of x20, was then used to capture high-quality virtual brightfield images of the 
ALDH2 WT and KO mouse sections stained with ORO and haematoxylin (Mehlem et al., 
2013).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12: ORO and Mayer’s haematoxylin staining protocol 
ALDH2 WT and KO liver and skeletal muscle sections were incubated with: 1) 60% 
isopropanol for five minutes, 2) ORO working solution for 15 minutes, and then 3) 60% 
isopropanol for five minutes (each stain was removed before applying the next). Half of 
the slides were also counterstained with Mayer’s haematoxylin for 1 minute. Finally, all 
liver and skeletal muscle sections were rinsed with tap water for 15 minutes, to remove 
excess stains. 
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2.2.6.3 Data analysis (ORO staining in ALDH2 WT and KO tissue samples) 
 
Zen 2 (blue edition) imaging software and ImageJ Fiji were used to quantify the level of 
ORO staining, and therefore lipid accumulation, within the ALDH2 WT and KO mouse liver 
and skeletal muscle tissue sections (Mehlem et al., 2013). Firstly, Zen 2 (blue edition) 
imaging software was used to capture 10 frames per brightfield image/tissue section. Each 
image was overlaid with a grid, before 10 frames were randomly selected and captured by 
another member of the lab to prevent selection bias. ImageJ Fiji was then used to quantify the 
percentage of ORO staining present in each frame. Each frame first underwent colour 
splitting (three channels; red, green and blue), before the red channel was analysed at a set 
threshold (previously established in control animals) to identify the percentage of red 
colouring and hence ORO staining in each frame. The data collected was then transferred to 
Prism Version 7.0 (Graphpad Software, Inc., La Jolla, CA) for statistical analysis. 
 
2.3 Statistical analysis 
 
Results are shown as a representative trace/blot or an average ± standard error of the mean 
(S.E.M.). Group differences were analysed using a variety of appropriate statistical tests, 
including one-way ANOVA or two-way ANOVA with a Bonferroni post-hoc test or 
Dunnett’s test for multiple comparisons, Fisher’s exact test, and unpaired t-test. P<0.05 was 
considered to be statistically significant. Prism Version 7.0 (Graphpad Software, Inc., La 
Jolla, CA) was used for the above analysis.  
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Chapter 3: Exploration of platelet function and nitrite in young vs old 
healthy volunteers. 
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3.1 Introduction  
It is well-documented that platelet count decreases with age and previous studies have 
demonstrated that platelet count remains mostly stable during middle age (~25-60 years of 
age), but falls by approximately 8% (~20,000 platelets/µL) in the elderly (~60+ years of age) 
(Biino et al., 2013; Jones, 2016; Segal and Moliterno, 2006). Furthermore, it has been 
suggested that platelet reactivity increases almost linearly with age (Jones, 2016). Numerous 
studies have shown in middle-aged men and women (25-65 years) that there is a progressive 
increase in platelet responsiveness to a variety of agonists, such as ADP, adrenaline, collagen 
and AA (Kasjanovová and Baláz, 1986; Johnson et al., 1975; Jones, 2016). These changes in 
platelet function have been associated with alterations in mRNA/microRNA expression, 
oxidative stress and a reduction in PGI2/5HT receptors on platelets (Dayal et al., 2013; Jones, 
2016; Modesti et al., 1985; Simon et al., 2014). Although platelet reactivity has been 
thoroughly explored in middle-aged subjects, very little evidence exists on the changes in 
platelet responsiveness in the elderly (>70 years of age; Jones, 2016). However, a few studies 
have suggested that platelet function may in fact decrease in older age (Gilstad et al., 2009; 
O’Donnell et al., 2001).  
 
Previous studies have reported decreased NO bioavailability with age, thus leading to the 
development of increased platelet activation and aggregation (Torregrossa et al., 2011). In 
particular, it has been revealed that endothelial function gradually declines with age, thus 
leading to significant reductions in NO production (Goubareva et al., 2007; Jones, 2016; 
Taddei et al., 2001). Moreover, the quantity of O2- generated by enzymes, such as NADPH 
oxidase, uncoupled eNOS and mitochondrial respiratory chain complexes, also increases with 
age (van der Loo et al., 2000). In the absence of compensatory antioxidant defences, NO is 
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readily scavenged by O2-, which in turn leads to reductions in NO bioavailability and the 
formation of ONOO- (Torregrossa et al., 2011; van der Loo et al., 2000). Oxidation of BH4 by 
ONOO- contributes to the uncoupling of the eNOS dimer into single dysfunctional 
monomers, whilst excessive nitration/S-nitrosation of proteins, lipids and DNA by ONOO- 
can lead to further deleterious cardiovascular effects, including DNA strand breakage and 
poly-ADP-ribose polymerase activation (Abudukadier et al., 2013; Bailey et al., 2014; 
Bendall et al., 2005; Förstermann and Sessa, 2012).  
 
In addition, platelet NO production and responsiveness are also thought to decrease with age 
(Goubareva et al., 2007; Torregrossa et al., 2011). Despite consistent observations regarding 
NO bioavailability, conflicting data from animal studies has demonstrated that eNOS 
expression and/or activation either decreases, remains unchanged or increases with age (Seals 
et al., 2011). In a recent platelet study involving young (<30 years of age) and middle-aged 
(>45 years of age) healthy volunteers, albuterol/collagen-mediated eNOS stimulation was 
absent from the older subjects, whilst eNOS phosphorylation was significantly greater in the 
younger subjects (Goubareva et al., 2007). Basal and albuterol/collagen-stimulated sGC 
expression and cGMP production were also greater in the younger subjects (Goubareva et al., 
2007). Sverdlov and colleagues have also demonstrated increases in ADP-induced platelet 
aggregation and significant reductions in platelet responsiveness to the NO donor, SNP, over 
a 4-year study period in healthy subjects over the age of 55 (Sverdlov et al., 2014).  
 
Despite the above findings, the lack of knowledge surrounding platelet function in older age 
is particularly concerning considering many anti-platelet therapies are prescribed to the 
elderly population (Jones, 2016). It has been suggested that the nitrate-nitrite-NO pathway is 
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not affected by age (Torregrossa et al., 2011), however nitrite still remains to be thoroughly 
investigated in the elderly population. Moreover, we have previously demonstrated that 
nitrite inhibits platelet aggregation and triggers cGMP production and VASPser239 
phosphorylation in washed platelets from young healthy subjects, via NO-dependent and -
independent mechanisms. The NO-independent effects of nitrite have been linked to an 
uncharacterised direct effect on sGC, however further research into the normal physiological 
nitrite mechanism in isolated platelets is still required (Borgognone et al., 2015). 
Furthermore, it has been revealed that the sGC stimulator, BAY 41-2272, does not require 
NO for its anti-platelet effects (Hobbs and Moncada, 2003), whilst the potential for nitrite to 
act synergistically with BAY 41-2272 in washed platelets remains to be explored across all 
age groups. Herein, platelet function, nitrite-mediated inhibition and the prospect for BAY 
41-2272 to potentiate the effects of nitrite was compared in young vs old healthy volunteers. 
The involvement of NO and sGC in nitrite-mediated platelet inhibition and VASPser239 
phosphorylation was also investigated in washed platelets obtained from healthy volunteers.  
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3.2 Hypothesis and specific aims 
3.2.1 Hypothesis 
NaNO2 activates sGC independently of NO to inhibit platelet aggregation and cause 
VASPser239 phosphorylation in washed platelets from healthy volunteers.  
3.2.2 Specific aims 
This study has five main aims:  
1) To determine the collagen concentration for platelet aggregation to be used in young 
vs old healthy volunteers and for HFpEF-AF/CAF experiments in Chapter 4. 
2) To compare platelet function and the effect of nitrite in young vs old healthy 
volunteers.  
3) To investigate the involvement of NO and sGC in nitrite-mediated platelet inhibition 
in young vs old healthy volunteers.  
4) To determine whether the sGC stimulator, BAY 41-2272, potentiates the effects of 
nitrite in young vs old healthy volunteers.  
5) To investigate the involvement of NO and sGC in nitrite-mediated VASPser239 
phosphorylation in washed platelets from young healthy volunteers.  
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3.3 Research methods  
Blood samples were obtained from young and old healthy volunteers as previously described 
in Section 2.1.3. To evaluate the effects of nitrite and BAY 41-2272 on platelet aggregation, 
washed platelets were prepared and counted for LTA experiments as described in Section 
2.1.3. Aggregatory responses were then quantified as discussed in Section 2.1.3. To 
investigate the effects of nitrite on platelet VASPser239 phosphorylation, platelet homogenates 
for Western blotting were also prepared and analysed as described in Section 2.1.4. 
 
3.4 Results  
3.4.1 Subject characteristics 
Table 3.1 shows the subject characteristics. Gender was well matched in the young and old 
healthy volunteers (P=0.61; Fisher’s exact test). There was a significant difference between 
the mean age of the young healthy volunteers, when compared with the mean age of the old 
healthy volunteers (P<0.001; unpaired t-test). 
 
Parameter Young Healthy Volunteers 
(YHV) 
(n=13) 
Old Healthy Volunteers 
(OHV) 
(n=11) 
Sex (M/F) 9/4 8/3 
Age, y (Mean ±SD) 28.0±5.8 72.3±5.0 
Table 3.1: Subject characteristics 
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3.4.2 Determining the concentration response to collagen on platelet aggregation in 
young and old healthy volunteers 
 
To determine a suitable collagen concentration for platelet aggregation experiments, a dose-
response to collagen (1µg/mL, 3µg/mL or 10µg/mL) was conducted in the young and old 
healthy volunteers. Representative traces are shown in Figures 3.1A and C, respectively. As 
depicted in Figure 3.1B, 3µg/mL and 10µg/mL collagen caused approximately 57.53% and 
64.47% aggregatory responses in platelets from young healthy volunteers, whilst 1µg/mL 
collagen induced approximately 29.00% platelet aggregation. Analysis revealed that there 
was no significant difference between the 3 µg/mL and 10µg/mL collagen doses. A similar 
trend was also observed in the older healthy volunteers (Figure 3.1D). Approximately 
41.08% platelet aggregation was induced by 1µg/mL collagen, whilst there was no significant 
difference between the aggregatory responses caused by the 3µg/mL (58.39%) and 10µg/mL 
(66.12%) collagen doses. Since 3µg/mL collagen achieved a 50% aggregatory response in 
both groups of healthy volunteers, this dose was selected for the present study.  
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Figure 3.1: Platelet aggregation responses to 1, 3 and 10µg/mL collagen in young and 
old healthy volunteers 
Washed platelets at a concentration of 2x108/mL from young (YHV) and old healthy 
volunteers (OHV) were activated with either 1µg/mL, 3µg/mL or 10µg/mL collagen and 
then studied by light transmission aggregometry (LTA) for 5 minutes.  
 
A/C: Representative traces demonstrating the influence of collagen concentration on 
platelet aggregation responses in young and old healthy volunteers.  
B/D: Quantitative analysis of repeat aggregation responses (% aggregation at 5 minutes). 
Bars represent means ± S.E.M. n=10-11. Statistical differences were determined using a 
repeated measures one-way ANOVA with a Bonferroni post-hoc test (*P<0.05, **P<0.01 
and ***P<0.001 (*’s compare to 1µg/mL collagen)).  
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3.4.3 NaNO2 inhibits platelet aggregation in young and old healthy volunteers 
 
The effects of NaNO2 on washed platelet aggregation responses to 3µg/mL collagen were 
compared in young vs old healthy volunteers. Representative traces are shown in Figures 
3.2A and B, respectively. In the young healthy volunteers, incubation with NaNO2 (10µM, 
100µM or 1mM) significantly attenuated collagen-induced platelet aggregation in a dose-
dependent manner, when compared to the control group (Figure 3.2C). As shown in Figure 
3.2C, NaNO2 also inhibited collagen-induced platelet aggregation in a concentration-
dependent manner in the older healthy volunteers. We observed a significant attenuation with 
both the 100µM and 1mM doses, when compared to the control group. Furthermore, there 
was not a significant interaction between the young and old healthy volunteers. 
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Figure 3.2: Platelet aggregation responses in young and old healthy volunteers 
following NaNO2 incubation  
Washed platelets at a concentration of 2x108/mL from young (YHV) and old healthy 
volunteers (OHV) were incubated with increasing concentrations of NaNO2 (10µM, 
100µM or 1 mM) for 5 minutes, before being activated with 3µg/mL collagen and studied 
by light transmission aggregometry (LTA) for 5 minutes.  
 
A/B: Representative traces demonstrating the influence of NaNO2 incubation on platelet 
aggregation responses in young and old healthy volunteers.  
C: Quantitative analysis of repeat aggregation responses (% aggregation at 5 minutes). 
Bars represent means ± S.E.M. n=11. Statistical differences were determined using a 
repeated measures two-way ANOVA with Dunnett’s test for multiple comparisons 
(*P<0.05, **P<0.01 and ***P<0.001).  
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3.4.4 SNP inhibits platelet aggregation in young and old healthy volunteers 
 
The NO donor, SNP, was used as a positive control in the present study. The representative 
traces shown in Figures 3.3A and B, illustrate the effects of SNP on washed platelet 
aggregation responses to 3µg/mL collagen in the young and old healthy volunteers, 
respectively. In the young healthy volunteers, incubation with SNP (10nM or 100nM) led to 
significantly lower collagen-induced platelet aggregation responses, when compared to the 
control group (Figure 3.3C). A similar trend was also observed in the older healthy volunteers 
(Figure 3.3C). Incubation with SNP attenuated platelet aggregation in response to collagen in 
a dose-dependent manner, when compared to the control group. Analysis demonstrated that 
there was not a significant interaction between the young and old healthy volunteers with 
SNP treatment.  
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Figure 3.3: Platelet aggregation responses in young and old healthy volunteers 
following SNP incubation  
Washed platelets at a concentration of 2x108/mL from young (YHV) and old healthy 
volunteers (OHV) were incubated with increasing concentrations of SNP (10nM or 
100nM) for 5 minutes, before being activated with 3µg/mL collagen and studied by light 
transmission aggregometry (LTA) for 5 minutes. 
 
A/B: Representative traces demonstrating the influence of SNP incubation on platelet 
aggregation responses in young and old healthy volunteers.  
C: Quantitative analysis of repeat aggregation responses (% aggregation at 5 minutes). 
Bars represent means ± S.E.M. n=11. Statistical differences were determined using a 
repeated measures two-way ANOVA with Dunnett’s test for multiple comparisons 
(*P<0.05, **P<0.01 and ***P<0.001). 
 
 
 
116 
 
3.4.5 NaNO2 inhibits platelet aggregation via NO-independent pathway in young and 
old healthy volunteers 
 
To assess whether NaNO2 inhibits platelet aggregation via a NO-dependent or -independent 
pathway in young and old healthy volunteers, the washed platelets were incubated with two 
different NO scavengers (OxyHb and PTIO), respectively. To test the efficacy of these NO 
scavengers, platelet aggregation in response to 3µg/mL collagen was also investigated in the 
presence of the NO donor, SNP. The representative traces shown in Figures 3.4A and C, 
demonstrate the effects of OxyHb (10µM; extracellular NO scavenger) on platelet 
aggregation in the absence and presence of SNP (100nM) or NaNO2 (1mM). In the young 
healthy volunteers, OxyHb incubations were able to revert the attenuation to platelet 
aggregation caused by SNP incubations (Figure 3.4B). However, the inhibition to platelet 
aggregation resulting from NaNO2 incubations, could not be reversed with OxyHb 
incubations (Figure 3.4B). A similar trend was also observed in the older healthy volunteers 
(Figure 3.4D). OxyHb reversed the inhibition to platelet aggregation resulting from SNP, 
whilst OxyHb could not revert the attenuation to platelet aggregation caused by NaNO2.  
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Figure 3.4: Platelet aggregation responses in young and old healthy volunteers 
following: a) SNP, b) NaNO2, c) OxyHb, d) OxyHb + SNP or e) OxyHb + NaNO2 
incubations 
Washed platelets at a concentration of 2x108/mL from young (YHV) and old healthy 
volunteers (OHV) were incubated with: a) 100nM SNP, 1mM NaNO2 or 10µM OxyHb 
for 5 minutes, or b) 10µM OxyHb + 100nM SNP or 1mM NaNO2 for 5 minutes (OxyHb 
was added immediately before the SNP or NaNO2). The washed platelets were activated 
with 3µg/mL collagen and studied by light transmission aggregometry (LTA) for 5 
minutes. 
 
A/C: Representative traces demonstrating the influence of SNP, NaNO2, OxyHb, OxyHb 
+ SNP or OxyHb + NaNO2 incubation on platelet aggregation responses in young and old 
healthy volunteers.  
B/D: Quantitative analysis of repeat aggregation responses (% aggregation at 5 minutes). 
Bars represent means ± S.E.M. n=8. Statistical differences were determined using a 
repeated measures one-way ANOVA with Dunnett’s test for multiple comparisons 
(*P<0.05, **P<0.01 and ***P<0.001). 
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To determine whether NaNO2 inhibited platelet aggregation in young and old healthy 
volunteers via an intracellular NO-dependent or –independent pathway, we next used PTIO 
(intracellular NO scavenger). The representative traces shown in Figures 3.5A and C, reveal 
the influence of PTIO (100µM) on platelet aggregation in the absence and presence of SNP 
(100nM) or NaNO2 (1mM). In the young healthy volunteers, PTIO incubations were also able 
to reverse the inhibition to platelet aggregation caused by SNP incubations (Figure 3.5B). 
However similarly to OxyHb, PTIO incubations could not reverse the attenuation to platelet 
aggregation resulting from NaNO2 incubations (Figure 3.5B). Once again, the trend observed 
in the older healthy volunteers was not dissimilar (Figure 3.5D). PTIO reverted the inhibition 
to platelet aggregation resulting from SNP incubations, but could not reverse the attenuation 
to platelet aggregation caused by NaNO2.  
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Figure 3.5: Platelet aggregation responses in young and old healthy volunteers 
following: a) SNP, b) NaNO2, c) PTIO, d) PTIO + SNP or e) PTIO + NaNO2 
incubations 
Washed platelets at a concentration of 2x108/mL from young (YHV) and old healthy 
volunteers (OHV) were incubated with: a) 100nM SNP, 1mM NaNO2 or 100µM PTIO for 
5 minutes, or b) 100µM PTIO + 100nM SNP or 1mM NaNO2 for 5 minutes (PTIO was 
added immediately before the SNP or NaNO2). The washed platelets were activated with 
3µg/mL collagen and studied by light transmission aggregometry (LTA) for 5 minutes. 
 
A/C: Representative traces demonstrating the influence of SNP, NaNO2, PTIO, PTIO + 
SNP or PTIO + NaNO2 incubation on platelet aggregation responses in young and old 
healthy volunteers.  
B/D: Quantitative analysis of repeat aggregation responses (% aggregation at 5 minutes). 
Bars represent means ± S.E.M. n=8. Statistical differences were determined using a 
repeated measures one-way ANOVA with Dunnett’s test for multiple comparisons 
(*P<0.05, **P<0.01 and ***P<0.001). 
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3.4.6 NaNO2 inhibits platelet aggregation via the sGC pathway in young and old 
healthy volunteers 
 
To further dissect the mechanism by which NaNO2 attenuated platelet aggregation in both 
young and old healthy volunteers, we then assessed the possible role for sGC. As depicted in 
Figures 3.6A and C, washed platelets were incubated in the presence and absence of the sGC 
inhibitor (ODQ; 10µM), before being activated with 3µg/mL collagen. In the young healthy 
volunteers, ODQ was able to reverse the attenuation to platelet aggregation caused by 100nM 
SNP (Figure 3.6B). A similar effect was also observed with 1mM NaNO2 incubations (Figure 
3.6B). ODQ successfully reverted NaNO2-mediated inhibition of platelet aggregation, when 
compared to the vehicle treatment group. A similar trend was also observed in the older 
healthy volunteers (Figure 3.6D). ODQ reverted both SNP- and NaNO2-mediated inhibition 
of platelet aggregation, when compared to the vehicle treatment groups. 
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Figure 3.6: Platelet aggregation responses in young and old healthy volunteers 
following: a) SNP, b) NaNO2, c) ODQ, d) ODQ + SNP or e) ODQ + NaNO2 
incubations 
Washed platelets at a concentration of 2x108/mL from young (YHV) and old healthy 
volunteers (OHV) were incubated with: a) 100nM SNP or 1mM NaNO2 for 5 minutes b) 
10µM ODQ for 20 minutes, or c) 10µM ODQ + 100nM SNP or 1mM NaNO2 for 5 
minutes (ODQ was added 15 minutes before the SNP or NaNO2). The washed platelets 
were activated with 3µg/mL collagen and studied by light transmission aggregometry 
(LTA) for 5 minutes. 
 
A/C: Representative traces demonstrating the influence of SNP, NaNO2, ODQ, ODQ + 
SNP or ODQ + NaNO2 incubation on platelet aggregation responses in young and old 
healthy volunteers.  
B/D: Quantitative analysis of repeat aggregation responses (% aggregation at 5 minutes). 
Bars represent means ± S.E.M. n=8. Statistical differences were determined using a 
repeated measures one-way ANOVA with Dunnett’s test for multiple comparisons 
(*P<0.05, **P<0.01 and ***P<0.001). 
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3.4.7 BAY 41-2272 (sGC stimulator) has a synergistic effect on NaNO2 platelet 
aggregation responses in young and old healthy volunteers 
 
As shown in Figures 3.7A and C, the sGC stimulator, BAY 41-2272 (10nM, 30nM or 
100nM), inhibited platelet aggregation in response to 3µg/mL collagen in a dose-dependent 
manner, when compared to the young healthy volunteer control group. A similar trend was 
also observed in the older healthy volunteers (Figures 3.7B and C). Incubations with BAY 
41-2272 inhibited collagen-induced platelet aggregation in a concentration-dependent 
manner, with significant attenuation at 30nM and 100nM, when compared to the control 
group. Furthermore, there was not a significant interaction between the young and old healthy 
volunteers with BAY 41-2272 treatment.  
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Figure 3.7: Platelet aggregation responses in young and old healthy volunteers 
following incubations with BAY 41-2272 
Washed platelets at a concentration of 2x108/mL from young (YHV) and old healthy 
volunteers (OHV) were incubated with increasing concentrations of BAY 41-2272 
(10nM, 30nM or 100nM) for 1 minute, before being activated with 3µg/mL collagen and 
studied by light transmission aggregometry (LTA) for 5 minutes. 
 
A/B: Representative traces demonstrating the influence of BAY 41-2272 on platelet 
aggregation responses in young and old healthy volunteers.  
C: Quantitative analysis of repeat aggregation responses (% aggregation at 5 minutes). 
Bars represent means ± S.E.M. n=3. Statistical differences were determined using a 
repeated measures two-way ANOVA with Dunnett’s test for multiple comparisons 
(*P<0.05, **P<0.01 and ***P<0.001). 
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To determine whether NaNO2 exhibited synergistic activity with BAY 41-2272, we chose to 
use the intermediate dose of BAY 41-2272 to inhibit platelet aggregation. In both the young 
and old healthy volunteers, 30nM BAY 41-2272 caused a significant inhibition of 3µg/mL 
collagen by approximately 13.70% and 14.93% aggregation, respectively (Figures 3.8B and 
D). In the young healthy volunteers, NaNO2 (10µM, 100µM or 1mM) produced a 
concentration-dependent inhibition of collagen-induced platelet aggregation (Figure 3.8A). 
However, in the presence of BAY 41-2272, the potency of NaNO2 was significant in a 
synergistic fashion when compared to NaNO2 alone (Figure 3.8B). Analysis showed that 
there was a significant difference between NaNO2 alone and BAY 41-2272 + NaNO2 at all 
concentrations. A similar trend was also observed in the older healthy volunteers (Figures 
3.8C and D). Incubation with both NaNO2 and BAY 41-2272 further inhibited collagen-
induced platelet aggregation when compared with NaNO2 alone.  
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Figure 3.8: Platelet aggregation responses in young and old healthy volunteers 
following: a) BAY 41-2272, b) NaNO2 or c) NaNO2 + BAY 41-2272 incubations 
Washed platelets at a concentration of 2x108/mL from young (YHV) and old healthy 
volunteers (OHV) were incubated with: a) 30nM BAY 41-2272 for 1 minute, b) an 
increasing concentration of NaNO2 (10µM, 100µM or 1 mM) for 5 minutes or c) an 
increasing concentration of NaNO2 (10µM, 100µM or 1 mM) + 30nM BAY 41-2272 for 1 
minute (NaNO2 was added 4 minutes before BAY 41-2272). The washed platelets were 
activated with 3µg/mL collagen and studied by light transmission aggregometry (LTA) 
for 5 minutes. 
 
A/C: Representative traces demonstrating the influence of BAY 41-2272, NaNO2 or 
NaNO2 + BAY 41-2272 incubation on platelet aggregation responses in young and old 
healthy volunteers.  
B/D: Quantitative analysis of repeat aggregation responses (% aggregation at 5 minutes). 
Bars represent means ± S.E.M. n=8-11. Statistical differences were determined using a 
repeated measures one-way ANOVA with a Bonferroni post-hoc test to make 
comparisons (*P<0.05, **P<0.01 and ***P<0.001).  
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To validate the effects of NaNO2 with the sGC stimulator, the experiments were also repeated 
with SNP (NO donor) as a positive control. As shown in Figures 3.9A and C, the washed 
platelets from both young and old healthy volunteers were incubated with either BAY 41-
2272, SNP or SNP + BAY 41- 2272. In both the young and old healthy volunteers, 30nM 
BAY 41-2272 significantly inhibited platelet aggregation in response to 3µg/mL collagen by 
approximately 13.14% and 14.93% aggregation, respectively (Figures 3.9B and D). SNP 
(10nM or 100nM) also produced a concentration-dependent inhibition of platelet aggregation 
in response to collagen in the young healthy volunteers (Figure 3.9A). However, in the 
presence of BAY 41-2272, there was a significant inhibition of platelet aggregation in 
response to collagen when compared to SNP alone (Figure 3.9B). A similar trend was also 
observed in the older healthy volunteers (Figures 3.9C and D). Comparisons revealed that 
incubations with both SNP and BAY 41-2272 increased the inhibition to collagen-induced 
platelet aggregation, when compared to SNP alone.  
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Figure 3.9: Platelet aggregation responses in young and old healthy volunteers 
following: a) BAY 41-2272, b) SNP or c) SNP + BAY 41-2272 incubations 
Washed platelets at a concentration of 2x108/mL from young (YHV) and old healthy 
volunteers (OHV) were incubated with: a) 30nM BAY 41-2272 for 1 minute, b) an 
increasing concentration of SNP (10nM or 100nM) for 5 minutes or c) an increasing 
concentration of SNP (10nM or 100nM) + 30nM BAY 41-2272 for 1 minute (SNP was 
added 4 minutes before BAY 41-2272). The washed platelets were activated with 3µg/mL 
collagen and studied by light transmission aggregometry (LTA) for 5 minutes. 
 
A/C: Representative traces demonstrating the influence of BAY 41-2272, SNP or SNP + 
BAY 41-2272 incubation on platelet aggregation responses in young and old healthy 
volunteers. 
B/D: Quantitative analysis of repeat aggregation responses (% aggregation at 5 minutes). 
Bars represent means ± S.E.M. n=9-11. Statistical differences were determined using a 
repeated measures one-way ANOVA with a Bonferroni post-hoc test to make 
comparisons (*P<0.05, **P<0.01 and ***P<0.001). 
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3.4.8 NaNO2 phosphorylates VASPser239 in platelets from young healthy volunteers 
 
In order to understand the normal physiological NaNO2 mechanism in washed platelets, we 
next investigated the effects of NaNO2 on the phosphorylation status of the downstream PKG 
substrate VASPser239. Representative pVASPser239 Western blots are shown in Figure 3.10A. 
As depicted in Figure 3.10B, VASPser239 phosphorylation increased in a concentration-
dependent manner following NaNO2 treatment as compared to the NO donor, SNP. 
Moreover, with all concentrations of NaNO2 and SNP, VASPser239 phosphorylation peaked at 
10 minutes, before falling to low levels at 45 minutes of incubation (Figure 3.10B). The 
levels of VASPser239 phosphorylation observed with 100µM and 1mM NaNO2 treatments 
were also similar to those triggered by 10nM and 100nM SNP, respectively (Figure 3.10B).  
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3.4.9 NaNO2 activates the sGC-cGMP-PKG-VASP signalling cascade via NO-
independent pathway in platelets from young healthy volunteers  
 
To establish whether the effect of NaNO2 on sGC was NO-dependent or independent, we next 
assessed pVASPser239 in the absence and presence of NO scavengers, OxyHb and PTIO 
(Figure 3.11A). As shown in Figure 3.11B, 1mM NaNO2 treatment phosphorylated 
VASPser239 in the presence of the NO scavengers. To confirm whether NaNO2 directly 
activated the sGC we next pre-incubated young healthy washed platelets with sGC inhibitor, 
ODQ. Under these conditions, NaNO2 did not phosphorylate VASPser239 (Figure 3.11B).  
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3.5 Discussion 
Although platelet reactivity and NO production/responsiveness are thought to decrease with 
age (Gilstad et al., 2009; Goubareva et al., 2007; O’Donnell et al., 2001; Torregrossa et al., 
2011), the effect of aging on platelet function still remains to be explored in the elderly 
population (>70 years of age). Further, the potential for nitrite to be used as an anti-platelet 
agent in older healthy volunteers also requires investigation, whilst the combined effect of 
nitrite and BAY 41-2272 (sGC stimulator) remains to be explored across all age groups.  
 
Numerous experimental studies have demonstrated nitrite to inhibit platelet aggregation 
following its conversion to NO by the reductase activity of partially deoxygenated 
haemoglobin (Parakaw et al., 2017; Srihirun et al., 2012). However, the majority of these 
experiments have been conducted in either whole-blood or PRP (Corti et al., 2013; Dautov et 
al., 2014; Parakaw et al., 2017), and the precise mechanism(s) of nitrite still remains unclear. 
Therefore, to determine the mechanism by which nitrite inhibits aggregation and to minimise 
contributions from other blood cells and proteins, we chose to use washed platelets for the 
present study. By using isolated platelets this also prevented interference from the well-
known NO scavenger, OxyHb, which is found in erythrocytes.  
 
Firstly, Figure 3.1 demonstrates that there was not a significant difference between the 
platelet responses to collagen in the young vs old healthy volunteers, who were well matched 
in terms of gender, but significantly separated by age. The aggregatory responses were also 
slightly higher in the old healthy volunteers for all three collagen concentrations. These 
observations are surprising and contradict previous findings by O’Donnell and colleagues, 
who suggested the effect of age on platelet function was not linear and that aggregability 
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decreases with increasing old age (>75 years) (O’Donnell et al., 2001). Conversely, a study in 
healthy individuals revealed that platelet activation and the stability of platelet adhesions 
increase with age. These findings indicate that platelet function may actually increase in older 
age, however only a small proportion of the participants were over the age of 65 (Cowman et 
al., 2015).  
 
In the present study, NaNO2 significantly attenuated collagen-induced platelet aggregation in 
a dose-dependent manner in both the young and old healthy volunteers (Figure 3.2). These 
trends demonstrate that nitrite-mediated platelet inhibition is not dependent upon other cell 
types or plasma proteins, as previously suggested (Corti et al., 2013). Both the 100µM and 
1mM NaNO2 concentrations also inhibited platelet aggregation to a greater degree in the 
older volunteers, however there was not a significant interaction between the two age groups. 
These findings suggest that higher concentrations of nitrite are just as effective in the elderly 
population and thus highlight the potential for nitrite to be used as an anti-platelet therapy 
across all ages.  
 
A significant concentration-dependent inhibition of collagen-induced platelet aggregation 
was also observed in both the young and old healthy volunteers with the NO donor and 
positive control, SNP (Figure 3.3). Whilst there was not a significant interaction between the 
two age groups, the 100nM SNP dose also inhibited platelet aggregation to a greater degree 
in the older volunteers. These findings suggest that NO responsiveness is in fact maintained 
in older age and therefore contradict previous observations by Goubareva/Sverdlov and 
colleagues (Goubareva et al., 2007; Sverdlov et al., 2014).  
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Moreover, the NO scavengers, OxyHb and PTIO, were not able to revert the attenuation to 
collagen-induced platelet aggregation caused by 1mM NaNO2 in both the young and old 
healthy volunteers (Figures 3.4 and 3.5). However, the inhibition provided by 100nM SNP 
was reversed by OxyHb and PTIO in both age groups (Figures 3.4 and 3.5). Since nitrite-
mediated inhibition was not reversed by the two NO scavengers this suggests that nitrite was 
not converted to NO in the washed platelets. Furthermore, the inhibition to collagen-induced 
platelet aggregation caused by 1mM NaNO2 and 100nM SNP was successfully reverted by 
the sGC inhibitor, ODQ, in both the young and old healthy volunteers (Figure 3.6). These 
findings indicate that nitrite activates sGC in the washed platelets and corroborate a recent 
study in healthy volunteers (Parakaw et al., 2017). Parakaw and colleagues documented 
decreases in platelet aggregation, P-selectin expression and platelet-monocyte/-lymphocyte 
interactions following NaNO2 inhalation, whilst nitrite-mediated increases in VASPser239 
phosphorylation were shown to be inhibited by ODQ in deoxygenated whole-blood (Parakaw 
et al., 2017). These observations suggest that nitrite may prove beneficial in conditions of 
platelet hyperaggregability, whilst also demonstrating the importance of sGC in the normal 
physiological nitrite mechanism. However, it is important to acknowledge that the 
experiments were conducted in whole-blood (oxygenated; in vivo, and deoxygenated; in 
vitro) and not isolated platelets (Parakaw et al., 2017). Therefore, our data (OxyHb, PTIO and 
ODQ) corroborates with their findings.  
 
The sGC stimulator, BAY 41-2272, has previously been shown to cause dose-dependent non-
NO-dependent anti-platelet effects in PRP/washed platelets from healthy humans and in vivo 
blood pressure measurements in rats (Hobbs and Moncada, 2003). In the present study, BAY 
41-2272 alone significantly attenuated collagen-induced platelet aggregation in a dose-
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dependent manner in both the young and old healthy volunteers (Figure 3.7). These findings 
indicate that the anti-aggregatory effects of BAY 41-2272 do not require NO, as recently 
suggested by Roger and colleagues (Roger et al., 2010), and therefore corroborate the study 
by Hobbs and colleagues, who also investigated 10nM, 30nM and 100nM BAY 41-2272 
concentrations (Hobbs and Moncada, 2003). In the present study, we also observed that both 
30nM and 100nM BAY 41-2272 concentrations inhibited platelet aggregation to a greater 
degree in the older healthy volunteers, however there was not a significant interaction 
between the two age groups. These findings suggest that BAY 41-2272 remains effective in 
the elderly population, thus highlighting the potential for BAY 41-2272 to be used to treat 
conditions hyperaggregability across all ages.  
 
The sGC-dependent effects of nitrite also exhibited synergistic activity with 30nM BAY 41-
2272 in both the young and old heathy volunteers (Figure 3.8). We show for the first time the 
effects of nitrite with BAY 41-2272 in washed platelets, thus these novel findings suggest 
that BAY 41-2272 could be used to potentiate the sGC-dependent effects of nitrite across all 
age groups in the future. The NO donor and positive control, SNP, also exhibited synergistic 
activity with 30nM BAY 41-2272 (Figure 3.9). Synergistic activity between BAY 41-2272 
and an alternate NO donor, GSNO, has previously been observed in human PRP and washed 
platelets by Hobbs and colleagues (Hobbs and Moncada, 2003). In addition, our findings also 
corroborate with an in vivo rabbit model, where BAY 41-2272 was shown to potentiate the 
effects of SNP, thus leading to stronger penile erections (Bischoff et al., 2003). 
 
We and others have previously shown that nitrite increases VASPser239 phosphorylation in 
both washed platelets and PRP in the presence of deoxygenated erythrocytes (Borgognone et 
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al., 2015; Srihirun et al., 2018). In the present study, we also observed nitrite to increase 
VASPser239 phosphorylation in washed platelets from young healthy volunteers (Figure 3.10), 
thus suggesting that nitrite inhibits platelet aggregation in the absence of other cells and 
proteins. Interestingly, VASPser239 phosphorylation also occurred in the presence of NO 
scavengers, OxyHb and PTIO, but not when washed platelets from the young healthy 
volunteers were incubated with the sGC inhibitor, ODQ (Figure 3.11). This data further 
supports the notion that the underlying mechanism of nitrite in washed platelets acts through 
sGC-PKG-VASPser239 independently of NO.  
 
3.5.1 Study limitations and future considerations  
In the present chapter, there are a number of study limitations in relation to both the LTA 
experiments and Western blotting analysis. Firstly, as collagen was the only agonist used 
throughout the LTA experiments, it cannot be assumed that platelet dysfunction was absent 
from both the young and old healthy volunteers (Dovlatova, 2015). Platelet dysfunction is 
caused by a plethora of factors, thus several agonists targeting a variety of receptors may be 
required to perceive certain defects (Dovlatova, 2015). Recently, it has been established that 
the use of five agonists, including ADP, AA, collagen, adrenaline and TXA2, at a single 
concentration, is sufficient to detect the majority of platelet function defects (Hayward et al., 
2009).  
 
Furthermore, pharmacological (10µM, 100µM and 1mM) and not physiological (200-
600nM) concentrations of nitrite were used in both the LTA experiments and Western 
blotting analysis, thus modulation of platelet function by normal plasma nitrite concentrations 
cannot be assumed from the above findings (Kevil et al., 2011; Srihirun et al., 2018). Despite 
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this, previous studies by other research groups have shown either 1-10µM NaNO2 to inhibit 
ADP-induced platelet aggregation in PRP+erythrocytes or 500µM NaNO2 to inhibit ADP-
induced platelet aggregation in plasma (Laustiola et al., 1991; Srihirun et al., 2018). 
Therefore, implicating that the pharmacological concentrations of nitrite may have the 
potential to be used as an anti-platelet therapy for all ages in the future (Laustiola et al., 1991; 
Srihirun et al., 2018).  
 
Moreover, whilst interference from other blood cell types and plasma proteins was prevented 
by experimentation in washed platelets, heme-containing components of the mitochondrial 
respiratory chain (e.g. cytochrome C) may have contributed to nitrite-mediated attenuation by 
converting nitrite to NO within the platelets (Kevil et al., 2011). Reduction of nitrite inside 
the platelet would certainly circumvent scavenging by the extracellular NO scavenger, 
OxyHb, whilst potentially influencing the efficacy of the intracellular NO scavenger, PTIO. 
Since the NO scavengers are limited by both the relative rate and location of NO production, 
further studies are therefore warranted to assess the involvement of heme-containing 
components in nitrite-mediated platelet attenuation. 
 
In addition, it is well-known that OxyHb absorbs light. As such, the addition of OxyHb to 
washed platelet samples could influence the aggregation traces. To control the effect of 
OxyHb on light transmission, the impact of the NO scavenger on the aggregation baseline 
was first tested. A consistent baseline was observed in the presence of OxyHb due to the low 
final concentration of the NO scavenger (10µM in 300µL washed platelets).  
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Furthermore, nitrite-mediated VASPser239 phosphorylation was only investigated in washed 
platelets from young healthy volunteers. To ensure that the underlying mechanism of nitrite 
in washed platelets is consistent across all age groups, it is important to investigate 
VASPser239 phosphorylation under the same conditions in old healthy volunteers.  
 
In addition, PKG activity was indirectly measured via VASPser239 phosphorylation status by 
Western blotting analysis. For instance, the increases in VASPser239 phosphorylation 
observed following NaNO2 treatment in washed platelets obtained from young healthy 
volunteers, suggested an increase in PKG activity under these conditions. Therefore, a PKG 
colorimetric activity assay would further support the notion that nitrite activates the VASP-
PKG pathway in both young and old healthy volunteers (Das et al., 2008). 
 
Finally, a longitudinal study (e.g. involving the same volunteers 2, 4 and 6 years later) would 
also help to demonstrate any changes to platelet function over time, in the elderly population 
(Jones, 2016). However, a study of this sort would not be without difficulties, due to the 
potential for old healthy volunteers to rapidly deteriorate and subsequently require 
medication. 
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3.5.2 Conclusions  
The results of this study reveal that NaNO2 activates sGC independently of NO to inhibit 
washed platelet aggregation in both young and old healthy volunteers, thus supporting the 
potential for nitrite to be used as an anti-platelet therapy across all ages. The synergistic 
activity observed between nitrite and BAY 41-2272 also alludes towards the prospect of a 
nitrite-based combination therapy to address conditions of hyperaggregability in the future. 
Overall, this study demonstrates that with the right application, nitrite may have the potential 
to inhibit platelet aggregation across all ages and possibly disease states. 
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Chapter 4: Evaluation of the phenomenon of “platelet NO resistance” and 
nitrite in patients with HFpEF-AF and CAF only. 
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4.1 Introduction  
It is well known that “platelet NO resistance” exists in patients with HFrEF (Anderson et al., 
2004), but whether this occurs in HFpEF still remains to be elucidated. It was demonstrated 
by Anderson and colleagues, that both the platelets and vasculature of the HFrEF patients are 
significantly less responsive to NO donors (e.g. SNP), when compared to healthy controls 
(Anderson et al., 2004; Chirkov and Horowitz, 2007, Procter et al., 2016). As such, it was 
implicated from this study that this may reduce the effectiveness of some NO-mediated HF 
therapies and thus may subsequently contribute to the pro-thrombotic state in HF patients 
(Chirkov and Horowitz, 2007). Therefore, HF patients would benefit from a novel treatment 
that circumvents the “platelet NO resistance” phenomenon.  
 
Recent studies by our research group and others have demonstrated nitrite as a potential 
therapeutic agent for HF (Borgognone et al., 2015; Borlaug et al., 2015; Ormerod et al., 
2015). Nitrite has been shown to have both NO-dependent and -independent beneficial 
effects in various physiological and pathophysiological conditions, such as MI, pulmonary 
hypertension, HFrEF and HFpEF. Furthermore, nitrite has also been shown to inhibit platelet 
aggregation in healthy volunteers (Kadan et al., 2015) and may potentially improve platelet 
function in patients with HFpEF.  
 
CAF often coexists with HFpEF and HFrEF (~40% and ~35%, respectively) and is also 
associated with intra-arterial thrombosis and thromboembolism (Lam et al., 2017; Linssen et 
al., 2011; Procter et al., 2015; Sartipy et al., 2017). Numerous research groups have observed 
an impaired platelet NO response in patients with AF, stable angina and acute coronary 
syndromes, and recently it has been revealed that this impairment contributes to platelet 
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hyperaggregability in patients with early onset AF (Chirkov et al., 2001; Chung and Lip, 
2006; Procter et al., 2015). Herein, “platelet NO resistance” and nitrite was investigated in 
both HFpEF-AF and CAF, due to the close association between the two disease states (Lam 
et al., 2017; Sartipy et al., 2017).  
 
4.2 Hypothesis and specific aims 
4.2.1 Hypothesis 
Nitrite circumvents the phenomenon of “platelet NO resistance” in washed platelets from 
patients with HFpEF-AF but not CAF alone.  
 
4.2.2 Specific aims 
This study has two main aims:  
1) To determine whether the phenomenon of “platelet NO resistance” exists in patients 
with: 1) HFpEF-AF and 2) CAF only. 
2) To compare the effects of nitrite in patients with HFpEF-AF or CAF and evaluate 
whether nitrite circumvents the phenomenon of “platelet NO resistance” in HFpEF 
patients.  
 
4.3 Research methods  
Blood was obtained from patients with HFpEF-AF and CAF alone as previously described in 
Section 2.1.3. To evaluate the effects of nitrite and BAY 41-2272 on platelet aggregation, 
washed platelets were prepared and counted for LTA experiments as described in Section 
2.1.3. Aggregatory responses were then quantified as discussed in Section 2.1.3.  
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4.4 Results  
4.4.1 Subject characteristics  
Table 4.1 shows the subject characteristics and drug therapies. The old healthy volunteers, 
HFpEF-AF patients and CAF patients were all age- (P>0.05; one-way ANOVA) and gender-
matched (P=0.22-0.65; Fisher’s exact test). 
Table 4.1: Subject characteristics 
 
 
Parameter Old Healthy 
Volunteers 
(OHV) 
(n=11) 
Heart Failure with Preserved 
Ejection Fraction with 
Chronic Atrial Fibrillation 
(HFpEF-AF) 
(n=29) 
Chronic 
Atrial 
Fibrillation 
(CAF) 
(n=8) 
 
Sex (M/F) 8/3 21/8 4/4 
Age, y (Mean ±SD) 72.3±5.0 74.3±6.2 73.9±7.9 
NYHA-Class I/II/III/ - 23/11/2 - 
Diabetes Mellitus - 2 2 
ACE-inhibitors - 10 2 
Angiotensin II 
receptor blocker 
- 2 2 
Diuretics - 2 4 
β-adrenoceptor 
antagonists  
- 8 6 
α-adrenoceptor 
antagonist 
- 2 - 
Calcium channel 
blocker  
- 9 1 
Statins - 10 2 
Cardiac glycoside - - - 
Digoxin - 4 2 
Anti-arrhythmic  - - 1 
Anti-diabetic - 2 2 
Anti-coagulant  - 26 8 
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4.4.2 NaNO2 circumvents the phenomenon of “platelet NO resistance” in HFpEF-AF 
patients 
 
In order to investigate whether NaNO2 circumvented “platelet NO resistance” in HFpEF-AF 
patients, the effects of NaNO2 on washed platelet aggregation responses to 3µg/mL collagen 
were first compared in old healthy volunteers vs HFpEF-AF patients. Representative traces 
are shown in Figures 4.1A and B, respectively. In the old healthy volunteers, NaNO2 (10µM, 
100µM or 1mM) attenuated platelet aggregation in a dose-dependent manner in response to 
collagen, when compared to the control group (Figure 4.1D). However, in HFpEF-AF 
patients, 10µM and 100µM NaNO2 treatment had no effect on platelet aggregation, whilst 
1mM NaNO2 significantly attenuated platelet aggregation responses to collagen, when 
compared to the control group (Figure 4.1D). 
 
To determine whether the responses observed in HFpEF-AF patients were caused by HF, 
CAF or a combination of both, the effects of NaNO2 on washed platelet aggregation 
responses to 3µg/mL collagen were also explored in patients with CAF only. Representative 
traces are shown in Figure 4.1C. In this sub-group of patients, NaNO2 also significantly 
attenuated platelet aggregation at the highest concentration (1mM), with modest attenuation 
at the lower concentrations (10µM and 100µM), when compared to the control group (Figure 
4.1D). 
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The effects of SNP on platelet aggregation responses to 3µg/mL collagen were also compared 
as a positive control in the old healthy volunteers, HFpEF-AF patients and CAF patients. 
Representative traces are shown in Figures 4.2A, B and C, respectively. As shown in Figure 
4.2D, SNP (10nM and 100nM) significantly attenuated platelet aggregation in a dose-
dependent manner, when compared to the old healthy volunteer control group. Furthermore, 
SNP also produced a concentration-dependent inhibition of collagen-induced platelet 
aggregation in the CAF patients. As depicted in Figure 4.2D, we observed a significant 
attenuation with both the 10nM and 100nM doses, when compared to the control group. 
Interestingly, in the HFpEF-AF group, SNP treatment had no effect on platelet aggregation, 
when compared to the control group (Figure 4.2D).  
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4.5 Discussion  
The phenomenon of “platelet NO resistance” has been shown to exist in patients with HFrEF 
(Anderson et al., 2004), but its occurrence in HFpEF remains to be defined. “Platelet NO 
resistance” is thought to reduce the effectiveness of some NO-mediated HF therapies, in 
addition to contributing to the pro-thrombotic state in HF (Chirkov and Horowitz, 2007). As 
such, HF patients would benefit from a novel treatment that circumvents “platelet NO 
resistance”. Nitrite has been shown to inhibit platelet aggregation in heathy volunteers 
(Borgognone et al., 2015; Kadan et al., 2015), however the potential for nitrite to address 
“platelet NO resistance” in HFpEF or CAF, which often coexist together, is yet to be 
investigated.   
 
In the present study, a diminished response to the NO donor, SNP, was observed in washed 
platelets from HFpEF-AF patients, when compared to the healthy volunteers and CAF patient 
group (Figure 4.2). These findings reveal that the phenomenon of “platelet NO resistance” 
may also exist in HFpEF. This novel concept has not yet been documented, however the 
identification of this underlying phenomenon may enable upcoming HFpEF therapies to be 
better tailored to the disease state and therefore help to improve future patient survival. 
Furthermore, a significant attenuation to platelet aggregation was observed following 
treatment with 1mM NaNO2 in HFpEF-AF patients (Figure 4.1). These original findings 
suggest that high concentrations of nitrite may be able to circumvent “platelet NO resistance” 
in HFpEF-AF and hence highlight the potential for nitrite to address hyperaggregability in 
HFpEF in the future. In addition, since both NaNO2 and SNP triggered concentration-
dependent attenuation of platelet aggregation in CAF patients, this suggests that “platelet NO 
resistance” is primarily associated with HFpEF and not CAF (Figures 4.1 and 4.2). Once 
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again, the identification of underlying phenomenon or phenotyping subsequently enables 
pharmacological treatment to be tailored to the individual and disease state (e.g. personalised 
medicine), depending upon their response to NO donors.  
 
As previously mentioned in Chapter 3, all experiments conducted in washed platelets to 
eliminate interference from other blood cell types and plasma proteins in nitrite-mediated 
effects. It is well known that O2- production by neutrophils contributes to a reduction in NO 
bioavailability and “platelet NO resistance” in HF (Anderson et al., 2004; Rajendran and 
Chirkov, 2008). However, since the phenomenon was observed in isolated platelets, this 
suggests that the production of O2- is not solely responsible for “platelet NO resistance” in 
HFpEF-AF.  
 
Furthermore, our group have extended the findings observed in the present study by 
investigating the underlying mechanisms of nitrite in washed platelets from HFpEF-AF 
patients (Borgognone et al., 2018). LTA experiments revealed that NO scavengers (OxyHb or 
PTIO) could not revert nitrite-mediated attenuation of collagen-induced platelet aggregation 
in HFpEF-AF patients, whilst the sGC inhibitor, ODQ, reversed nitrite-dependent platelet 
inhibition in this patient group. However, SNP-mediated inhibition was shown to be reverted 
by OxyHb, PTIO and ODQ in HFpEF-AF patients (Borgognone et al., 2018). These findings 
therefore suggest that nitrite acts through sGC independently of NO to cause an attenuation of 
platelet aggregation in HFpEF-AF patients (Borgognone et al., 2018), and thus corroborate 
with our findings in heathy volunteers (Chapter 3).  
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Nitrite was also shown to increase VASPser239 phosphorylation in washed platelets from 
HFpEF-AF patients (Borgognone et al., 2018). VASPser239 phosphorylation occurred in the 
presence of NO scavengers, OxyHb and PTIO, but not when washed platelets from the 
HFpEF-AF patients were incubated with the sGC inhibitor, ODQ (Borgognone et al., 2018). 
These findings therefore indicate that nitrite acts through sGC-PKG-VASPser239 
independently of NO in washed platelets from HFpEF-AF patients (Borgognone et al., 2018), 
and hence corroborate with the results of the LTA experiments and our findings in healthy 
volunteers (Chapter 3). 
 
4.5.1 Study limitations and future considerations 
This study also has a few limitations which will now be addressed. Firstly, the only platelet 
agonist used during the LTA experiments was collagen. As discussed in Chapter 3, this is a 
key limitation as the presence or absence of platelet dysfunction in the healthy volunteers, 
HFpEF-AF patients and CAF patients cannot be assumed from one agonist (Dovlatova, 2015; 
Hayward et al., 2009). A decreased platelet aggregation response to collagen was observed in 
washed platelets obtained from CAF patients, when compared to the healthy volunteers and 
HFpEF-AF patient group. To our knowledge the effect of collagen on washed platelets from 
CAF has not been investigated before, but our group have previously reported PRP 
aggregation in response to 2mg/mL collagen to be inhibited by approximately 24% in 
patients with CAF on no anti-thrombotic therapy (Kamath et al., 2002). Furthermore, the 
complexity of events of platelet activation in AF have been documented (Kamath et al., 2002; 
Kamath et al., 2003) and therefore further studies involving multiple agonists (e.g. ADP, AA, 
collagen, adrenaline and TXA2) are required to explore platelet function and the role of NO 
donors/nitrite in this disease state. 
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Furthermore, high concentrations of nitrite (1mM) were used in the present study. As 
discussed in Chapter 3, this is a major drawback as any modulation of platelet function by 
normal plasma nitrite concentrations cannot be assumed when using non-physiological 
concentrations of NaNO2 (Kevil et al., 2011; Srihirun et al., 2018). 
 
Moreover, a number of the HFpEF-AF (10/29) and CAF patients (2/8) were taking ACE- 
inhibitors, which have previously been linked to reductions in “platelet NO resistance”. 
Despite this, the ACE-inhibitors seemed not to influence “platelet NO resistance” under these 
circumstances as the phenomenon appeared in all HFpEF-AF patients.  
 
Finally, the potential for nitrite to exhibit synergistic activity with BAY 41-2272 also remains 
to be investigated in HFpEF-AF patients. To determine whether the applications of BAY 41-
2272 exceed healthy volunteers and establish whether nitrite can circumvent “platelet NO 
resistance” more effectively in the presence of BAY 41-2272, further studies are warranted.  
 
4.5.2 Conclusions  
The results of this study demonstrate that nitrite circumvents the phenomenon of “platelet NO 
resistance” in washed platelets from patients with HFpEF-AF but not CAF alone. Therefore, 
highlighting the potential for nitrite therapy to address hyperaggregability in HFpEF in the 
future. Additional studies by our research group suggest that nitrite acts through sGC-PKG-
VASPser239 independently of NO, to cause an attenuation of platelet aggregation in HFpEF-
AF patients. Further, HFpEF-AF patient phenotyping and subsequent stratification of 
pharmacological treatment according to NO response, may also help to reduce the morbidity 
and mortality of HFpEF in the future.  
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Chapter 5: Exploration of nitrite, lipid content and tissue morphology in 
ALDH2 WT and KO mice. 
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5.1 Introduction  
Over the last 30 years, the role of ALDH2 in the two-stage process of ethanol metabolism has 
been thoroughly explored (Chen et al., 2014). ALDH2 belongs to a superfamily of 
detoxifying enzymes which function to maintain cellular haemostasis by oxidising reactive 
aldehydes to non-toxic carboxylic acids (Budas et al., 2009). These tetrameric enzymes are 
found in the mitochondrial matrix of most tissues, but ALDH2 is present at the highest 
concentration in the liver (Budas et al., 2009; Chen et al., 2014).  
 
Mitochondrial ALDH2 has also emerged as an important mediator of cardioprotection (Budas 
et al., 2009). There is increasing evidence to suggest that myocardial ALDH2 enzymes 
mediate the detoxification of reactive aldehydes, such as acetaldehyde or 4-
hydroxynonenal (4-HNE)/malondialdehyde (MDA), and protect the heart from oxidative 
stress (Budas et al., 2009; Chen et al., 2014). During HF and myocardial ischaemia 
reperfusion injury (IRI), excessive ROS production exacerbates the peroxidation of 
polyunsaturated fatty acids, including AA, linoleic acid and cardiolipin, which are present in 
the mitochondrial and plasma membranes. Lipid hydroperoxides formed by this process 
subsequently give rise to toxic end-products, 4-HNE and MDA, which then go on to form 
adducts and cause myocardial damage (Bolli et al., 1989; Roede and Jones, 2010; Uchida and 
Stadtman, 1992). 4-HNE is the most reactive of the endogenous aldehydes generated during 
lipid peroxidation and due to its amphiphilic nature, 4-HNE can easily diffuse across 
membranes and react with cysteine, histidine and lysine residues to form protein adducts via 
Michael addition (>99%) and Schiff base (<1%) reactions (Chen et al., 2014; Uchida and 
Stadtman, 1992). During IRI, a build-up of 4-HNE adducts within the myocardium impairs 
cardiac contractility and promotes cardiac cell damage/death by: 1) increasing mitochondrial 
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permeability and dysfunction, 2) inhibiting the electron transport chain and Krebs cycle, 3) 
inhibiting ALDH2 activity, 4) reducing membrane integrity, 5) inhibiting proteasomal 
function, 6) triggering unfolded protein accumulation, and 7) causing DNA damage (Chen et 
al., 2014). Accumulation of 4-HNE and its adducts, has also been linked to the development 
of HF, cardiomyopathies, hypertension, peripheral artery disease, stroke and atherosclerosis 
(Chen et al., 2014; Gueldner et al., 2016; Guo et al., 2013). 
 
Furthermore, the contribution of the mitochondrial ALDH2 enzyme in cardioprotection was 
originally discovered downstream of mitochondrial protein kinase C type ϵ (PKCϵ) activation 
(Budas et al., 2010; Chen et al., 2008; Chen et al., 2014). A broad range of stimuli, including 
PKCϵ-/PI3K-dependent phosphorylation (endogenous stimuli) and aldehyde dehydrogenase 
activators (Aldas; exogenous stimuli) have also been shown to activate ALDH and protect the 
heart against myocardial IRI. These findings both allude towards a fundamental role for 
ALDH2 in cardioprotection (Garlid et al., 2009).  
 
Moreover, aldehyde detoxification occurs rapidly in individuals with fully functioning 
ALDH2 enzymes (e.g. individuals with two WT ALDH2*1 alleles), whilst individuals with 
reduced ALDH2 activity (e.g. carriers of the ALDH2*2 allele) experience an accumulation of 
toxic aldehydes, such as acetaldehyde and 4-HNE (Chen et al., 2014; Dandre et al., 1995; 
Goedde et al., 1992; Li et al., 2006). The ALDH2*2 polymorphism is characterised by a 
single base mutation resulting in the replacement of the amino acid glutamate with lysine and 
is found in approximately 35-40% of East Asians (e.g. Chinese, Korean, Japanese and 
Taiwanese people) (Budas et al., 2009; Chen et al., 2014; Yoshida et al., 1984). Moreover, 
the mutant ALDH2*2 allele has recently been shown to exert a dominant effect over its WT 
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ALDH2*1 allele. Much less than 50% of the WT enzymatic activity has been observed in 
heterozygous individuals (ALDH2*1/*2), whilst only ~1-4% of the WT ALDH2 activity has 
been seen in homozygous individuals (ALDH2*2/*2) (Chen et al., 2014; Farres et al., 1994; 
Ferencz-Biro and Pietruszko, 1984; Zhou and Weiner, 2000).  
 
Human epidemiological studies have also revealed that ALDH2*2 carriers exhibit increased 
susceptibility to cardiac disease, including MI, atherosclerosis and pulmonary arterial 
hypertension (Chen et al., 2014; Gueldner et al., 2016; Xu et al., 2017). Whilst, experimental 
studies in ALDH2*2 mice have shown increased ROS production, endothelial dysfunction 
and exacerbated cardiac damage following IRI (Chen et al., 2014). Experimental approaches 
to enhance ALDH2 activity through genetic overexpression or pharmacological activation of 
ALDH2 have demonstrated improved 4-HNE detoxification and subsequent protection 
against both acute (e.g. IRI and stroke) and chronic (e.g. HF) CVDs (Chen et al., 2014). 
 
In addition, carriers of the mutant ALDH2*2 allele have a diminished response to organic 
nitrates, such as GTN, which are currently used to treat angina, acute MI and HF (Bailey et 
al., 2014; MacAllister, 2000; Mackenzie et al., 2005). ALDH2 is considered to be the 
principle enzyme responsible for vascular GTN bioactivation and NO release, thus the 
mitochondrial enzyme plays a pivotal role in the vasodilatory and anti-platelet effects of 
organic nitrates (Li et al., 2006; Mackenzie et al., 2005; Mollace et al., 2014). Oxidative 
stress resulting from the production of free radicals, O2- and ONOO-, has been linked to the 
development of nitrate tolerance (Daiber and Münzel, 2015; D’Souza et al., 2011; Mollace et 
al., 2014). In a recent study by Mollace and colleagues, prolonged GTN incubation was 
shown to reverse GTN-mediated attenuation of thrombin-induced platelet aggregation, whilst 
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also reducing cGMP levels in washed platelets (Mollace et al., 2014). These effects were 
associated with a reduction in GTN-induced nitrite formation and the nitration of ALDH2 at 
tyrosine residues, thus indicating that GTN tolerance resulted from a reduction in NO 
production associated with ALDH2 impairment (Mollace et al., 2014). Co-incubation of the 
platelets with the SOD mimetic/ONOO- scavenger, Mn(III) tetrakis (4-benzoic acid) 
porphyrin (MnTBAP), was also shown to reverse nitrate tolerance in washed platelets. These 
findings therefore confirmed the role of O2- and ONOO- in ALDH2 inactivation and the 
development of nitrate tolerance (Mollace et al., 2014).  
 
A few studies have also revealed interactions between mitochondrial ALDH2 and nitrite.  
Firstly, ALDH2 plays a critical role in the reduction of nitrite to NO in the ‘nitrate-nitrite-NO 
pathway’ (Li et al., 2008). This process is regulated by oxygen tension, pH and a reduction in 
substrate concentrations, and has been shown to be much more prominent in tissues than in 
the blood (Li et al., 2008). Furthermore, in a recent study of ischaemia in the human forearm, 
the administration of nitrite during the second window of pre- and post-conditioning was 
shown to reduce endothelial dysfunction in ALDH2*2 carriers (Ormerod et al., 2017). Since 
reductions in IRI were absent from individuals homozygous for the ALDH2*1 allele, these 
findings indicate that the effects of nitrite-mediated pre/post-conditioning may be dependent 
on ALDH2 genotype (Ormerod et al., 2017). ALDH2 has also emerged as an important 
mediator of hypoxic vasodilation in HF (Arif et al., 2015). Nitrite-mediated dilation 
diminished in rat aorta and human resistance vessels following the inhibition of ALDH2 by 
cyanamide or propionaldehyde, especially under hypoxic conditions (Arif et al., 2015). 
Finally, in a recent metabolomic/proteomic study, nitrite-dependent phosphorylation of 
ALDH2 at Thr431 was observed in rat hearts (Perlman et al., 2009). Phosphorylation of 
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ALDH2 at Thr431 is also mediated by PKCϵ and has been shown to cause cardioprotective 
increases in enzyme activity, thus these findings suggest that interactions between nitrite and 
ALDH2 may be important for nitrite-mediated cardioprotection (Chen et al., 2008; Perlman 
et al., 2009).  
 
Since a number of recent studies propose a role for mitochondrial ALDH2 in nitrite-mediated 
effects of vascular and cardiac disease, this suggests that this mechanism may have some 
benefits on platelet function. We have previously shown that nitrite significantly attenuates 
platelet aggregation in both healthy volunteers (Chapter 3) and patients with HFpEF-AF 
(Chapter 4), but the mechanism of nitrite in platelet aggregation remains to be fully 
elucidated. As such, further research is warranted to assess whether ALDH2 contributes to 
nitrite-mediated attenuation of platelet aggregation.  
 
Finally, the mutant ALDH2*2 allele is thought to be a novel risk factor for the development 
of non-alcoholic fatty liver disease (NAFLD), which is characterised by the deposition of fat 
in the liver (Oniki et al., 2016). A recent study examining the association of hepatic steatosis 
with common subclinical/clinical CVD outcomes, has revealed a link between hepatic 
steatosis and CVD (Mellinger et al., 2015). As such, further research into the relationship 
between tissue lipid content (e.g. liver and skeletal muscle tissue) and ALDH2 
expression/activity is warranted.  
 
Herein, the contribution of ALDH2 to nitrite-mediated attenuation of washed platelet 
aggregation will first be explored in ALDH2 WT and KO mice. The influence of the ALDH2 
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expression, and therefore activity, on neutral lipid accumulation and tissue morphology will 
also be compared in ALDH2 WT vs KO tissues (e.g. liver and skeletal muscle tissue). 
 
5.2 Hypothesis and specific aims 
5.2.1 Hypothesis  
ALDH2 plays an essential role in nitrite-mediated attenuation of collagen-induced platelet 
aggregation in mouse washed platelets, whilst inactivation of the ALDH2 gene increases the 
lipid content of mouse liver and skeletal muscle tissue.  
 
5.2.2 Specific aims 
This study has three main aims:  
1) To determine ALDH2 expression in washed platelets and tissues (liver, skeletal 
muscle and cardiac tissue) obtained from ALDH2 WT and KO mice, respectively. 
2) To compare the effects of nitrite in ALDH2 WT vs KO mice, and determine the 
contribution of ALDH2 to nitrite-mediated attenuation of platelet aggregation. 
3) To compare the lipid accumulation/tissue morphology of liver and skeletal muscle 
tissue sections from ALDH2 WT vs KO mice. 
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5.3 Research methods  
Blood and tissue (liver, skeletal muscle and cardiac tissue) samples were obtained from 
ALDH2 WT and KO mice as previously described in Section 2.2.3. To evaluate the effects of 
ALDH2 and nitrite on platelet aggregation, washed platelets were prepared and counted for 
LTA experiments as described in Section 2.2.4. Aggregatory responses were then quantified 
as discussed in Section 2.2.4. Platelet and tissue homogenates for Western blotting were also 
prepared and analysed as described in Section 2.2.5. To compare lipid accumulation and 
tissue morphology in ALDH2 WT and KO mice, liver and skeletal muscle tissue samples 
were first sectioned and stained with ORO, before counterstaining with Mayer’s 
haematoxylin, as previously described Section 2.2.6. The extent of lipid accumulation 
revealed by ORO staining was analysed as discussed in Section 2.2.6. 
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5.4 Results  
5.4.1 ALDH2 expression in ALDH2 WT and KO mice 
To determine whether ALDH2 is expressed in washed platelets, liver, skeletal muscle and 
cardiac tissue, Western blot analysis was conducted. As depicted in Figures 5.1A and B, 
ALDH2 was expressed in all of the ALDH2 WT samples, but the level of ALDH2 expression 
varied between the sample types. Densitometric analysis revealed that ALDH2 expression 
was 18-fold higher in the WT liver tissue and 3-fold higher in the WT cardiac tissue, when 
compared with ALDH2 expression in the WT platelets (Figure 5.1B). Whilst there was a 0.6-
fold decrease in ALDH2 expression in the WT skeletal muscle tissue, when compared to the 
WT platelets. Conversely, ALDH2 was not expressed in any of the KO samples (Figures 
5.1A and B). 
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Figure 5.1: ALDH2 expression in platelets and tissues obtained from ALDH2 WT 
and KO mice 
5x108/mL washed platelets obtained from ALDH2 WT and KO mice were incubated for 
10 minutes before being lysed with 5x sample buffer. ALDH2 WT and KO tissue (liver, 
skeletal muscle and cardiac tissue) homogenates, containing ~25µg of protein, were also 
prepared. The platelet and tissue homogenates were then used for SDS-PAGE (8%) and 
Western blot. The blot was probed with anti-ALDH2 (1:1000), anti- α-Tubulin (1:5000) or 
anti-GAPDH (1:20,000), and the appropriate secondary antibodies (anti-goat or anti-
mouse; 1:10.000). 
 
A: Representative Western blot demonstrating ALDH2 expression in platelets and tissues 
(liver, skeletal muscle and cardiac tissue) harvested from ALDH2 WT and KO mice. α-
Tubulin and GAPDH were used as loading controls.  
B: Quantitative analysis of the representative Western blot (ALDH2/α-Tubulin (platelets) 
or GAPDH (liver, skeletal muscle and cardiac tissue); grey intensity). n=1. 
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5.4.2 Does NaNO2 inhibit platelet aggregation via ALDH2? 
 
To determine the contribution of ALDH2 to nitrite-mediated platelet inhibition, washed 
platelet aggregation was compared in ALDH2 WT vs KO mice. As shown in Figures 5.2A 
and B, the NO donor, SNP, was used as a positive control for the present study. In the 
ALDH2 WT mice, 100nM SNP significantly attenuated washed platelet aggregation to 
3µg/mL collagen, when compared to the control group (Figure 5.2C). NaNO2 (10µM, 100µM 
or 1mM) also inhibited collagen-induced platelet aggregation in a concentration-dependent 
manner, when compared to the control group (Figure 5.2C). In contrast, neither SNP nor 
NaNO2 significantly inhibited collagen-induced platelet aggregation in the ALDH2 KO 
washed platelets, when compared to the control group. SNP inhibited platelet aggregation by 
approximately 11.80%, whilst there was no apparent platelet inhibition with 10µM, 100µM 
or 1mM NaNO2 (Figure 5.2C), when compared to the control. However, comparisons 
between the genotypes revealed that there was not a significant difference between the effects 
of SNP in ALDH2 WT and KO platelets (Figure 5.2C).  
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Figure 5.2: Platelet aggregation responses in ALDH2 WT and KO mice following 
SNP or NaNO2 incubation  
Washed platelets at a concentration of 2x108/mL from ALDH2 WT and KO mice were 
incubated with 100nM SNP or increasing concentrations of NaNO2 (10µM, 100µM or 1 
mM) for 5 minutes, before being activated with 3µg/mL collagen and studied by light 
transmission aggregometry (LTA) for 5 minutes. 
 
A: Representative traces demonstrating the influence of SNP or NaNO2 incubation on 
platelet aggregation responses ALDH2 WT and KO mice. 
B/: Quantitative analysis of repeat aggregation responses (% aggregation). Bars represent 
means ± S.E.M. n=6-7. Statistical differences were determined using repeated measures 
two-way ANOVA with Dunnett’s test for multiple comparisons and unpaired t-tests 
(*P<0.05, **P<0.01 and ***P<0.001). 
 
ns ns ns * ns 
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5.4.3 ALDH2 WT and KO tissue staining  
 
5.4.3.1 ORO staining in liver tissue 
 
ORO staining was used to visualise neutral lipid accumulation within ALDH2 WT and KO 
mouse livers. Figure 5.3A shows representative images of ORO stained ALDH2 WT and KO 
liver sections, respectively. The variation in ORO staining in the ALDH2 WT and KO liver 
tissue is highlighted by the magnified insets shown at the bottom right corner of the images in 
Figure 5.3A. As shown in Figure 5.3B, there was a significant increase in the % of ORO 
staining in ALDH2 KO liver sections, when compared to the ALDH2 WT liver sections.  
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Figure 5.3: ORO staining in ALDH2 WT and KO liver tissue sections  
Liver tissue samples obtained from ALDH2 WT and KO mice were sectioned using a 
cryostat. The 6µM liver tissue sections were then stained with ORO to enable the 
visualisation and quantification of the contained lipids.  
A: Representative images demonstrating fat cell and neutral lipid accumulation in liver 
tissue sections from ALDH2 WT and KO mice. Scale bars represent 100µM and the 
magnification is x20. To highlight tissue morphology, insets from the images have been 
magnified 3x. 
B: Quantitative analysis of repeat ORO staining (% ORO staining). Bars represent means ± 
S.E.M. n=7. Statistical differences were determined using an unpaired t-test (*P<0.05).   
100µM 100µM 
ORO 
Staining 
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5.4.3.2 ORO staining in skeletal muscle tissue 
 
ORO staining was also analysed in ALDH2 WT and KO mouse skeletal muscle. 
Representative images are shown in Figure 5.4A. As depicted in Figure 5.4B, there was a 
significant rise in the % of ORO staining in ALDH2 KO skeletal muscle sections, when 
compared to the ALDH2 WT liver sections. Once again, the variation in ORO staining is 
highlighted by the magnified insets shown at the bottom right corner of the images in Figure 
5.4A. 
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Figure 5.4: ORO staining in ALDH2 WT and KO skeletal muscle tissue sections 
Skeletal muscle tissue samples obtained from ALDH2 WT and KO mice were sectioned 
using a cryostat. The 6µM skeletal muscle tissue sections were then stained with ORO to 
enable the visualisation and quantification of the contained lipids.  
A: Representative images demonstrating fat cell and neutral lipid accumulation in skeletal 
muscle tissue sections from ALDH2 WT and KO mice. Scale bars represent 100µM and 
the magnification is x20. To highlight tissue morphology, insets from the images have been 
magnified 3x. 
B: Quantitative analysis of repeat ORO staining (%ORO staining). Bars represent means ± 
S.E.M. n=6. Statistical differences were determined using an unpaired t-test (*P<0.05). 
 
 
100µM 100µM 
ORO 
Staining 
Endomysium 
Endomysium 
 
 
168 
 
5.4.3.3 Mayer’s haematoxylin counterstaining in liver and skeletal muscle tissue  
 
Liver sections that had been previously stained with ORO were then counterstained with 
Mayer’s haematoxylin. This staining enabled tissue morphology and cell nuclei to be 
visualised.  Figures 5.5A and B show representative images of Mayer’s haematoxylin stained 
ALDH2 WT and KO liver (Figure 5.5A) and skeletal muscle (Figure 5.5B) sections. As 
depicted in Figures 5.5A and B, both ALDH2 WT and KO liver and skeletal muscle had a 
normal morphology. The normal morphology is also highlighted by the magnified insets 
shown at the bottom right corner of these images.  
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Figure 5.5: Mayer’s haematoxylin counterstaining in ALDH2 WT and KO liver and 
skeletal muscle tissue 
Liver and skeletal muscle tissue samples obtained from ALDH2 WT and KO mice were 
sectioned using a cryostat. The 6µM liver and skeletal muscle tissue sections were stained 
with ORO, before being counterstained with Mayer’s haematoxylin to enable the tissue 
morphology and cell nuclei to be visualised. 
 
A/B: Representative images demonstrating the tissue morphology of liver and skeletal 
muscle tissue sections from ALDH2 WT and KO mice. Scale bars represent 100µM and 
the magnification is x20. To further highlight tissue morphology, insets from the images 
have been magnified 3x. 
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5.5 Discussion  
It is widely recognised that ALDH2 plays an essential role in cardioprotection and is thought 
to be associated with the detoxification of reactive aldehydes, such as acetaldehyde and 4-
HNE (Budas et al., 2009; Chen et al., 2014). Furthermore, studies have revealed an 
interaction between ALDH2 and GTN, which is largely responsible for vascular GTN 
bioactivation and NO release, and therefore fundamentally involved in the anti-platelet 
effects of organic nitrates (Mackenzie et al., 2005; Mollace et al., 2014). A role for ALDH2 
in nitrite-mediated cardioprotection and vasodilatation have also been suggested (Arif et al., 
2015; Ormerod et al., 2017). In addition, our group have very recently reported that nitrite 
inhibits platelet aggregation in both healthy and HFpEF-AF patients (Borgognone et al., 
2018). However, the mechanism of nitrite in platelet aggregation remains to be fully 
elucidated, and to the best of our knowledge the role of ALDH2 in nitrite-mediated platelet 
aggregation has not been investigated. Herein, we show for the first time that nitrite inhibits 
platelet aggregation in the presence of ALDH2.  
 
We first validated the ALDH2 expression in the platelet and tissue samples. As expected, 
Western blot analysis revealed that ALDH2 was expressed in the WT mouse liver, skeletal 
muscle and cardiac tissue, and interestingly in the washed platelets (Figure 5.1). The ALDH2 
enzyme was not expressed in any of the KO samples (Figure 5.1). Our findings are supported 
by a recent mouse study, where ALDH2 was expressed in the liver and heart of ALDH2 WT 
mice (Oyama et al., 2005). Oyama and colleagues also suggested that the tissue-distribution 
of the enzyme was very similar in mice and humans, thus adding translatability and relevance 
to our mouse study (Oyama et al., 2005). Whilst ALDH2 has also been shown to be 
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expressed in mouse skeletal muscle (Zhang et al., 2017), ALDH2 expression has not 
previously been demonstrated in isolated platelets from mice.  
 
Numerous whole-blood and PRP aggregation studies from healthy subjects and mice have 
shown nitrite to inhibit platelet aggregation following its conversion to NO by the reductase 
activity of partially deoxygenated haemoglobin (Corti et al., 2013; Parakaw et al., 2017; Park 
et al., 2013; Srihirun et al., 2012). It has been revealed that a reduction of nitrite via nitrite 
reductases, such as deoxyhaemoglobin, XOR and ALDH2, helps to maintain NO production 
during hypoxia and acidosis (Calvert and Lefer, 2009; Vitturi and Patel, 2011). The XOR 
inhibitor, febuxostat, was also shown to partially reverse the anti-thrombotic effects of 
NaNO2 in rats (Kramkowski et al., 2016). Furthermore, our research group have very recently 
demonstrated that nitrite acts through sGC-PKG-VASPser239 independently of NO, to cause 
an attenuation of platelet aggregation in healthy volunteers and HFpEF-AF patients (Chapters 
3 and 4). Despite these findings, aspects of the platelet nitrite-mechanism remain unclear. 
Numerous interactions between mitochondrial ALDH2 and nitrite have been documented, 
thus suggesting that nitrite may also interact with ALDH2 to mediate an attenuation of 
platelet aggregation.  
 
In the present study, we demonstrate that active ALDH2 is required for nitrite-mediated 
attenuation of washed platelet aggregation in response to collagen (Figure 5.2). The effects of 
the NO donor, SNP, were shown to be almost identical in the ALDH2 WT and KO washed 
platelets, however a more significant attenuation of platelet aggregation was observed with 
higher concentrations of NaNO2 (Figure 5.2). These novel findings therefore suggest that 
nitrite may in fact interact with ALDH2 to inhibit platelet aggregation, since mutant ALDH2 
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mice abolished nitrite’s effect on platelet function. By developing our understanding of 
ALDH2-/nitrite-mediated platelet function this could help to improve the efficacy of anti-
platelet therapies and additional treatments in HF and other CVDs in the future.   
 
Tissues with a high energy demand and therefore mitochondrial content, such as the liver and 
skeletal muscle, are more severely affected by mitochondrial dysfunction (Boengler et al., 
2017). Recent studies have reported that the ALDH2*2 allele may be a risk factor for liver 
steatosis and NAFLD development (Oniki et al., 2016). The effect of ALDH2 deficiency on 
skeletal muscle lipid content still remains to be investigated, however the accumulation of 
triglycerides within skeletal muscle has been linked to obesity, insulin resistance and type 2 
diabetes (Goodpaster and Wolf, 2004). In the present study, we demonstrated that the lipid 
content was significantly increased in the ALDH2 mouse KO liver and skeletal muscle tissue, 
when compared to their respective WT controls (Figures 5.3 and 5.4). These findings suggest 
that the ALDH2*2 allele may also be a risk factor for lipid accumulation in skeletal muscle 
tissue. Further research into the effect of ALDH2 deficiency on tissue lipid content is 
therefore warranted, especially as hepatic steatosis has now been associated with CVD, 
(Mellinger et al., 2015), whilst lipid accumulation within skeletal muscle was previously 
linked to obesity, insulin resistance and type 2 diabetes (Goodpaster and Wolf, 2004).   
 
Finally, despite increases in lipid content in ALDH2 KO liver and skeletal muscle tissue, all 
ALDH2 WT and KO tissues sections had a normal morphology (Figure 5.5). It is well 
recognised that morphological changes only occur during the development of fatty vacuoles 
in the liver (Gerspach et al., 2017). Since morphological changes were not observed in 
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ALDH2 KO sections, this suggests that extensive lipid infiltration does not occur in liver and 
skeletal muscle tissue with ALDH2 deficiency.  
 
5.5.1 Study limitations and future considerations 
In the present chapter, there are a couple of study limitations in relation to the LTA 
experiments and ORO tissue staining. Firstly, collagen was the only agonist used to trigger 
washed platelet aggregation. As discussed in Chapters 3 and 4, this limitation restricts the 
evaluation of platelet function. Additional experiments involving multiple agonists are 
therefore required to investigate platelet function in both ALDH2 WT and KO mice 
(Dovlatova, 2015; Hayward et al., 2009).   
 
In addition, as previously explained in Chapters 3 and 4, non-physiological concentrations of 
nitrite were used in the LTA experiments. The use of pharmacological NaNO2 concentrations 
is a major disadvantage as changes to platelet function by normal plasma nitrite 
concentrations cannot be assumed from these studies (Kevil et al., 2011; Srihirun et al., 
2018). 
 
Furthermore, whilst the present study has revealed the importance of ALDH2 in nitrite-
mediated attenuation of washed platelet aggregation in mice, further studies are warranted to 
confirm these findings in man. In ALDH2 KO mice, gene disruption prevents all ALDH2 
expression. However, in the human population ALDH2 KOs do not exist and heterozygous 
(ALDH2*1/*2; less than 50% enzyme activity)/homozygous individuals (ALDH2*2/*2: 
approximately 1-4% enzyme activity) can be seen to express varying levels of WT enzymatic 
activity (Chen et al., 2014; Farres et al., 1994; Ferencz-Biro and Pietruszko, 1984; Zhou and 
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Weiner, 2000). As such, a genetic mouse ALDH2*2 strain could be used to give a more 
accurate representation of the interactions between ALDH2 and nitrite in the human 
population (Jin et al., 2015).  
 
Moreover, it is well known that ALDH2 functions as a nitrite reductase, to reduce nitrite and 
hence cause NO release, in conditions such as hypoxia and acidosis (Calvert and Lefer, 2009; 
Vitturi and Patel, 2011). As such, active ALDH2 may have contributed to nitrite-mediated 
attenuation of washed platelet aggregation in mice through a NO-dependent mechanism. The 
potential involvement of NO is somewhat contradictory to our findings in human platelets, 
where NaNO2 was shown to activate sGC independently of NO to inhibit washed platelet 
aggregation (Chapters 3 and 4). To further explore the underlying nitrite mechanism in mouse 
washed platelets, additional experiments in the presence of NO scavengers, OxyHb and 
PTIO, and the sGC inhibitor, ODQ, are warranted in ALDH2 WT and KO platelets. These 
investigations would reveal whether nitrite activates sGC independently of NO in mouse 
washed platelets and potentially corroborate with our findings in human platelets. The 
importance of ALDH2-nitrite interactions in nitrite-mediated sGC activation and the 
attenuation of platelet aggregation could also be explored under these circumstances to 
further delineate the cardioprotective mechanisms of ALDH2 and nitrite.  
 
Whilst Mollace and colleagues have previously reported ALDH2 to play a pivotal role in 
organic nitrate (GTN) tolerance in platelets, and since our group have very recently shown 
nitrite to circumvent the phenomenon of platelet NO resistance (Borgognone et al., 2018; 
Mollace et al., 2014). It would be essential to assess whether nitrite induces tolerance 
following long-term treatment in vivo in ALDH2 KO and WT mice, respectively. 
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Furthermore, ORO staining may not provide the most accurate representation of lipid 
accumulation in tissues. Polar lipids, such as phospholipids, are not stained by ORO, whilst 
tissues with low lipid contents are very difficult to stain. Moreover, ORO staining can only be 
used to quantify the general accumulation of lipids in tissues and not specific lipid types. 
Quantification of the staining is also very laborious and time consuming, as a result of the 
computer software used. Finally, large data sets are preferable for this type of analysis, 
therefore a larger sample size of n>8 is required (Mehlem et al., 2013).  
 
5.5.2 Conclusions  
We show two major findings in this study, firstly that nitrite requires ALDH2 to inhibit 
platelet aggregation. Secondly, that inactivation of ALDH2 increases the lipid content of 
mouse liver and skeletal muscle tissue without affecting tissue morphology. Further studies 
are warranted to evaluate the impact of ALDH2 in nitrite anti-platelet therapy, and develop 
our understanding of ALDH2 in skeletal muscle. Especially when approximately 40% of the 
East Asian population have ALDH2 deficiency and is associated with high prevalence of 
cardiovascular disease.  
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Chapter 6: General discussion 
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6.1 Introduction summary  
Since the discovery of NO in vasculature, a substantial amount of research has been 
undertaken to investigate the role of NO in platelets. It is well established that NO 
bioavailability and responsiveness decrease with age, thus leading to increases in platelet 
activation and aggregation (Goubareva et al., 2007; Jones, 2016; Torregrossa et al., 2011). 
However, very little evidence exists on the changes to platelet function in the elderly (>70 
years of age; Jones, 2016). Furthermore, the phenomenon of “platelet NO resistance” has 
been demonstrated in patients with HFrEF (Anderson et al., 2004), but whether this exists in 
HFpEF patients still remains to be elucidated. As such, the pro-thrombotic state in HF is 
likely to be exacerbated by this phenomenon, whilst the effectiveness of some NO-mediated 
HF therapies may also be reduced (Chirkov and Horowitz, 2007). Pharmacotherapeutic 
agents, such as ACE inhibitors, Beta-blockers and Digoxin, are frequently used in HFrEF to 
target associated neurohormonal dysregulation and haemodynamic instability. However, 
these drugs remain ineffective in HFpEF (Loudon et al., 2016) and the discovery of a novel 
agent that circumvents “platelet NO resistance” in HFpEF is therefore desirable. Currently, 
nitrite is being investigated with the potential of becoming a novel therapeutic agent for many 
CVDs and has been shown to have numerous protective effects in HF (Borlaug et al., 2015; 
Ormerod et al., 2015), whilst also inhibiting platelet aggregation in healthy volunteers 
(Borgognone et al., 2015). A few studies have also revealed interactions between nitrite and 
the mitochondrial enzyme, ALDH2, which has previously emerged as an important mediator 
for hypoxic vasodilator in HF patients (Arif et al., 2015) and very recently in second window 
pre-/post-conditioning (Ormerod et al., 2017). Whether ALDH2 plays a role in nitrite-
mediated inhibition of platelet aggregation remains to be fully elucidated. Therefore, in the 
present thesis the aim was to develop our understanding of the following: 1) platelet function 
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in young vs old healthy subjects (Chapter 3), 2) the potential for nitrite to be used as an anti-
platelet agent in patients with HFpEF-AF and CAF alone (Chapter 4), and 3) the role of 
ALDH2 on nitrite responses to platelet aggregation (Chapter 5).  
 
6.2 Discussion  
Numerous whole blood and platelet rich plasma (PRP) aggregation studies from healthy 
subjects and animals have shown that nitrite inhibits platelet aggregation through an 
erythrocyte-dependent mechanism (Corti et al., 2013; Dautov et al., 2014; Parakaw et al., 
2017). Under these conditions, nitrite inhibits platelet aggregation via the conversion to NO 
by the reductase activity of partially deoxygenated haemoglobin, and increases VASP 
phosphorylation at the Ser239 site in platelets (Parakaw et al., 2017; Srihirun et al., 2012). To 
determine whether nitrite inhibits platelet aggregation independently of haemoglobin and 
other plasma proteins, we conducted our experiments in washed platelets and to the best of 
our knowledge, we are the only research group to date to have investigated nitrite in washed 
platelets.  
 
In the present study we show that nitrite activates sGC independently of NO to inhibit 
washed platelet aggregation in both young and old healthy volunteers, whilst also 
demonstrating synergistic activity between nitrite and BAY 41-2272 in both age groups. The 
sGC stimulator, BAY 41-2272, was also shown to have NO-independent anti-aggregatory 
effects. These novel findings therefore highlight the potential for nitrite to be used, both alone 
and in combination with BAY 41-2272, as an anti-platelet therapy across all ages in the 
future. 
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Since our results show that nitrite inhibits platelet aggregation in the elderly healthy subjects, 
we next evaluated the effects of nitrite on platelet function in patients with HFpEF-AF. We 
demonstrated a diminished response to the NO donor, SNP, in washed platelets from HFpEF-
AF patients, when compared to the healthy volunteers and CAF patient group, whilst 
revealing a significant attenuation to platelet aggregation following 1mM NaNO2 treatment in 
HFpEF-AF patients. With these findings we show for the first time that “platelet NO 
resistance” exists in HFpEF-AF and that high concentrations of nitrite circumvent this 
phenomenon in HFpEF-AF patients. Since NaNO2 and SNP both triggered concentration-
dependent attenuation of platelet aggregation in CAF patients, we also show that “platelet NO 
resistance” is primarily associated with HFpEF and not CAF. Additional experiments 
completed by our research group demonstrate that nitrite also activates sGC independently of 
NO to inhibit washed platelet aggregation in HFpEF-AF patients. (Borgognone et al., 2018). 
Overall, these innovative findings highlight the potential for nitrite therapy to address 
conditions of hyperaggregability in the future, especially in patients with HFpEF-AF.  
 
Since a number of recent studies propose a role for mitochondrial ALDH2 in nitrite-mediated 
effects of vascular and cardiac disease, this suggests that this mechanism may have some 
benefits on platelet function. We have previously shown that nitrite significantly attenuates 
platelet aggregation in both healthy volunteers and patients with HFpEF-AF, however the 
mechanism of nitrite in platelet aggregation remains to be fully elucidated. Our data shows 
for the first time that activate ALDH2 is required for nitrite to inhibit platelet aggregation and 
to prevent lipid accumulation in the liver and skeletal muscle tissue of ALDH2 mice. The 
effect of ALDH2 deficiency on skeletal muscle lipid content still remains to be investigated, 
however recent studies have reported that the ALDH2*2 allele as a risk factor for liver 
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steatosis and NAFLD development (Oniki et al., 2016). These novel findings contribute to 
our understanding of nitrite- and ALDH2-mediated cardioprotection, thus may help to 
improve the effectivity of anti-platelet therapies in the future.  
 
6.3 Study limitations and future directions  
There are a couple of major limitations regarding the LTA experiments, Western blotting 
analysis and ORO staining in the present project. Firstly, heme-containing components of the 
mitochondrial respiratory chain (e.g. cytochrome C) may have contributed to nitrite-mediated 
inhibition by converting nitrite to NO within the washed platelets (Kevil et al., 2011). It is 
likely that intraplatelet nitrite reduction circumvents NO scavenging by OxyHb and PTIO, 
therefore further studies are warranted to investigate the influence of heme-containing 
components on nitrite-mediated platelet inhibition.  
 
Furthermore, the underlying nitrite mechanism and potential for BAY 41-2272 to act 
synergistically with nitrite was only investigated in washed platelets obtained from healthy 
volunteers. Therefore, further studies are essential to determine whether the synergistic effect 
of nitrite and BAY 41-2272 (sGC stimulator) would be of benefit in patients with HFpEF-AF 
and/or CAF patients. 
 
Moreover, whilst the present study has revealed the importance of ALDH2 in nitrite-
mediated attenuation of washed platelet aggregation in mice, further studies in a genetic 
mouse ALDH2*2 strain are warranted to confirm these findings in man. (Jin et al., 2015). 
Additional experiments in the presence of NO scavengers, OxyHb and PTIO, and the sGC 
inhibitor, ODQ, are also warranted in ALDH2 WT and KO platelets to determine whether 
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ALDH2-nitrite interactions activate sGC independently of NO to cause the attenuation of 
washed platelet aggregation. 
 
6.4 Conclusion  
In summary, we show for the first time in man that nitrite attenuates platelet aggregation in 
healthy volunteers and patients with HFpEF-AF. Furthermore, we demonstrate for the first 
time that the phenomenon of “platelet NO resistance” exists in HFpEF-AF, whilst also 
revealing that high concentration nitrite is able to circumvent “platelet NO resistance” in 
washed platelets independently of NO. We also show that ALDH2 is required for nitrite to 
inhibit platelet aggregation in mice. Overall, these novel findings highlight the potential for 
nitrite to be used as an anti-platelet therapy in the future, especially in patients with HFpEF-
AF, however further research into the influence of heme-containing components on nitrite-
mediated platelet inhibition, nitrite-BAY 41-2272 combination therapy in HFpEF-AF patients 
and ALDH2-nitrite interactions in a genetic mouse ALDH2*2 strain is warranted.  
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